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AASLD: the American association for the Study of Liver Diseases 
ACC1: acetyl-coenzyme A carboxylase 1 
ACG: the American College of Gastroenterology 
ADIPOR2: adiponectin receptor 2  
AGA: the American Gastroenterological Association 
ALP: alkaline phosphatase 
ALT: alanine aminotransaminase 
ApoB: apolipoprotein B  
ARBs: angiotensin receptors blockers  
AST: aspartate aminotransaminase 
AT: adipose tissue 
BMI: body mass index 
CB1: cannabinoid receptor 1 
CB2: cannabinoid receptor 2 
CD36: hepatic fatty acid translocase 
ChREBP: carbohydrate response element binding protein 
CK18: caspase-cleaved cytokeratin-18  
CPT1: carnitine palmitoyl-transferse 1 
CPT2: carnitine palmitoyl-transferse 2 
CRP: c-reactive protein 
CT: computed tomography  
CVD: cardiovascular disease 
DAG: diacylglycerol 
DNL: de novo lipogenesis 
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EC: endogenous cannabinoids 
ECM: extracellular matrix 
ER: endoplasmic reticulum 
FA: fatty acids 
FABP4: fatty acid binding protein 4 
FAS: fatty acid synthase 
FATP: fatty acid transporter protein  
FFA: free fatty acids 
FxR: farnesoid X receptor 
GGT: γ-glutamyl transferase 
GLP-1: glucagon-like peptide-1  
GNG: gluconeogenesis  
GWAS: genome-wide association studies  
HbA1c: glycosylated hemoglobin 
HCC: hepatocellular carcinoma 
HDL: high density lipoprotein cholesterol 
HGP: hepatic glucose production  
HOMA2-IR: homeostatic model assessment method insulin resistance 
HSC: hepatic stellate cells 
HSL: hormone-sensitive lipase  
IL1β: interleukin 1β 
IL6: interleukin 6 
IL8: interleukin 8  
IR: insulin resistance 
UNIVERSITAT ROVIRA I VIRGILI 
DEREGULATION OF FATTY ACID METABOLISM AND CANNABINOID RECEPTORS IN LIVER OF MORBIDLY 
OBESE WOMEN WITH NON-ALCOHOLIC FATTY LIVER DISEASE. 
Alba Berlanga Bustos 
Dipòsit Legal: T 1705-2015
I. ABBREVIATIONS 
 
17 
 
KC: kupper cells 
LDL: low density lipoprotein cholesterol 
LPL: lipoprotein lipase 
LPS: lipopolysacharide 
LxRα:  liver X receptor alpha 
MetS: metabolic syndrome 
MR: nuclear magnetic resonance  
mTORC1: mammalian target of rapamycin complex 1  
MTP: microsomal triglyceride transfer protein  
MUFA: monounsaturated fatty acids 
NAFLD: non-alcoholic fatty liver disease 
NAS: NAFLD activity score  
NASH: non-alcoholic steatohepatitis 
NEFA: non-sterified fatty acids 
NFS: NAFLD fibrosis score  
NL: normal liver 
PKCε:  protein kinase-Cε  
PNPLA3: patatin-like phospholipase domain-containing protein 3  
PPARα: peroxisome-proliferator-activated receptor α 
PPARγ: peroxisome-proliferator-activated receptor γ 
PPARδ: peroxisome-proliferator-activated receptor δ 
PTX: Pentoxyphylline  
PUFAs: polyunsaturated fatty acids  
QM: chylomicrons 
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RAS: renin–angiotensin system  
ROS: reactive oxygen species  
SFA: saturated fatty acids 
SREBP1c: sterol-regulatory-element-binding protein 
SS: Simple steatosis 
T2DM: type 2 diabetes mellitus 
TCA: tricarboxylic acid cycle 
TG: triglycerides 
TGFβ1: transforming growth factor beta-1  
TNFRI:  tumour necrosis factor receptor I 
TNFRII: tumour necrosis factor receptor II 
TNFα: tumour necrosis factor alpha 
TZD: thiazolidinedione  
UDCA: Ursodeoxycholic acid  
VLDL: Very low density lipoprotein 
WAT: white adipose tissue  
WC: waist circumference. 
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1. NON-ALCOHOLIC FATTY LIVER DISEASE 
 
Non-alcoholic fatty liver disease (NAFLD) is becoming an 
increasingly important health issue due to the fact that it is the most 
common cause of chronic liver disease in the Western world, and its 
incidence is increasing rapidly1. NAFLD is a progressive inflammatory 
disease that encompasses a wide spectrum of liver damage, ranging from 
simple steatosis to non-alcoholic steatohepatitis (NASH). Simple steatosis is 
defined by hepatic fat accumulation in form of triglycerides (TG), exceeding 
5% of liver mass, in the absence of high alcohol intake. NASH includes the 
presence of simple steatosis, lobular inflammation, and hepatocellular injury 
(balloning) with or without fibrosis2,3. While simple steatosis is generally a 
benign, non-progressive clinical entity, NASH can progress to cirrhosis, 
which in rare cases gives rise to hepatocellular carcinoma (HCC)4 (Figure 
1).  
 
Figure 1. The disease spectrum of non-alcoholic fatty liver disease. The accumulation of 
triglycerides (TG) within lipid droplets in hepatocytes causes simple steatosis. Simple steatosis  
associated with lobular inflammation and hepatocellular injury (ballooning) with or without 
fibrosis is referred to as NASH. Both simple steatosis and NASH are considered reversible 
through weight-loss, changes in diet and increased physical activity. However, NASH can 
progress to irreversible fibrosis, leading to cirrhosis and a high risk of hepatocellular carcinoma 
(HCC) 5. 
 
 
Simple SteatosisNormal liver NASH Cirrhosis
HCC
• TG acummulation • TG acummulation
• Inflammation
• Hepatocellular injury
• With/without fibrosis
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NAFLD has frequently been associated with components of the 
metabolic syndrome (MetS) such as obesity, dyslipidaemia, insulin 
resistance (IR) and type 2 diabetes mellitus (T2DM)6,7, and thought to 
represent the hepatic manifestation of MetS. However, many people with 
NAFLD are not obese, and many people with NAFLD do not have T2DM. 
Increasing evidence indicates that the presence and severity of NAFLD not 
only further increases the risk of T2DM, but is also an independent risk 
factor of cardiovascular and chronic kidney disease; this suggests that 
NAFLD is a multisystem disease, affecting extra-hepatic organs and 
regulatory pathways. Although the primary liver pathology in NAFLD affects 
hepatic structure and function, causing morbidity and mortality from 
cirrhosis, liver failure and HCC, the majority of deaths among NAFLD 
patients are attributable to cardiovascular  disease (CVD)8,9.  
 
Table 1 shows the risk factors associated with NAFLD. Although obesity, 
insulin resistance, T2DM, and dyslipidaemia are the most important risk 
factors, other endocrine conditions are also associated with NAFLD2. 
 
 Table 1. Risk factors associated with NAFLD 
Conditions with established 
associations 
Conditions with emerging 
associations 
 
Obesity 
 
Polycystic ovary syndrome 
Insulin resistance Hypothyroidism 
Type 2 diabetes mellitus Obstructive sleep apnea 
Dyslipidaemia Hypopituitarism 
Metabolic syndrome* Hypogonadism 
 Pancreato-duodenal resection 
 
*Metabolic syndrome, as defined by the Adult Treatment Panel (ATP) III criteria, is 
defined by the presence of three or more of the following: (1) waist circumference 
greater than 102 cm in men or greater than 88 cm in women; (2) triglyceride level 
higher than 150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides; (3) 
highdensity lipoprotein (HDL) cholesterol level lower than 40 mg/dL (1.03 mmol/L) in 
men and less than 50 mg/dL (1.29 mmol/L) in women or on drug treatment for low 
HDL; (4) systolic blood pressure ≥130 mm Hg or diastolic pressure ≥85 mm Hg or 
treatment for hypertension; and (5) fasting plasma glucose level≥110mg/dL or drug 
treatment for elevated blood glucose10. 
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1.1 NAFLD epidemiology  
 
The prevalence of NAFLD worldwide varies between different 
countries and regions, which can be divided into three different groups: 
high, low and unknown prevalence groups11. However, the globally 
accepted worldwide prevalence of NAFLD based on a variety of 
assessment methods ranges from 6.3% to 33%, with a median of 20% in 
the general population, while the estimated prevalence of NASH is lower, 
ranging from 3 to 5%12. Moreover, NAFLD has been reported as more 
prevalent among obese subjects and in patients with type 2 diabetes, 
regardless of the degree of obesity. The prevalence increases to 57% in 
obese subjects, 70% in diabetic subjects and 90% in morbidly obese 
people13. 
The high prevalence group is mostly represented by "Western" 
countries where the population has an “urban” lifestyle. This group includes 
the United States and Europe, as well as the Middle- East, Latin America, 
Australia, Japan and China. The prevalence rates are constantly and rapidly 
increasing in these countries, due to the increase in obesity, IR, lipid 
impairments and T2DM related to incorrect dietary habits and sedentary life-
styles. The prevalence of NAFLD In these populations ranges between 20% 
and 30%, and the prevalence of NASH from 3% to 16%.  
The low prevalence group is mostly represented by Asian 
countries and developing countries. The majority of the population in these 
countries resides in rural areas where traditional diets and lifestyles are still 
present, and the reported prevalence of NAFLD is therefore about 10%. 
Nevertheless, in these same countries, people that reside in urban areas 
have a higher prevalence, similar to rates in Western countries. These data 
suggest that adoption of a sedentary lifestyle and the globalization of the 
Western diet are associated with an increase in the prevalence of NAFLD in 
developing countries.  
The unknown prevalence group is mostly represented by "third-
world" countries, and particularly those in Africa. As these are developing 
countries, with a high proportion of the population residing in rural areas, it 
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is reasonable to expect that the prevalence should be similar to the "low 
prevalence group"11. Indeed, a Nigerian study estimated the prevalence at 
around 9%14. 
 
Apart from obesity, IR, dyslipidaemia, MetS and diabetes, age, 
gender, and ethnicity are also risk factors associated with a differential 
prevalence for NAFLD. A number of studies have shown that the 
prevalence of NAFLD and NAFLD-related fibrosis increases with age2,12, 
and reach the higher value in the age ranges between 40 and 65 years11.  
Although a smaller prevalence in children (2.6-9.6%) compared to adults 
was previously reported, it is rapidly increasing, particularly among obese 
children, ranging between 10-80%15, in whom NAFLD has become the most 
common cause of chronic liver disease16. This is likely to expose patients to 
liver injury for a longer period of time, increasing the risk of progression and 
complications, and could change the natural history of this disease. This is 
currently represents a major public health problem, which requires the full 
attention of Institutions responsable for providing appropriate prevention 
strategies in the near future11. 
It is now a universally accepted fact that there is a higher 
prevalence in men than in women, perhaps related to men’s tendency 
towards visceral obesity11. Most epidemiological studies have demonstrated 
that NAFLD is almost twice prevalent in males compared to females. For 
instance, the prevalence of NAFLD in the Dallas Heart Study was 42% in 
white men, compared with only 24% in white women and this difference was 
not attributable to differences in body weight or insulin sensitivity17. Studies 
have suggested that estrogen may reduce the risk of developing NAFLD in 
women18.  
The contribution of ethnicity to the prevalence of NAFLD has been 
extensively studied. Various USA-based studies have demonstrated that the 
rates of NAFLD are decreasing at different rates among East Asian Indians 
(higher rates), Hispanics, Asians, white Caucasians and African Americans 
(lower rates), with the latter apparently protected from developing NAFLD 
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despite higher rates of obesity11,19.  Recently, in accordance with these 
results, Williams et al. evaluated 328 individuals who underwent right upper 
quadrant ultrasound examinations, and found that Hispanics have the 
highest prevalence of NAFLD (58%) followed by Caucasians (44%) and 
African-Americans (35%)20.  
 
Smoking and alcohol intake are other risk factors associated with 
NAFLD. Modest alcohol consumption (one alcoholic beverage per day) had 
not been shown to increase the prevalence of NAFLD, and modest wine 
consumption would appear to reduce its incidence21. In a retrospective 
study, Hamabe et al. demonstrated over a 10-year period that smoking was 
an independent risk factor for NAFLD regardless of the presence of other 
metabolic risk factors22. Furthermore, the incidence of advanced hepatic 
fibrosis is high in smokers23. 
 
1.2 Natural history of NAFLD 
 
Progression in NAFLD is difficult to assess, requiring years of 
follow-up and repeat biopsies that are prone to sampling errors24. The 
prognosis of subjects with NAFLD depends on the histological subtype of 
the disease. Subjects with simple steatosis (SS) have a relatively benign 
course and are at low risk of developing liver-related morbidity or mortality. 
Today, SS is widely accepted as a ‘benign’ adaption to lipid loading in the 
liver. By contrast, NASH is more frequently progressive and may lead to 
cirrhosis with complications of HCC, liver failure and liver-related death, or 
the need for liver transplantation25. Although only a small percentage of 
patients with NAFLD will eventually develop cirrhosis, and given the large 
number of patients with NAFLD, this represents a significant disease 
burden. Estimates suggest that approximately 5% of patients with NAFLD 
develop cirrhosis26.   
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A long prospective study of the natural history of NAFLD using 
repeat biopsies, has reported that 47% of patients with SS progressed to 
NASH, and 25–50% of patients with NASH developed advanced fibrosis or 
cirrhosis in 8–13 years27. Patients with NAFLD-associated cirrhosis have 
been shown to have a very poor 10-year prognosis, with 50% needing a 
liver transplant, 20% dying from a liver-related cause and 7% developing  
HCC28 (Figure 2). 
 
 
Adapted from Proceedings of the Nutrition Society (2010), 69, 211–22024 
Figure 2. Progression and stages of NAFLD  
 
  
More recently, in a long-term follow-up evaluation of NAFLD 
patients, Rafiq et al. confirmed that NASH patients have increased liver 
related mortality compared to non-NASH patients29. This study also 
revealed that independent predictors of liver-related mortality not only 
include having histological NASH, but also T2DM and older age.   
 
Both NASH and T2DM increase the risk of hepatocellular 
carcinoma. The underlying mechanisms by with NASH or T2DM increase 
the risk of developing HCC are not fully understood, but mechanisms 
involved in inflammation, metabolic stress and IR that are shared between 
NASH and T2DM may be also involved in HCC development9. Indeed, 
NASH is the third most common indication for liver transplantation in the 
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United States, and NASH has been predicted to be the most common 
underlying disease in patients requiring liver transplantation in 202030. In 
addition to liver-related mortality, subjects with NASH are at increased risk 
of cardiac morbidity and mortality25.  
 
1.3 Diagnosis and staging of NAFLD 
The American association for the Study of Liver Diseases (AASLD), 
the American College of Gastroenterology (ACG) and the American 
Gastroenterological Association (AGA) published new guidelines for the 
diagnosis and management of NAFLD2. They stipulated that the diagnosis 
of NAFLD requires (a) evidence of hepatic steatosis either by imaging or by 
histology, (b) the absence of significant alcohol consumption, and (c) the 
absence of secondary causes of hepatic steatosis. Common secondary 
causes of hepatic steatosis are summarized in Table 2.  
Table 2. Common causes of Secondary Hepatic Steatosis 
Macrovesicular steatosis 
    Excessive alcohol consumption 
men: >21 drinks/week or 30g/day 
      women: >14 drinks/week or 20g/day 
    Hepatitis C 
    Wilson's disease 
    Lipodystrophy  
    Starvation 
    Parenteral nutrition 
    Abetalipoproteinemia 
    Medications (e.g corticosteroids) 
 
Microvesicular steatosis 
   Reye's syndrome 
    Medications (e.g anti-retroviral medicines) 
    Acute fatty liver of pregnancy 
    HELLP syndrome 
    Inborn errors of metabolism 
 
Gastroenterology 2012;142:1592-16092 
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NAFLD should be suspected in individuals who are either obese, 
diabetic or have metabolic syndrome. However, it is frequently 
underdiagnosed, as it is mostly asymptomatic. Several non-invasive 
methods are used for diagnosis of NAFLD. In clinical practice, plasma liver 
aminotransferase levels and ultrasound are the most common diagnostic 
techniques31. Elevated alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels in the absence of other liver diseases may 
support NAFLD, and an AST/ALT ratio less than 1 is also seen in NAFLD 
and supports NASH32. Both aminotransferase levels and ultrasonography 
are widely available, easy to perform and have a low cost; however, they 
have low sensitivity for fatty liver. Other imaging techniques, such as 
computed tomography (CT) and nuclear magnetic resonance (MR) can also 
detect liver steatosis. CT provides a semiquantitative method and can be 
used to diagnose moderate to severe hepatic steatosis, but has relatively 
low sensitivity and is not usually used for this purpose. MR remains the 
gold-standard technique, with a high sensitivity and specificity for steatosis 
(5.5 % intrahepatic TG content considered diagnostic for NAFLD), involves 
no radiation and allows quantification of liver steatosis, but it has limited 
availability and requires expensive hardware and software, making each 
test costly 31. On the other hand, the Fatty Liver Index is an algorithm based 
on four markers: body mass index (BMI), waist circumference, triglyceride 
and γ-glutamyltransferase (GGT), which has been confirmed as accurately 
identifying NAFLD32 (Figure 3). 
 
It is important to note that serum aminotransferase levels and 
imaging tests do not reliably assess the presence of steatohepatitis and 
fibrosis in patients with NAFLD. Liver biopsy is currently the gold standard 
for characterizing liver histology (the degree of hepatocyte injury and level 
of fibrosis and inflammation) in patients with NAFLD. However, it is a 
procedure that is invasive and expensive, and involves some morbidity and 
very rare mortality risk. Nevertheless, liver biopsy should be considered in 
those patients with fatty liver who after imaging techniques, laboratory 
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abnormalities and/or non-invasive methods, are considered to be at 
increased risk of having NASH and advanced fibrosis 2. 
 
Since liver biopsy still remains the gold standard, there is a 
significant interest in developing non-invasive biomarkers for identifying 
steatohepatitis in NAFLD. In this respect, circulating levels of caspase-
cleaved cytokeratin-18 (CK18) fragments have been investigated as a 
promising biomarker for the presence of steatohepatitis in patients with 
NAFLD33. Moreover, recent breakthroughs have enabled non-invasive 
techniques to be used to diagnose the level of fibrosis/inflammation (Figure 
3). The NAFLD fibrosis score (NFS) evaluates six variables: age, 
hyperglycemia, BMI, platelet count, albumin and AST/ALT ratio. This tool is 
widely used in practice to exclude advanced fibrosis. Another tool used in 
clinical practice is the FibroMeter, which uses age, weight, fasting glucose, 
AST, ALT, ferritin and platelet count to diagnose significant fibrosis and the 
percentage of hepatic fibrosis. This tool provides a more reliable diagnosis 
for significant fibrosis than the NFS; it can be used to confirm or rule out 
advanced fibrosis in NAFLD patients. FibroScan, also known as transient 
elastography, is another non-invasive method for assessing liver fibrosis. 
This method measures liver stiffness, and was originally designed for the 
hepatitis C population, but is being used in the NAFLD population to 
determine the stage of fibrosis. However, it has been shown to provide 
inacurate liver stiffness measurement in overweight and obese patients32. 
   
UNIVERSITAT ROVIRA I VIRGILI 
DEREGULATION OF FATTY ACID METABOLISM AND CANNABINOID RECEPTORS IN LIVER OF MORBIDLY 
OBESE WOMEN WITH NON-ALCOHOLIC FATTY LIVER DISEASE. 
Alba Berlanga Bustos 
Dipòsit Legal: T 1705-2015
II. INTRODUCTION 
 
30 
 
 
 
 
 
Adapted from Schwenger K et al. Clinical approaches to NAFLD. World J Gastroenterol 201432  
 
Figure 3. Diagnosis and staging of non-alcoholic fatty liver disease 
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1.4 Histopathology of NAFLD  
Important pathological classifications of NAFLD/NASH were 
proposed by Matteoni, by Brunt and the NASH Clinical Research Network 
(CRN) Pathology Committee. In the 1999 classification by Matteoni et al. 34, 
the authors distinguished between NASH and non-NASH. They defined 
histological types 1 and 2 of NAFLD as “non-NASH”, while types 3 and 4 
were classified as NASH. When Matteoni’s classification was published, 
Brunt et al.35 proposed a semiquantitative grading and staging system for 
NASH. The authors graded steatosis, inflammation and ballooning 
degeneration, and the staging was based on the degree of fibrosis. This 
classification is only applicable to NASH, and not to the entire spectrum of 
NAFLD. In 2005, the pathology committee of the NASH CRN group 
therefore developed and validated a histological scoring system for use in 
NAFLD, based on Brunt’s classification3 (Table 3).  
 
The NAFLD activity score (NAS) system is applicable to both adults 
and pediatric patients. The NAS represents the sum of the scores for 
steatosis (0-3), lobular inflammation (0-3) and ballooning degeneration (0-
2). An NAS of 5 or more correlates with the diagnoses of NASH, scores of 
less than 3 correlates with “not NASH”, while scores of 3 or 4 are uncertain 
for the diagnosis of NASH. Fibrosis is scored separately to give a fibrosis 
stage of between 0 and 4 (Table 3).  
 
In short, the histological spectrum of NAFLD is characterized by 
steatosis, lobular inflammation, ballooning of hepatocytes, fibrosis, and 
other features that may or may not be present, such as Mallory–Denk 
bodies and portal inflammation. The NASH CRN grading and staging 
system of NASH is based on the use of haematoxylin and eosin and 
Masson’s trichrome stain, so it can be used routinely by histopathologists36. 
Figure 4 shows the histologic features, grading, and staging of NAFLD. 
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         Table 3. Histological scoring system.  
 
From Kleiner et al.3 
 
 
Adapted from Nalbantoglu I et al.37 
Figure 4. Histologic features, grading, and staging of NAFLD. A: Mixed large 
and small droplet steatosis, single droplet, with nucleus pushed to one side, HE stain, 600×; 
B: Microvesicular steatosis, HE stain, 600 ×; C: Ballooned hepatocytes with flocculent 
cytoplasm, HE stain, 600 ×; D: Mallory-Denk body, HE stain, 600 ×; E: Mallory-Denk body in 
blue-green color and dense perisinusoidal fibrosis, Trichrome stain, 600 ×; F: Delicate 
perisinusoidal fibrosis, Trichrome stain, 600 ×; G: Bridging fibrosis, Trichrome stain, 200 
×.HE: haematoxylin and eosin    
A B
G
D
C
F
E
Steatosis grade Lobular inflammation Hepatocyte balloning 
 
0: <5% 0: None 0: None 
1: 5-33% 1: <2 foci 1: Mild 
2: 34-66% 2: 2-4 foci 2: Moderate 
3: >66% 3: >4 foci 
 
NAFLD activity score (NAS) 0-2 not NASH 
3-4 uncertain for NASH 
5-8 NASH 
Fibrosis Staging  
     
Stage 1: 1A. Mild zone 3 perisinusoidal fibrosis;  
               2B. Moderate zone 3 perisinusoidal fibrosis; 1C. Portal fibrosis 
Stage 2: perisinusoidal and portal/periportal fibrosis 
Stage 3: bridging fibrosis 
Stage 4: cirrhosis 
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1.5 Management of NAFLD 
 
The best approach for the management of NAFLD remains 
controversial due to the incomplete understanding of the natural history of 
the disease. While many cases of NAFLD can be diagnosed using plasma 
aminotransferase levels and imaging, a liver biopsy is still required to 
confirm the diagnosis and stage of the disease31. 
The most recent guidelines suggest management and treatment of 
patients with NAFLD, considering both the liver disease and the associated 
metabolic co-morbidities, such as obesity, dyslipidaemia, IR and T2DM2. At 
present, there are three approaches to focusing on management strategies 
in NAFLD: lifestyle modification, liver-directed pharmacotherapy, and 
managing the complications of cirrhosis38. All patients with NAFLD require 
advice about lifestyle modification, as well as treatment of any associated 
metabolic risk factors. However, patients with NASH and fibrosis require 
more aggressive lifestyle modification and if this fails liver-directed 
pharmacotherapy can be considered. For patients who have progressed to 
cirrhosis, surveillance for HCC is essential and some treatments have been 
shown to reduce the risk of HCC38. Interventions for the treatment of NAFLD 
are summarized in Table 4. 
 
1.5.1. Lifestyle modification 
Reduction in caloric intake and exercise: lifestyle modification, 
aimed at weight loss and increased physical activity, is still the mainstay of 
management of patients with NAFLD, irrespective of their underlying liver 
histology. A calorie-restricted diet (600 Kcal less than a person needs to 
remain at the same weight) should be recommended aiming to lose 0.5–1 
kg per week until the target weight is achieved. Ideally, patients should be 
encouraged to lose >10% of their body weight and maintain the weight 
loss38. Previous studies have shown that >7%39 and ≥9%40 loss of body 
weight was associated with reduced steatosis, hepatocellular injury and 
hepatic inflammation. A higher level of physical activity is associated with 
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lower levels of steatosis41. Although the optimum exercise to treat NAFLD is 
not known, aerobic exercise has been shown to improves insulin sensivity42. 
Furthermore, moderate, high and resistance exercise have shown 
improvements in liver enzymes and reduction in liver fat, independent of 
weight loss, but the effects on histology remain unknown38. One approach is 
to recommend 30 min of moderate exercise five times weekly43. 
 
Weight loss therapies: a weight loss therapy using pharmacological 
agents can be considered for subjects who have not achieved their target 
weight by lifestyle intervention and have a BMI >30 kg/m2. National Institute 
of Health and Care Excellence (NICE) guidelines43 for obesity recommend 
Orlistat in these cases. Orlistat is an enteric lipase inhibitor that leads to 
malabsorption of dietary fat and can aid weight loss in subjects with obesity 
in conjunction with lifestyle modification. Zelber-Sagi et al. reported that 
Orlistat improved ALT and steatosis, but its effect on liver histology could 
not be evaluated44. However, Harrison et al. demonstrate that Orlistat did 
not improve body weight or liver histology40.   
The endocannabinoid CB1 receptors expressed in hepatocytes and hepatic 
myofibroblasts contribute to high fat storage, alcohol-induced steatosis, 
fibrogenesis and insulin resistance. In contrast to CB1, although the role of 
CB2 receptors in the development of fatty liver has not been extensively 
investigated, there is some evidence of a potentially anti-fibrotic effect of 
CB2 receptor activation. CB1 receptor antagonism and CB2 receptor 
agonism have therefore been identified as promising therapeutic strategies 
for the management of liver diseases45. Rimonabant (a CB1-antagonist) 
was initially approved for the management of overweight, liver steatosis and 
related cardio-metabolic risks, but it was withdrawn due to an alarming rate 
of adverse effects on mood, which were primarily psychiatric in nature due 
to its concentration in the brain46. 
Meanwhile, NICE guidelines suggest that bariatric surgery should be 
considered as a treatment for obesity in patients with BMI > 40 kg/m2 or 
between 35 and 40 kg/m2 with another significant disease that could be 
improved with weight loss, as well as a first-line option for the treatment of 
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obesity in adults with a BMI greater than 50 kg/m2. Weight loss after 
bariatric surgery has beneficial effects on the components of the metabolic 
síndrome, including improving insulin sensitivity and the lipid profile, as well 
as reducing long-term mortality47,48. It also has specific effects on liver 
histology, including reduced steatosis, steatohepatitis and fibrosis49. 
However, it cannot be considered as a primary treatment for NASH1. 
 
1.5.2 Liver directed-pharmacotherapy 
1.5.2.1 Targeting components of the metabolic syndrome 
Insulin sensitizers: given the importance of IR in the pathogenesis 
of NAFLD, insulin sensitizers such as metformin, thiazolidinedione (TZDs) 
and incretin-based therapies have been extensively studied in the treatment 
of T2DM and the MetS in NAFLD50. 
 Metformin is a biguanide insulin sensitizer, whose major action is mediated 
through activation of AMPK. Although metformin has no significant effect on 
liver histology and is not recommended as a specific treatment for liver 
disease in adults with NASH2, it is recommended as the first-line 
pharmacological treatment for T2DM. This improves peripheral glucose 
intake, reduces hepatic gluconeogenesis and lipogenesis, and also 
increases beta oxidation of free fatty acids51. 
TZDs are agonists for the peroxisome-proliferator-activated receptor γ, a 
transcriptor factor that is very abundant in adipose tissue, and their actions 
in NAFLD are probably indirect and largely relate to their effects on adipose 
tissue. Since several studies have demonstrated that Pioglitazone improves 
insulin sensitivity as well as reducing hepatic steatosis and inflammation in 
subjects with NASH and T2DM, it has been considered a second-line 
treatment of T2DM in subjects with NASH52,53. However, there are also 
some concerns about its long-term safety due to its association with weight 
gain, increased risk of congestive cardiac failure, bladder cancer and 
reduced bone density38.  
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Glucagon-like peptide-1 (GLP-1) is an incretin secreted by ileal L-cells 
dependent on the presence of food in the small intestine. It increases insulin 
sensitivity, inhibits gastric emptying and decreases food intake by 
increasing satiety in the brain. Analogues of GLP-1 should be considered as 
an alternative to insulin as a third-line treatment of T2DM in subjects with 
NASH. They reduce glycosylated hemoglobin (HbA1c) by 1% and patients 
frequently lose an average of 3 kg weight38. Furthermore, they have been 
associated with an improvement of liver enzymes as well as reduced 
steatosis54. However, recent evidence suggests that an GLP-1 agonist 
might induce pancreatitis55. 
 
Lipid lowering drugs: as mentioned above, patients with NAFLD and 
NASH are at an increased risk of CVD, and several studies have 
established CVD as their most common cause of death56. An effective 
treatment of dyslipidaemia is therefore vital in the management of NAFLD to 
reduce patients’ cardiovascular risk profile. Statins, fibrates and omega-3 
polyunsaturated fatty acids (PUFAs) are used to manage dyslipidaemia in 
patients with NAFLD and NASH57. Several studies have provided 
compelling evidence that lipid-lowering agents are safe and effective in 
patients with either NAFLD or NASH, and that some of these agents can 
induce a reduction in the extent of the hepatic steatosis57. 
 
Hypertension: angiotensin receptor blockers (ARBs) are widely 
used as antihypertensive agents with a well-characterized safety profile. 
Targeting the renin–angiotensin system (RAS) might be beneficial in all 
patients with NAFLD, as the RAS plays a role in liver fibrogenesis and 
blocking the RAS inhibits the proliferation of stellate cells, and reduces both 
inflammation and fibrosis58. Small-sample human studies have suggested 
that ARBs improve serum liver enzyme levels, insulin sensitivity and 
histological features of NAFLD59; however, further larger clinical trials are 
needed to corroborate these findings. A previous meta-analysis also 
showed a 20% reduction in the incidence of new onset diabetes with the 
use of ARBs60.  
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1.5.2.2 Antioxidants and cytoprotective therapies 
 
Vitamin E: vitamin E, a fat-soluble vitamin, has an anti-oxidant 
property and has been widely investigated for the treatment of NAFLD and 
NASH in both pediatric and adult populations. It has been shown to be 
associated with decreased aminotransferase levels and improvements in 
steatosis, inflammation, ballooning and resolution of steatohepatitis in adults 
with NASH61. Similar results were obtained in a pediatric population (the 
TONIC study)62. However, there are concerns about its long-term safety, 
since it has been shown to increase all-cause mortality, the risk of 
haemorrhagic stroke and prostate cancer at high doses38. Vitamine E is 
recommended as a first-line treatment for NAFLD patients with histologically 
confirmed NASH in the actual NAFLD AASLD guidelines, but it is not 
recommended for NASH patients with diabetes2. 
 
Ursodeoxycholic acid (UDCA): UDCA is a hydrophilic bile acid with 
cytoprotective and antioxidant properties. However, only limited data on the 
efficacy of UDCA in NAFLD is available63. In fact, two well-designed 
randomized controlled trials showed that UDA failed to show any significant 
improvement in the liver histology of patients with biopsy-proven NASH64,65. 
AASLD guidelines do not recommend UDCA for the treatment of patients 
with NAFLD or NASH2. 
 
1.5.2.3 Other drugs 
 
The manipulation of microbiota through probiotics, prebiotics, and 
antibiotics is providing encouraging results for the treatment of obesity, 
diabetes, and NAFLD/NASH, but data in humans are scarce. It has been 
shown that probiotics may reduce NAFLD liver injury and may improve liver 
enzymes. Moreover, fructo-oligosaccharides are now becoming increasingly 
popular due to their prebiotic effects, but the existing data are difficult to 
reconcile, given the use of different strains, dosages and durations of 
treatment. Studies in an experimental model of non-alcoholic steatohepatitis 
indicate that anti- tumour necrosis factor alpha  (TNFα)  antibodies are 
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effective against liver necrosis, inflammation and fibrosis, but more studies 
on animal models are needed before testing these molecules on humans45. 
Furthermore, Pentoxyphylline (PTX) is a TNFα inhibitor which has been 
also evaluated in NASH for its anti-inflammatory properties. A meta-analysis 
of randomized, double-blinded, placebo-controlled trials showed that PTX 
could reduce aminotransferase activities and improve histological 
parameters in NAFLD patients66. These results need to be confirmed in 
larger studies, and the underlying mechanism responsible for the beneficial 
effects of PTX in NASH remains unidentified. Finally, elevated iron indices 
are described in NAFLD, and as such, iron reduction has been suggested 
as a potential therapy45.  
 
1.5.3 Managing the complications of cirrhosis and liver 
transplantation 
Patients with NASH cirrhosis are at risk of the same complications 
of cirrhosis as with any other aetiology of liver disease, such as 
hepatocellular carcinoma. There is emerging evidence that metformin 
reduces the risk of cancer (including HCC) in patients with diabetes in a 
dose-dependent manner67, and statins might reduce the incidence of 
HCC68. Moreover, in patients with end-stage liver disease due to NAFLD, 
liver transplantation is the only definitive treatment69.  
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Table 4. Interventions for the treatment of NAFLD 
 
Lifestyle 
intervention 
Weight loss 
 
Calorie restricted diet 
Anti-obesity drugs: Orlistat 
Rimonabant 
Bariatric surgery 
Exercise 30 min moderate 5x/week 
 
Targeting 
components 
of the 
metabolic 
syndrome 
Insulin 
sensitizers 
 
Metformin 
Thiazolidinedione (TZDs): Pioglitazone 
Incretin based therapies: GLP-1 
analogues 
Dyslipidaemia Statins 
Fibrates 
Omega-3 polyunsaturated fatty acids 
(PUFAs) 
Hypertension Angiotensin receptor blockers (ARBs) 
 
Antioxidants 
and 
cytoprotective 
therapies 
Vitamin E 
Ursodeoxycholic acid (UDCA)
 
Others Probiotics/Prebiotics 
Anti-TNFα antibodies
Pentoxifylline (PTX)
Iron depletion
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2. PATHOGENESIS OF NAFLD 
 
2.1 The two-hit vs multi-hit hypothesis 
 
The molecular mechanism underlying NAFLD progression has often 
been interpreted in terms of a “double-hit” process, which was proposed in 
1998 by Day et al70. The primary insult or the “first hit” includes the 
accumulation of TG and free fatty acids (FFA) in hepatocytes. Insulin 
resistance and subsequent hyperinsulinemia, typically associated with 
weight gain or obesity, appears to be the key component of the “first hit” that 
results in hepatic steatosis. These changes have been postulated as 
resulting in increased sensitivity to the “second hit”, which involves pro-
inflammatory cytokines, mitochondrial dysfunction, oxidative stress and 
subsequent lipid peroxidation, leading to hepatocyte damage, inflammation 
and the development of steatohepatitis.  
This paradigm suggests that in the “first hit”, TG accumulation predisposes 
to further liver damage in the pathogenesis of NASH. However, it has 
recently been replaced by a more complex model in which hepatic TG 
accumulation seems to be a benign symptom of hepatic steatosis, while 
FFA and TG-derived metabolites may be the true lipotoxic agents that 
contribute to the development of NASH; and TG breakdown via metabolic 
lipases contributes to the pathogenesis and progression of NAFLD71.  
 
The classic “two-hit” hypothesis has been modified by the “multiple 
parallel hits” hypothesis to explain the development of NAFLD and the 
progression from simple steatosis to NASH72. In the “multi-hit” hypothesis, 
imbalanced lipid metabolism and insulin resistance are considered as the 
“first hit”, leading to the development of hepatic steatosis. After the 
development of steatosis, the liver becomes more vulnerable to many hits 
that may act in parallel, including gut-derived bacterial toxins, 
adipokine/cytokine imbalance, mitochondrial dysfunction, oxidative damage, 
dysregulated hepatocyte apoptosis, release of pro-fibrogenic factors and 
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pro-inflammatory mediators from impaired organelles, and hepatic stellate 
cell and Kupffer cell activation. These factors may collectively stimulate 
inflammation, apoptosis, fibrosis and finally tumour development73 (Figure 
5). Iron accumulation and genetic factors are also involved in the 
development of NASH74.  
 
 
Adapted from Int. J. Mol. Sci. 2014, 15, 6184-622373 
 
Figure 5. The Multi-hit hypothesis of NAFLD pathogenesis. The “first hit”, 
insulin resistance and lipid metabolism dysregulation, leads to the development of 
simple steatosis and hepatocytes become susceptible to “multi-hits”. 
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3. THE LIVER: a key organ in metabolic homeostasis 
 
The liver is the central organ responsible for both carbohydrate and 
lipid homeostasis. Insulin, an anabolic hormone released from pancreatic β-
cells when dietary carbohydrates or amino acids are abundant, plays an 
essential role in this process.  
 
3.1 Regulation of hepatic glucose metabolism 
 
One of the principal functions of the liver is to contribute to 
maintaining blood glucose levels. In response to increased circulating levels 
of glucose after a meal, insulin is secreted by pancreatic β-cells. The result 
of insulin signalling in the liver is: 1) reduced hepatic glucose production 
(HGP) via decreased gluconeogenesis (glucose biosynthesis) and 
glycogenolysis (glycogen breakdown), and 2) conversion into glycogen of a 
large proportion of the glucose absorbed from the small intestine taken up 
by hepatocytes. This means that the liver is a pivotal location for glucose 
uptake and storage with decreased HGP. However, when nutrient 
availability is limited and circulating glucose levels fall, the liver becomes the 
main center for glucose production and secretion, via glycogenolysis and 
gluconeogenesis activation, which are largely governed by the combined 
actions of glucagon and glucocorticoids75(Figure 6). 
 
Figure 6. The liver’s contribution 
to maintaining blood glucose 
levels. In response to elevated 
glucose levels, insulin is secreted 
from pancreatic β-cells. As a result 
of insulin signaling, the liver 
becomes a pivotal location for 
glucose uptake and storage, via 
decreasing gluconeogenesis and 
glycogenolysis with an increased 
glycogen storage. However, in 
response to low blood glucose 
levels, the liver becomes the main 
center for glucose production, via 
glycogenolysis or gluconeogenesis.  
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3.2 Regulation of hepatic lipid metabolism 
 
Because the liver is not used as a storage depot for fat, the steady 
state concentration of hepatic triglycerides is low under physiological 
conditions. Nevertheless, there is considerable trafficking of both TG and 
fatty acids (FA) into and out of the liver in response to feeding and fasting76 . 
Under feeding conditions, dietary FA are absorbed from the small 
intestine, assembled into TG and incorporated into chylomicrons (QM). 
These are secreted into lymphatics and enter the plasma as triglyceride-rich 
QM, where they mainly deliver their FA to adipose tissue (for storage) and 
muscle (for energy) by the action of lipoprotein lipase (LPL) activity, an 
endothelium-associated enzyme which catalyses the hydrolysis of 
triglyceride-rich QM releasing FA. After the delipidation of chylomicrons by 
intravascular lipolysis, they are transform into QM remnant particles, which 
are taken up by the liver after further hydrolysis by intravascular hepatic 
lipase (HL)77. In addition, in the setting of excess carbohydrates, FA are 
also newly made within the liver through de novo lipogenesis (DNL). Under 
fasting conditions, FA are released from white adipose tissue and return to 
the liver by way of plasma non-sterified fatty acids (NEFA)76. 
 
In the liver, FA derived from 
either peripheral tissue, 
endogenous synthesis, or 
diet, can then be used for 1) 
energy and ketone body 
production via mitochondrial 
β-oxidation; or 2) sterified into 
TG that can be stored as lipid droplets within hepatocytes or packaged with 
apolipoprotein B (ApoB) 100 into very low density lipoproteins (VLDL) to be 
secreted into the circulation78. Alterations in any of these processes 
therefore influence both hepatic and whole-body energy metabolism and 
may contribute to disease development (Figure 7).   
Dietary sugars
Intestine
Dietary fats
Tg
Tg QM Tg
Tg
DNL
FA
Liver
TG
NEFA 
POOL
β-oxidation
Tg
Tg VLDL Tg
Tg
Adipose
Tissue
ApoB 100
ketone
bodies
Figure 7. Hepatic lipid metabolism
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4. PATHOPHYSIOLOGICAL MECHANISMS LEADING TO 
NAFLD 
 
 
The unequivocal histological hallmark of NAFLD in both adults and 
children is steatosis, defined as the histological manifestation of 
intracytoplasmic hepatic lipid accumulation in the form of triglycerides; the 
generally accepted dogma in NAFLD pathogenesis is that TG accumulation 
occurs when hyperinsulinemia and insulin resistance, commonly 
associated with obesity and T2DM, are present74.  
In NAFLD patients, the presence of IR is common at liver, adipose tissue 
and muscle level79. 
 
Insulin signalling 
Under normal physiological conditions, insulin is released into the 
circulation from the beta cells in the islets of Langerhans in the pancreas in 
response to the ingestion of a meal. Upon binding to its receptor, insulin 
stimulates a well-described signaling cascade80 involving the 
phosphorylation, docking and translocation of a series of signaling 
molecules, ultimately leading to alterations in specific endpoints of glucose 
and lipid metabolism. In muscle and adipose tissue insulin increases 
glucose uptake by the translocation of the glucose transporter GLUT4 from 
intracellular sites to plasma membrane, and in liver inhibits hepatic glucose 
production. Insulin also stimulates cell growth and differentiation, and 
promotes the storage of substrates in adipose tissue, liver and muscle by 
stimulating lipogenesis, glycogen and protein synthesis, and inhibiting 
lipolysis, glycogenolysis and protein breakdown81. Figure 8 summarizes the 
main biological functions of insulin in glucose and lipid homeostasis. 
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Figure 8. Biological functions of insulin in glucose and lipid homeostasis. Insulin is 
produced by the pancreatic beta cells, mainly in response to postprandial hyperglycemia. The 
main insulin target tissues are skeletal muscle, adipose tissue and liver. In skeletal muscle, 
insulin promotes glucose uptake and also stimulates glycogen synthesis. In adipose tissue, 
insulin stimulates glucose uptake and lipid synthesis, and additionally represses lipolysis. In 
liver, actions of insulin are the suppression of gluconeogenesis and the promotion of glycogen 
and lipid synthesis.  
 
 
Under physiological conditions, insulin binds to the insulin receptor 
resulting in the phosphorylation of tyrosine residues on insulin receptor 
substrates (IRS), which leads the activation of phosphatidylinositol-3-OH 
kinase activation (PI3K). Activated PI3K phosphorylates membrane 
phospholipids, the major product being phosphatidylinositol-3,4,5-
trisphosphate (PIP3), which in turn activates the enzyme PIP3-dependent 
kinase 1 (PDK-1), resulting in the phosphorylation and recruitment of Akt 
(also known as protein kinase B, PKB) to the cell membrane. There are 
three members of the PKB/Akt family identified as Akt1, Akt2, and Akt3. It is 
Akt2 that is important in insulin-mediated glucose homeostasis. 
Phosphorylated Akt is thought to suppress hepatic glucose production 
through two key mechanisms: first, by phosphorylation and nuclear 
exclusion of the forkhead box protein FoxO1, resulting in the decreased 
transcription of its pro-gluconeogenic targets genes, such as glucose-6-
phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK); 
and second, by phosphorylation and inactivation of glycogen synthase 
kinase-3β (GSK-3), resulting in the dephosphorylation and activation of 
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glycogen synthase (GS). Additional targets of Akt include AKT Substrate of 
160KDa (AS160).  AS160 normally inhibits translocation of GLUT4 through 
its interaction with RabGTPase protein. However, phosphorylation of AS160 
by Akt relieves the inhibitory effect on GLUT4, facilitating glucose uptake in 
adipocytes and muscle cells by allowing the translocation of GLUT4 to the 
plasma membrane. Akt also phosphorylates and inhibits the TSC1/2 
complex (also known as tuberous sclerosis complex-1 and -2), resulting in 
the activation of the mammalian target of rapamycin (mTOR) pathway, 
which regulates protein synthesis80. On the other hand, Insulin also 
stimulates the mitogen-activated protein (MAP) kinase extracellular signal-
regulated kinase (ERK). This pathway involves the tyrosine phosphorylation 
of IRS proteins and/or SHC, which in turn interact with the adapter protein 
Grb2, recruiting the Son-of-sevenless (SOS) exchange protein to the 
plasma membrane for activation of Ras. Once activated, Ras operates as a 
molecular switch, stimulating a serine kinase cascade through the stepwise 
activation of Raf, MEK and ERK. Activated ERK can translocate into the 
nucleus, initiating a transcriptional programme that leads to cellular 
proliferation or differentiation81 (Figure 9). 
 
Figure 9. Insulin signaling pathway. 
SHC, Src Homology 2 domain. Grb2, growth factor receptor-bound protein. 
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Insulin resistance 
The insulin resistance state is defined as the pathological condition 
in which cells fail to respond to the normal actions of the hormone insulin. 
Insulin resistance occurs primarily in liver, adipose tissue and muscle, the 
main insulin target tissues.  
 
Impaired insulin signalling in liver: under IR conditions, the ability of 
insulin to stimulate liver glycogen synthesis and suppress hepatic glucose 
production is diminished, resulting in increased plasma glucose 
concentrations82 (Figure 10). 
 
 
 
 
 
 
 
 
Figure 10. Hepatic insulin resistance Reduced phosphorylation of IRS and 
PI(3)K impairs Akt2 activity by reductions in PDK1 activity. Impaired Akt2 activity 
reduces the phosphorylation of GSK3. In its active (non-phosphorylated) form, 
GSK3 catalyzes phosphorylation and inactivation of glycogen synthase (GS), thus 
reducing glycogen synthesis. Impaired Akt2 activity also reduces insulin 
suppression of hepatic gluconeogenesis by promoting FOXO1 to the nucleus due 
to reduced phosphorylation, and subsequent increasing expression of 
gluconeogenic proteins, such as glucose-6-phosphatase (G6Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK). IRS: insulin receptor substrate; 
PI(3)k: phosphatidylinositol-3-OH kinase; PDK1: 3-phosphoinositide dependent 
protein kinase 1; GSK3: glycogen synthase kinase-3β; FOXO1: forkhead box 
protein. 
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Impaired insulin signalling in adipose tissue: adipose tissue is the major 
site for storage of excess energy in form of triglycerides, and it contains 
multiple cell types, including adipocytes, preadipocytes, endothelial cells 
and immune cells. During positive energy balance, triglycerides are stored 
in the lipid droplets within the adipocytes, which are mobilized by lipolysis to 
release FFA into the circulation when energy is needed between meals or 
during physical activity. The resulting FFA are then transported to other 
tissues to be used as an energy source73. Under IR conditions, adipose 
tissue becomes resistant to the antilipolytic effect of the insulin. Insulin fails 
to inhibit the hormone-sensitive lipase, the enzyme which regulates the 
release of FFA from adipose tissue, resulting in an increased delivery of 
FFA to the liver83,84.  
 
Impaired insulin signalling in muscle: skeletal muscle insulin resistance 
typically accompanies insulin resistance at other sites. The independent 
effect of muscle insulin resistance on exacerbating NAFLD has been 
demonstrated in rodents85,86 and translated to humans, in which selective 
muscle insulin resistance in healthy young lean individuals has been shown 
to predispose them to increased hepatic de novo lipogenesis, hepatic TG 
accumulation and atherogenic dyslipidaemia after eating high-carbohydrate 
meals. This is because ingested glucose is diverted away from muscle 
glycogen storage to the liver, where it is converted to TG driven by the 
compensatory hyperinsulinemia that is secondary to muscle insulin 
resistance87. However, there is evidence that these defects in muscle insulin 
signaling can be reversed by a single 45-minute bout of exercise, resulting 
in increased postprandial muscle glycogen synthesis following carbohydrate 
ingestion, and a 40% and 30% reduction in hepatic DNL and hepatic TG 
synthesis, respectively88 (Figure 11).  
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Figure 11. Skeletal muscle 
insulin resistance.  
In insulin-sensitive subjects, insulin 
stimulates glycogen synthesis in 
both liver and muscle; however, in 
those with skeletal muscle insulin 
resistance, insulin fails to promote 
glycogen synthesis, diverting the 
substrate to the de novo 
lipogenesis. The increased lipid 
synthesis contributes to non-
alcoholic fatty liver disease 
(NAFLD).  
 
 
 
 
 
4.1 “First-hit” Imbalanced lipid metabolism and IR 
As mentioned above, in patients with NAFLD, the presence of IR is 
common not only in muscle but also in liver and adipose tissue, resulting in 
increased insulin (hyperinsulinemia) and glucose (hyperglycemia) 
circulating levels.  
High insulin levels should inhibit adipose tissue lipolysis, but this 
does not occur in these patients, due to the adipose tissue IR, thereby 
increasing FFA flux to the liver79. Moreover, as a consequence of muscle 
IR, impaired glucose uptake is observed in this tissue, contributing to 
elevated plasma glucose concentrations. Hepatic IR also contributes to 
hyperglycemia in NAFLD, due to the fact that insulin cannot suppress the 
hepatic gluconeogenesis, leading to excess glucose production. The 
pancreatic beta islet cells adapt to hyperglycemia by increasing insulin 
secretion, leading to hyperinsulinemia. Chronic elevated plasma glucose 
concentrations therefore promote an increase in hepatic DNL through two 
distinct mechanisms: 1) directly, by increasing tricarboxylic acid cycle 
activity and the synthesis of Acetyl-CoA, which acts as a substrate of DNL, 
and 2) indirectly, by activating the expression of the carbohydrate response 
element binding protein (ChREBP), which in turn promotes gene 
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De novo lipogenesisGlycogen synthesis
NAFLD
Glycogen synthesis Glycogen synthesis
UNIVERSITAT ROVIRA I VIRGILI 
DEREGULATION OF FATTY ACID METABOLISM AND CANNABINOID RECEPTORS IN LIVER OF MORBIDLY 
OBESE WOMEN WITH NON-ALCOHOLIC FATTY LIVER DISEASE. 
Alba Berlanga Bustos 
Dipòsit Legal: T 1705-2015
II. INTRODUCTION 
 
50 
 
transcription of lipogenic enzymes. Meanwhile, elevated insulin levels also 
stimulate DNL by activativating the sterol-regulatory-element-binding protein 
(SREBP1c), which in turn also promotes gene transcription of lipogenic 
enzymes79 (Figure 12). All these metabolic alterations result in ectopic lipid 
accumulation in the form of triglycerides. 
In patients with NAFLD, 26% of fatty acids in the liver have been 
demonstrated to derive from hepatic DNL, 59% from lipolysis of adipose 
tissue storage, and 15% from diet89. 
 
 
Figure 12. Systemic insulin resistance and hepatic triglyceride 
accumulation in NAFLD. Insulin resistance (IR) in adipose tissue (AT) results in 
an increased rate of lipolysis, with the consequent release of fatty acids (FA) to the 
liver. In skeletal muscle, glucose absortion decreases, while in the hepatocyte 
gluconeogenesis (GNG) and de novo lipogenesis (DNL) increase; resulting in hepatic 
triglyceride (TG) accumulation. ChREBP: carbohydrate response element binding 
protein; SREBP1c: sterol-regulatory-element-binding protein; TCA: tricarboxylic acid 
cycle. 
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When the biosynthesis of triglycerides exceeds the rate of 
secretion, TG excess accumulates into lipid droplets in the liver resulting in 
steatosis. Indeed, in NAFLD patients, TG accumulation in the cytoplasm of 
hepatocytes arises from an imbalance between lipid acquisition and 
removal: the influx of lipids, via increased fatty acid import or de novo fatty 
acid synthesis, exceeds the ability of hepatic lipid clearance by fatty acid 
oxidation or triglyceride export78,90,91 (Figure 13). This highlights the fact 
that there is no a single pathway that is universally responsible for the 
development of steatosis, and the difficulty of understanding the 
pathogenesis of NAFLD. 
 
 
Figure 13. Imbalanced hepatic lipid metabolism in NAFLD. The 
hallmark of NAFLD is triglyceride accumulation in the cytoplasm of hepatocytes 
as a result of an imbalance between lipid input and output, 1. An increase in fatty 
acids (FA) uptake derived from the circulation, due to the increased lipolysis from 
insulin resistance (IR) adipose tissue and/or from the diet in form of chylomicrons 
(QM); 2. An increase in glucose and insulin levels in response to carbohydrate 
intake that promotes de novo lipogenesis (DNL); 3. A decrease in FA 
mitochondrial β-oxidation; 4. A decrease in triglyceride (TG) hepatic secretion by 
packaging with apolipoprotein B (ApoB) into very low density lipoproteins (VLDL).  
ChREBP: carbohydrate response element binding protein; SREBP1c: sterol-
regulatory-element-binding protein 
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4.2 Progression of steatosis to NASH 
As described previously, steatosis develops once excessive 
triglycerides have been accumulated in the liver. However, to develop 
NASH, multiple pathways or “multiple hits” are required to develop 
inflammation, cellular injury, and fibrosis74. ‘Hits’ that may contribute include 
direct hepatic lipotoxicity, oxidative stress, mitochondrial dysfunction, 
hepatocyte apoptosis, hepatic stellate cell and Kupffer cell activation, 
activation of pro-fibrogenic factors and pro-inflammatory mediators, 
hormones derived from adipose tissue (adipokines), endotoxins of intestinal 
origin, iron accumulation, and genetic factors. All these mechanisms are not 
mutually exclusive, but are more likely to act in a coordinated and 
cooperative manner79. Figure 14 shows the molecular mechanisms leading 
to the formation of steatosis, as well as to the progression from steatosis to 
NASH. 
 
4.2.1 Lipotoxicity  
The current theory of lipotoxicity focuses on an increase in the flux 
of FFA within hepatocytes, which is a direct consequence of an increased 
dietary fats intake, de novo lipogenesis and adipose tissue lipolysis in the 
setting of insulin resistance and impairment of compensatory oxidative 
processes. This leads to the generation of toxic lipid FFA-derived 
metabolites, such as ceramides, diacylglycerols, lysophosphatidyl choline, 
and oxidized cholesterol metabolites, which act as reactive oxygen species 
(ROS),  causing lipotoxic hepatocellular injury manifested as endoplasmic 
reticulum stress, inflammation, apoptosis, and necrosis92. Triglyceride 
accumulation may therefore actually be a protective response to prevent 
lipotoxicity from free fatty acid-derived metabolites. 
 
4.2.2 Oxidative stress  
 
Oxidative stress is a condition due to an altered balance between 
the production of reactive oxygen species (ROS) and the antioxidant 
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defenses capacity. FA catabolism in liver takes place mainly via 
mitochondrial β-oxidation. If there is an excessive overload of FFA, this 
process can lead to the generation of ROS in the mitochondrial chain which 
act upon the fatty acids of the cell membranes, causing lipid peroxidation. 
Once the mitochondria are exhausted or their function is impaired, FFA are 
then metabolized at other sites of hepatocyte, including the endoplasmic 
reticulum (ω-oxidation) and perixosomes (β-oxidation), also leading to the 
generation of ROS93,94. These cytotoxic ROS and lipid peroxidation 
products can diffuse into extracellular space, affecting Kupffer cells and 
hepatic stellate cells (HSC). This cellular oxidative stress from hepatocytes 
and the direct uptake of FFA or free cholesterol in Kupffer cells induces the 
activation of nuclear transcription factors such as NF-kβ, which regulates 
the synthesis of several pro-inflammatory cytokines, such as: a) tumour 
necrosis factor alpha (TNFα), which activates the caspase pathway and 
leads to hepatocyte apoptosis; b) transforming growth factor beta-1 
(TGFβ1), which activates collagen synthesis due to HSC; c) the Fas ligand 
that cause ‘fratricide deaths’ between adjacent hepatocytes; and d) 
interleukin 8 (IL8), a powerful neutrophil chemotactic95. Furthermore, the 
end-products of lipid peroxidation, such as 4-hydroxynonenal and 
malondialdehyde, are also involved in the pathogenesis of liver damage. 
These molecules exert a chemotactic action on neutrophils, and may 
activate HSC and nonparenchymal cells of the liver and synthesis of the 
extracellular matrix, which increase the production and deposition of fibrous 
tissue96. 
 
4.2.3 Adipokines 
 
Obesity, which is often associated with IR, is seen as a chronic 
systemic low grade of inflammation, in which adipose tissue has a central 
role97,98. Adipose tissue, and particularly white adipose tissue (WAT), has 
been recognized as an active endocrine organ that communicates with 
other tissues by secreting different soluble factors that are called adipokines 
(including chemokines, cytokines and hormones)99. Both an increased 
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release of free fatty acids from WAT and a dysregulated adipokine 
secretion, characterized by increased pro-inflammatory and decreased anti-
inflammatory adipokine secretion, are observed in the obese state73. Many 
of these pro-inflammatory adipokines have been reported as promoting 
insulin resistance100–102, leading to enhanced delivery of FFA to the liver, 
and thence to hepatic steatosis. Moreover, these molecules may cause 
direct damage to the liver or act indirectly by increasing oxidative stress, 
liver fibrosis, and tumor development by activating the oncogenic factor 
STAT372. Clinical studies suggest that the expression of adipokines can 
vary in patients with NAFLD/NASH compared to healthy controls. In 
particular, serum levels of pro-inflammatory adipokines such as leptin, 
resistin, visfatin, TNFα and interleukin 6 (IL6) are significantly higher in 
NAFLD/NASH patients, while levels of insulin-sensitizing adipokines with 
anti-inflammatory properties, such as adiponectin, are significantly 
reduced103. Although adipose tissue secretes the majority of adipokines, 
they are also produced by other organs. In this regard, in human liver 
biopsies, hepatic adiponectin receptor mRNA increased in biopsy-proven 
NASH104. By contrast, Kaser S et al. found low mRNA expression of 
adiponectin and adiponectin receptor 2 (ADIPOR2) in the liver of patients 
with NASH compared to those with simple steatosis, and ADIPOR2 
expression was inversely related to alanine aminotransferase and the 
fibrosis stage105. More recently, Moschen et al. demonstrated in a 
prospective study that rapid weight loss after bariatric surgery results in a 
significant improvement of both histological and biochemical liver 
parameters, accompanied by an increase of adiponectin serum levels, as 
well as hepatic mRNA adiponectin expression106. Hepatic TNFα and TNFα 
receptor I (TNFRI) expression was increased in patients with NASH 
compared with an obese group of similar age without NASH. In these 
patients, more advanced fibrosis was also accompanied by increased 
hepatic expression of TNFα107. As for IL6, Wieckowska et al. demonstrated 
a marked increase in hepatic IL6 expression in NASH patients compared to 
those with simple steatosis or a normal liver, and its expression positively 
correlated with the degree of inflammation, stage of fibrosis and IR108. In 
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another study, weight loss resulted in a dramatic decrease in IL6 expression 
in liver109. Recently, Chuan Shen et al. have demonstrated that hepatic 
resistin overexpression in NASH patients is associated with the severity of 
liver inflammation and fibrosis110. Finally, our research group has recently 
found that serum and hepatic visfatin to be higher in morbidly obese women 
with NAFLD than in those with normal liver histology111. 
 
4.2.4 Gut microbiota 
A number of recent reviews have highlighted the importance of gut 
microbiota, which is now also considered a metabolic organ, in the 
pathogenesis of metabolic and inflammatory diseases such as obesity, 
T2DM and NAFLD112–116. Aron-Wisnewsky et al.117 summarized the 
influence of gut microbiota in stimulating fat deposition and promoting 
NASH through 5 mechanisms: 1) it promotes obesity by improving the 
energy yield from food; 2) it regulates gut permeability, low-grade 
inflammation and immune balance; 3) it modulates dietary choline 
metabolism; 4) it regulates bile acid metabolism; 5) it increases endogenous 
ethanol production by bacteria. All these factors are molecular mechanisms 
by which microbiota can induce NAFLD and its progression.  
Bacterial overgrowth and increased intestinal permeability, characterized by 
disruption of the intracellular tight junctions, have been observed in patients 
with NAFLD118. When the tight junction is impaired, intestinal permeability 
increases, leading to the delivery of gut-derived bacterial products such as 
endotoxin (lipopolysacharides, LPS) to the liver via the portal vein. Ruiz et 
al. demonstrated that plasma endotoxin levels were elevated in fatty liver 
patients, which were further increased in individuals with NASH, and were 
associated with a rise in TNFα gene expression in the hepatic tissue119. 
Moreover, Zhu et al. found an increased abundance of alcohol production in 
the microbiota of NASH patients, as well as elevated blood-ethanol 
concentrations, leading to increased oxidative stress and liver inflammation 
due to alcohol metabolism120. In addition, ethanol also contributes to 
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functional and morphological damage to the small bowel, increasing its 
permeability to endotoxins derived from the intestinal lumen118.  
 
4.2.5 Iron accumulation 
Some studies have shown that increased hepatic iron concentration 
in patients with NAFLD is associated with IR and may therefore indirectly 
contribute to disease progression121,122. Ferritin levels reflect total body iron 
stores, and as such raised levels indicate iron overload. Studies suggest 
that ferritin can act as a cytokine to induce the release of further tissue 
cytokines and activate Kupffer and stellate cells, thereby exacerbating 
fibrosis123. However, despite the observation of correlations between serum 
ferritin levels and the presence of NASH124–126, the importance of raised 
ferritin in NASH and the role of iron as a source of oxidative stress remain 
unresolved127.  
 
4.2.6 Genetic factors 
Genome-wide association studies (GWAS) have suggested that 
patatin-like phospholipase domain-containing protein 3 (PNPLA3), also 
known as adiponutrin, is a genetic factor responsible for a higher 
prevalence of NAFLD and contributes to its development and 
progression128–130. PNPLA3 encodes a protein that is highly expressed in 
the liver and is involved in the metabolism of triglycerides. A single 
nucleotide polymorphism (rs738409) of PNPLA3 has been associated with 
the hepatic fat content, the progression of fibrosis131–133 and with an 
increased risk of HCC in patients with NAFLD/NASH134.  
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Figure 14. Molecular mechanisms involved in NAFLD development and 
progression. The mechanisms involved in steatosis formation via increased 
hepatic triglyceride content are shown in blue, and include insulin resistance and 
obesity, increased sugar and fats intake, increased de novo lipogenesis, 
increased free fatty acid flux from adipose tissue to the liver, impaired VLDV 
secretion, and decreased β-oxidation due to mitochondrial damage (especially in 
the presence of NASH). The multiple hits involved in the progression from 
steatosis to NASH are in green, and include lipotoxicity, hepatocellular oxidative 
stress secondary to ROS formation during β- and ω-oxidation of fatty acids, role 
of adipokines, role of iron accumulation, role of microbiota, and genetic factors. 
AT: adipose tissue; DNL: de novo lipogenesis; ECM: extracellular matrix; ER: 
endoplasmic reticulum; FA: fatty acids; FFA: free fatty acids; HEP: hepatocyte; 
HSC: hepatic stellate cells; IL: interleukin; IR: insulin resistance; KC: Kupffer 
cells; Mit: mitochondrial; NASH: non-alcoholic steatohepatitis; ROS: reactive 
oxygen species; TG: triglycerides; TGFβ: transforming growth factor beta-1; 
TNFα: tumour necrosis factor alpha; VLDL: very low density lipoprotein 
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5. DISSOCIATION BETWEEN IR AND NAFLD 
 
In the previous sections, we have seen that NAFLD is strongly 
associated with insulin resistance, not only at the level of the liver, but also 
at muscle and adipose tissue level. However, whether NAFLD is a 
consequence or a cause of IR is a matter of debate. 
 
5.1 NAFLD as a consequence of insulin resistance 
Insulin exerts its action by binding to the extracellular portion of the 
insulin receptor, and triggers a cascade of intracellular signaling events 
involving three critical nodes which are sequential phosphorylation and 
activation of insulin receptor substrates, PI(3)K and Akt80. In normal liver, 
intact insulin signaling inhibits glucose production and promotes fatty acid 
synthesis81. Multiple animal models support a direct causal relationship 
between insulin resistance, hyperinsulinemia, and hepatic steatosis135,136. 
Evidence that insulin resistance causes steatosis in humans comes from 
patients with Akt2 mutations137, who showed strong resistance to the 
glucoregulatory actions of insulin when suffering from this pathological 
condition, but presumably retained sensitivity to the lipogenic effects of the 
hormone. In fact, hyperinsulinemia activates the transcriptional factor 
SREBP1c, promoting lipogenic enzyme gene expression in spite of insulin 
resistance138. These data support the theory that insulin sensitivity 
contributes to hepatosteatosis, but how does insulin resistance contribute to 
a vicious cycle that exacerbates this condition? To resolve this paradox, 
Brown and Goldstein formulated the concept of “selective insulin 
resistance”139. This proposes that, although the insulin-mediated 
suppression of hepatic gluconeogenesis is blunted due to disruption of 
some aspects of insulin signaling in the liver, other insulin signaling 
mechanisms remain intact and continue to drive hepatic lipogenesis. Li S, et 
al. suggested that the mammalian target of rapamycin complex 1 
(mTORC1) is such a bifurcation point of the insulin signaling that lies 
downstream of Akt140. The inhibition of mTORC1 in rats blocked the insulin-
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induced upregulation of lipogenic genes expression, but it did not affect the 
insulin-mediated suppression of gluconeogenic genes expression. These 
results establish mTORC1 as an essential component in the insulin- 
regulated pathway for hepatic lipogenesis but not gluconeogenesis, and 
may help to resolve the paradox of selective insulin resistance in livers of 
diabetic rodents140. However, an alternative explanation for the concomitant 
elevation of gluconeogenesis and lipogenesis in human type 2 diabetes or 
models of IR is that lipogenic and gluconeogenic enzymes are both target 
genes of ChREBP induced by hyperglycemia (See section 6.2.3). 
 
5.2 NAFLD as a cause of insulin resistance 
The coincident occurrence of hepatic steatosis and IR has led to the 
hypothesis that excess triglyceride in liver causes insulin resistance. 
However, this hypothesis is contradicted by observations in mice with 
defects in diverse pathways that cause hepatic steatosis without the 
development of IR135,141. 
Samuel, V.T et al. demonstrated the induction of NAFLD in rats, 
which after just 3 days of being fed a high-fat diet, developed hepatic 
steatosis and IR, with no changes in body weight, adiposity or IR in skeletal 
muscle142. Interestingly, an increase in the FFA-derived metabolite 
diacylglycerol (DAG) was observed in the liver of these animals. The 
relationship between hepatic accumulation of DAG and IR could be 
attributable to the activation of protein kinase-Cε (PKCε), highly expressed 
in the liver. These changes were associated with reductions in the 
phosphorylation of the insulin receptor and the Akt2 activity. In this model, 
the activity of insulin to induce glycogen synthesis and inhibit 
gluconeogenesis is therefore diminished due to DAG-mediated activation of 
PKCε (Figure 15). PKCε is a novel isoform of the PKC family with a much 
higher affinity for DAG than the conventional PKC isoforms143. The crucial 
role of PKCε in mediating lipid-induced hepatic IR has been convincingly 
demonstrated in a study in which antisense oligonucleotides were used in 
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rats to knockdown the hepatic expression of PKCε144. The authors were 
able to show that knocking down PKCε expression in the liver protected rats 
from lipid-induced hepatic IR, despite increases in hepatic lipid content. In 
addition, they found that PKCε activation caused hepatic IR by directly 
binding to and inhibiting insulin receptor kinase activity. These results were 
replicated in PKCε knockout mice, which were protected from IR induced by 
high-fat feeding145. Moreover, the interaction between DAG, PKCε activation 
and hepatic RI has been demonstrated in numerous other rodent models of 
NAFLD-associated hepatic IR146. 
This model for lipid-induced hepatic IR has also been translated to 
humans. Kumashiro et al. evaluated the possible mechanisms involved in 
hepatic IR in a group of patients with morbid obesity and NAFLD. In these 
patients, hepatic DAG content and PKCε activation were the strongest 
predictors of IR in liver147. However, they found no association between 
insulin sensitivity and other factors involved in the development of hepatic 
IR, such as ceramides, endoplasmic reticulum (ER) stress markers or 
inflammatory cytokines. These results were replicated in another study, in 
which the content of DAG in liver was also the best predictor of hepatic IR in 
obese humans, whereas no association with the content of ceramides or 
markers of inflammation was found148. In fact, it has been suggested that 
liver inflammation is a consequence rather than a cause of insulin 
resistance149. 
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Figure 15. Mechanism of DAG-PKCε-mediated hepatic insulin 
resistance71. Membrane-near intracellular DAG lead to activation of PKCε, which 
in turn inhibits the insulin receptor kinase. This then leads to decreased insulin-
stimulated tyrosine phosphorylation of IRS-1 and -2, PI(3)K activation and 
downstream insulin signaling. The net result is a decrease in hepatic glycogen 
synthesis, resulting from decreased activation of glycogen synthase (GS), and 
increased hepatic gluconeogenesis through reduced inactivation of forkhead box 
protein O (FOXO1). DAG: diacylglycerol; PKCε: protein kinase-Cε; IRS: insulin 
receptor substrate; PI(3)k: phosphatidylinositol-3-OH kinase; PDK1: 3-
phosphoinositide dependent protein kinase 1; GSK3: glycogen synthase kinase-3β; 
G6Pase: glucose-6-phosphatase;PEPCK: phosphoenolpyruvate carboxykinase. 
 
The model described, which explains the relationship between DAG, 
PKCε and hepatic IR, focuses mainly on the inability of insulin to alter 
hepatic glucose metabolism. However, the ability of insulin to activate 
lipogenesis appears to be intact in most NAFLD models. It is well 
established that it is possible to experimentally induce insulin resistance 
without NAFLD, or induce NAFLD without insulin resistance under certain 
conditions82. ChREBP and SREBP1c have recently been independently 
implicated in dissociating NAFLD and IR in mice and humans150,151. To 
explain this paradox, Cantley et al. examined the subcellular localization of 
DAG in liver cells, and observed that the knockdown of the gene encoding 
CGI -58, an activator of adipose tissue triglyceride lipase (ATGL) involved in 
the hydrolysis of TG, promotes DAG accumulation in lipid droplets, 
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protecting against DAG accumulation in the cell membrane and the 
subsequent translocation of PKCε152. These results suggest that 
compartmentalization of DAG in hepatocytes could be an important factor in 
the pathogenesis of hepatic IR. Indeed, the compartmentalization of DAG 
and TG in neutral compartments, where it cannot activate PKCε, may 
explain why hepatic DAG content may not always correlate with hepatic 
insulin resistance in some animal models. Figure 16 summarizes the 
metabolic pathways leading to hepatic DAG accumulation. 
 
 
Figure 16. Metabolic pathways leading to hepatic DAG accumulation71. 
The glycerol 3-phosphate (Glycerol 3P) pathway represents the de novo 
lipogenesis route in the synthesis of triglycerides (TG) and phospholipids. 
Glycerol-3-phosphate acyltransferase (GPAT) catalyzes the acylation of 
glycerol 3P with acyl-coenzyme A (Acyl-CoA) to generate lysophosphatidic 
acid (LPA), which is thought to be the rate-controlling step in TG synthesis. 
The enzymes acyl-glycerol-phosphate acyl transferase (AGPAT), 
phosphatidic acid phosphatase (PAP) and diacylglycerol acyltransferase 
(DGAT) then catalyze the formation of phosphatidic acid (PA), diacylglycerol 
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(DAG) and TG, respectively. LPA and PA require translocation through the 
cytosol for TG synthesis at the endoplasmic reticulum (ER) if they are not 
synthesized in the ER. In the liver, TG are either deposited in intracellular 
vacuoles or exported in particles of very low density lipoproteins (VLDL). In 
the lipid droplets, the conversion from TG to diacylglycerol (DAG) is mediated 
by adipose triglyceride lipase (ATGL) during lipolysis, and then DAG can be 
hydrolyzed to monoacylglycerol (MAG) by hormone-sensitive lipase (HSL) 
and subsequently to glycerol by monoglyceride lipase (MGL); which can be 
used as a substrate for gluconeogenesis. These reactions also release fatty 
acids (FA). Phospholipase C can release DAG from membrane lipids. DAG 
activates protein kinase-Cε (PKCε) membrane translocation, which in turn, 
inhibits the insulin receptor kinase. However, whether DAG derived from 
phospholipase C pathway and lipid droplets can lead to PKCε activation and 
hepatic insulin resistance remains to be determined. 
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6. MECHANISMS OF HEPATIC FAT ACCUMULATION IN 
NAFLD 
 
Steatohepatitis develops in only a fraction of patients with NAFLD, 
while the majority only present simple steatosis. Lipid accumulation thus 
appears to be a prerequisite for the development of NASH, and the early 
and crucial step in NAFLD manifestation. It is therefore important to 
understand the events that lead to initial lipid accumulation in the liver. 
Figure 15 shows the transcriptional regulation of mechanisms leading to 
hepatic lipid accumulation. 
 
6.1 Hepatic fatty acid uptake and transport 
Free fatty acids in the plasma can be taken up by the liver, and are 
important sources for hepatic TG synthesis. Plasma FFA is normally 
generated by white adipocytes via lipolysis, which is induced by beta 
adrenergic receptor agonists such as catecholamine under fasting 
conditions83. This process involves the regulation of protein kinase A (PKA)-
dependent phosphorylation and activation of hormone-sensitive lipase 
(HSL), a key rate-limiting enzyme in the lipolysis, to promote this pathway. 
This pathway is reversed by insulin under feeding conditions, limiting the 
liberation of FFA and instead inducing de novo lipogenesis in this tissue. 
However, the IR state goes along with increased adipocyte lipolysis, leading 
to abundant FFA in the plasma pool regardless of the nutritional status153. 
Studies in humans have shown that uptake of exogenous FFA is the single 
largest source of FA in stored hepatic TG, and that this contribution is 
further increased with fasting and NAFLD89,154. Moreover, increased visceral 
fat content is correlated with hepatic TG content155,156 and has been 
implicated in NAFLD etiology. Meanwhile, clearance of the chylomicron-
remnant TG also contributes to the hepatic FA pool.  
The rate of FA uptake from plasma into cells depends on the FA 
concentration in the plasma and the hepatocellular capacity for FA uptake, 
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which also depends on the number and activity of transporter proteins in the 
sinusoidal plasma membrane of the hepatocyte. The main plasma 
membrane transporters for FFA are FA transporter protein (FATP), 
caveolins, FA translocase (FAT/CD36), and FA-binding protein (FABP)78. 
Six FATP isoforms have been identified in mammalian cells, which contain 
a common motif for FA uptake and fatty acyl-CoA synthetase function157. Of 
these isoforms, FATP2 and FATP5 are highly expressed in the liver, and 
are utilized as major FATPs for the normal physiological context. Hepatic 
FA uptake is decreased in mice lacking FATP2 or FATP5 in the liver158,159. 
In humans, a promoter polymorphism in the liver-specific FATP5 is 
associated with features of the metabolic syndrome and steatosis160. 
Caveolins consist of three protein family members termed caveolins 1, 2, 
and 3, and are found in the membrane structures called caveolae, which are 
important for protein trafficking and the formation of lipid droplets. Caveolin-
1 knockout mice exhibited lower TG accumulation in the liver161. Some 
authors suggest that there is an involvement of caveolin-1 in abnormal 
lipogenesis and mitochondrial function typical of steatotic hepatocytes in 
NAFLD162. FAT/CD36 is a transmembrane protein that accelerates FA 
uptake via facilitated diffusion163. Its hepatic expression is normally weak, 
but its expression is enhanced in rodents with fatty liver164. Moreover, some 
authors have demonstrated that FAT/CD36 mRNA levels increase 
concomitantly with hepatic TG content in different animal models of liver 
steatosis165,166. Further studies have shown that FAT/CD36 is a common 
target gene of the liver X receptor, pregnane X receptor, and peroxisome-
proliferator-activated receptor γ in promoting hepatic steatosis in a murine 
model167. However, little is known about the significance of FAT/CD36 in 
human liver diseases. In morbidly obese patients with NAFLD, Greco et al. 
showed that hepatic FAT/CD36 mRNA levels were positively related to liver 
fat content168 and Bechmann et al. found a significant correlation between 
hepatic FAT/CD36 mRNA and apoptosis in patients with NASH169. Other 
authors have reported that hepatic FAT/CD36 upregulation is significantly 
associated with IR, hyperinsulinemia, and increased steatosis in patients 
with NASH170. FABPs are cytosolic lipid binding proteins that facilitate the 
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intracellular transport of FFA163. The functions of FABPs include 
enhancement of FFA solubility and transport to specific enzymes and 
cellular compartments (to the mitochondria and peroxisomes for oxidation; 
to the endoplasmic reticulum for reesterification; into lipid droplets for 
storage; or to the nucleus for gene expression regulation)171. Few studies 
have assessed the involvement of hepatic FABP4 expression in NAFLD. 
For instance, Greco et al. has described FABP4 as being upregulated in 
subjects with high liver fat content168. Moreover, the expression of FABP4 
and FABP5 in the liver has been correlated with hepatic fatty infiltration in 
NAFLD patients172. 
Peroxisome-proliferator-activated receptor γ (PPARγ) is the master 
transcriptional regulator in the control of genes involved in lipogenic 
pathways of adipocytes, promoting the uptake of fatty acid and adipocyte 
differentiation (adipogenesis). PPARγ also confers sensitization to insulin 
through the transcriptional activation of adiponectin gene in adipocytes, up-
regulating its expression173. The net effect of this process is to increase 
triglyceride storage in adipose tissue, reducing delivery of fatty acids to the 
liver. Despite PPARγ is present in the liver to a lesser degree than in 
adipose tissue, increased PPARγ expression is a feature of steatotic liver. 
Several studies attribute a casual role to PPARγ in liver triglyceride 
accumulation by mechanisms involving activation of lipogenic genes and de 
novo lipogenesis173–177, suggesting a pro-steatotic role of hepatic PPARγ. In 
contrast to these studies, which show a deleterious effect of PPARγ on 
NAFLD, other studies have shown PPARγ to have anti-inflammatory and 
anti-fibrotic effects in stellate cells, macrophages, and endothelial cells 
(Review in Tailleaux et al.177). Westerbacka and Paulina Pettinelli et al. 
have described that PPARγ as being over-expressed in the fatty liver of 
obese human subjects172,178. 
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6.2 De novo synthesis of fatty acids 
As described above, the non-esterified fatty acids that are 
incorporated into triglycerides within the liver may be derived from the 
plasma or may be newly synthesized from glucose by de novo lipogenesis. 
Dysregulation of DNL is observed in patients with obesity, metabolic 
syndrome or NAFLD.  
 
DNL is an integrated pathway that consist of glycolysis (conversion 
of glucose to acetyl-CoA), biosynthesis of saturated fatty acid followed by 
desaturation, and the formation of TG. Key rate limiting enzymes in the 
process include glucokinase (GK) and L-pyruvate kinase (L-PK) in the 
glycolysis, acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) in 
the fatty acid synthesis, long chain fatty acid elongase 6 (ELOVL6) and 
stearoyl-CoA desaturase 1 (SCD1) in the formation of monounsaturated 
fatty acids, and glycerol-3-phosphate acyltransferase (GPAT), lipins, and 
acyl-CoA:diacylglycerol acyltransferase (DGAT) in the formation of TG163.  
During DNL, glucose is converted to acetyl-CoA, and it is then converted to 
malonyl-CoA by ACC1. FAS catalyzes the formation of palmitic acid from 
malonyl-CoA and acetyl-CoA. Palmitic acid is then elongated and 
desaturated by ELOVL6 and SCD1 to generate monounsaturated fatty 
acids, which are the major fatty acid constituents of triglycerides. GPAT 
then catalyzes the esterification of glycerol-3-phosphate from glycolysis with 
the newly synthesized fatty acid to generate lysophosphatidic acids. 
Lysophosphatidic acids are substrates for GPAT to catalyze the formation of 
phosphatidic acids. Phosphatidic acids are then processed to 
diacylglycerols by lipin 1, followed by the formation of triglycerides through 
DGAT76 (Figure 17). 
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Postic C et al. J Clin Invest. 200890. 
Figure 17. Metabolic pathways leading to the synthesis of TGs in liver. The synthesis of 
TGs in liver is nutritionally regulated. The ingestion of a LF/HC diet causes a marked induction 
of enzymes involved in key metabolic pathways, including (i) glucokinase (GK) and L-PK for 
glycolysis; (ii) ATP citrate lyase, ACC, and FAS for lipogenesis; (iii) ELOVL6 and SCD1 for fatty 
acid elongation and desaturation steps; and finally (iv) GPAT and DGAT for TG synthesis. 
Under these nutritional conditions, elevation in malonyl-CoA concentrations, the product of the 
lipogenic enzyme ACC, inhibits L–CPT I, the rate-limiting enzyme of β-oxidation (v), which 
regulates the transfer of long-chain acyl-CoAs from the cytosol into the mitochondria, thus 
resulting in a shift from an oxidative (production of ketone bodies) to an esterification pathway 
(TG synthesis). F6P, fructose 6-phosphate; F1, 6P2, fructose 1,6 diphosphate; G3P, glycerol 
3-phosphate; G6P, glucose 6-phosphatase; PEP, phosphoenol pyruvate; LCFA, long-chain 
fatty acids; CPT II, carnitine palmitoyltransferase II. 
 
 
The rate of DNL is regulated primarily at the transcriptional level 
(Figure 18). Several nuclear transcription factors such as liver X receptor 
alpha (LxRα), SREBP1c, ChREBP, and farnesoid X receptor (FxR) are 
involved. Chronic hyperinsulinemia and hyperglycemia, as found in NAFLD, 
promote DNL through the upregulation of lipogenic transcription factors. In 
humans, NAFLD has been associated with increased hepatic expression of 
several genes involved in de novo lipogenesis179,180. Moreover, a recent 
study has confirmed that increased de novo lipogenesis is a distinct 
characteristic of subjects with NAFLD181. 
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6.2.1 LxRs 
LxRs are ligand-activated transcription factors that belong to the 
nuclear receptor superfamily. There are two LxR isoforms termed α and β. 
LxRα is mainly expressed in the liver, adipose tissue, and intestine, 
whereas LxRβ is ubiquitously expressed. In addition to modulating choles-
terol metabolism, LxRs have been characterized as major regulators of 
hepatic FA biosynthesis.  A major function of LxRα in the liver is the 
stimulation of de novo lipogenesis, through the direct transcriptional 
activation of lipogenic enzymes, such as ACC and FAS, but also indirectly 
via the insulin-mediated transcriptional activation of SREBP1c182,183 (Figure 
18). Several authors have described an enhanced expression of LxRα and 
SREBP1c in NAFLD180,184–187. More recently, Sang Bong Ahn et al. have 
demonstrated that LxRα expression is positively correlated with the degree 
of hepatic fat deposition, as well as with hepatic inflammation and fibrosis in 
NAFLD patients; suggesting that it could be an attractive target for the 
treatment and regulation of hepatic inflammation and fibrosis188.  
 
6.2.2 SREBP1c 
SREBPs are a family of membrane-bound transcription factors that 
are synthesized as precursors embedded in the endoplasmatic reticulum. A 
proteolytic cleavage then allows the accumulation of mature SREBP in the 
nucleus. There are different SREBP isoforms: SREBP1c and SREBP2 that 
are expressed in the liver, and SREBP1a expressed only at very low levels 
in the liver of adult mice, rats, and humans. SREBP1c is the predominant 
isoform in the liver and preferentially affects the transcription of genes that 
regulate DNL. However, SREBP2 regulates genes involved in cholesterol 
biosynthesis and metabolism. SREBP1a isoform, despite its very low levels 
in the liver, transactivates both lipogenic and cholesterol genes78,189. To 
date, the main regulation demonstrated for SREBP1c is at the 
transcriptional level. SREBP1c transcription is induced by two quite 
disparate stimuli: insulin, released in response to carbohydrate intake and 
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leading to a parallel increase in both the membrane-bound precursor and 
the mature nuclear form, and by LxRα. In response to feeding, SREBP1c 
promotes the expression of lipogenic genes, including ACC and FAS, the 
two rate-limiting enzymes in de novo FA synthesis, thereby stimulating 
DNL190–192 (Figure 18). 
Various authors have described an enhanced expression of 
SREBP1c and LxRα in NAFLD180,184–187. However, Nagaya et al. 
demonstrated the downregulation of the hepatic SREBP1c-mediated 
lipogenic pathway in advanced NASH patients; SREBP1c mRNA levels 
were inversely correlated with the fibrosis stage193. These discrepancies 
might be explained by differences in the cohort of patients studied. For 
example, Higuchi et al. included normal weight patients with NAFLD184 and 
Lima-Cabello et al. included patients with NAFLD and with steatosis related 
to chronic hepatitis C virus infection in mildly overweight men and 
women185. Moreover, Higuchi et al. did not evaluate either histological 
findings nor protein levels or intracellular localization of SREBP1c184. 
 
6.2.3 ChREBP 
ChREBP is a glucose-responsive transcription factor that relocates 
to the nucleus in response to increased glucose concentrations. It was first 
identified as a regulator for hepatic glycolysis by activating transcription of 
the L-PK gene, but in recent years, ChREBP has also been reported as 
playing an important role in glucose-mediated lipogenesis within the liver194. 
Interestingly, ChREBP has also been identified as a direct target of LXRs, 
an important regulator of the lipogenic pathway through the transcriptional 
control of SREBP1c and lipogenic enzymes195. Although oxysterols are 
known ligands of LXRs, glucose has been shown to activate LXRs and to 
induce their target genes, including ChREBP196 (Figure 18).  
Postprandial hyperglycemia raises the hepatic concentrations of 
phosphorylated intermediates, causing activation of ChREBP, which binds 
to the promoter of its target genes. ChREBP target genes include not only 
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enzymes of glycolysis and lipogenesis that predispose to hepatic steatosis, 
but also glucose 6-phosphatase (G6Pase), which catalyzes the final 
reaction in glucose production, and glucokinase regulatory protein (GCKR), 
which inhibits hepatic glucose uptake197,198. Transcriptional induction of 
G6PC and GCKR manifests as hepatic glucose intolerance or IR199.   
Study results of the role and impact of ChREBP in glucose and lipid 
metabolism have been contradictory, with global ChREBP deficiency 
resulting in IR in one murin model200 vs. improved hepatic steatosis and 
other related metabolic alterations, including IR201–203. Benhamed et al. 
hypothesized that these opposite phenotypes in these murine models may 
be due to the fact that ChREBP controls both glycolysis and lipogenesis, 
and that the beneficial effect of ChREBP deficiency may only be apparent in 
the context of lipid overload151. The authors showed that, on a standard diet, 
mice overexpressing ChREBP remained insulin sensitive, despite increased 
lipogenesis resulting in hepatic steatosis. However, mice that overexpress 
ChREBP, on a high-fat diet, showed normal insulin levels and improved 
insulin signaling and glucose tolerance compared to the controls, despite 
having greater hepatic steatosis. This effect seems to be mediated by the 
fact that ChREBP modifies the monounsaturated FA/saturated FA 
(MUFA/SFA) balance in favor of MUFA, by stimulating SCD1 activity. Taken 
together, these results show that increasing ChREBP, by buffering 
detrimental FA and favoring lipid partitioning, can dissociate hepatic 
steatosis from IR, with beneficial effects on both glucose and lipid 
metabolism. Interestingly, ChREBP expression in liver biopsies from 
patients with NASH was higher when steatosis was greater than 50% and 
lower in the presence of severe IR151, supporting this conclusion. 
6.2.4 FxR 
The FxR is a member of the nuclear hormone receptor superfamily 
and a receptor for bile acids. It is mainly expressed in the liver, intestine, 
kidneys, and the adrenal glands, with less expression in adipose tissue and 
the heart204. FxR has emerged as a master regulator of both lipid and 
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glucose homeostasis in the liver, as well as of inflammatory processes at 
hepatic and extrahepatic sites. Moreover, it has been demonstrated in 
mouse models that FxR needs to be activated in order to reduce the 
expression of SREBP1c205 .  
FxR knockout mice exhibited severe fatty liver accompanied by 
elevated circulating levels of FFA, elevated glucose levels and impaired 
IR206. The activation of the nuclear receptor FxR also improved 
hyperglycemia and hyperlipidemia in diabetic mice207. These results 
suggest a key role for FxR in lipid and glucose metabolism. In addition, a 
number of synthetic FxR agonists have been used in the treatment of 
different hepatic and metabolic disorders, resulting in a lower inflammatory 
and fibrogenic process208. For instance, treatment of obese db/db (diabetic) 
mice with a dual agonist for FxR and TGR5 (Takeda G-protein couples 
receptor 5; a bile acid receptor) improved the histological features of NASH, 
and increased the number of intrahepatic monocytes with an anti-
inflammatory phenotype209. Moreover, Obeticholic acid (OCA) is an specific 
FxR agonist that does not activate other nuclear hormone receptors, and 
beneficially controls liver inflammation in an NF-Kβ-dependent 
manner210,211. The first controlled clinical trial demonstrating the efficacy and 
safety of an OCA FxR receptor agonist in patients with T2DM and NAFLD 
has been published recently212. In the light of the positive results on insulin 
sensitivity and markers of liver fibrosis, the National Institute of Health 
initiated a Phase IIb clinical study with this agent in patients with NASH (the 
FLINT study), comparing placebo and 25mg OCA dialy for 72 weeks 
(http://www.clinicaltrials.gov; NCT01265498). Analysis showed that 
treatment with OCA resulted in a highly statistically significant improvement 
in the primary histological end point, defined as a decrease in the NAFLD 
Activity Score of at least two points with no worsening of fibrosis, compared 
to the placebo. Another hepatic protective mechanism of FxR activation has 
been shown to be maintenance of gut integrity against gut-derived 
endotoxins through the induction of antibacterial factors such as angiogenin, 
inducible nitric oxide (NO) synthase, and interleukin-18 (IL18)213. 
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Regarding the role of FxR in lipid metabolism, the majority of 
literature seems to point to the fact that FxR activation is beneficial in 
situations of excess, such as obesity and diabetes. FxR activation seems to 
reduce TG levels by: 1) reducing FA synthesis in the liver, through the 
reduction of SREBP1c and LxR expression; 2) inducing the expression of 
PPARα, which promotes FFA catabolism via β-oxidation; 3) increasing TG 
clearance; and 4) increasing adipose tissue storage and altering adipokine 
patterns204. Patients with NAFLD have lower protein and mRNA FxR levels, 
which has been attributed to higher TG synthesis and induced expression of 
SREBP1c and LxRα214. 
6.2.5 Lipogenic enzymes 
FAS and ACC, the two rate-limiting enzymes in fatty acid 
biosynthesis, are currently considered an attractive target for regulating the 
human diseases of obesity, diabetes, cancer, and cardiovascular 
complications78. Two isoforms of ACC exist, with each one differing in its 
physiological function. ACC1 is primarily cytosolic and produces malonyl-
CoA that is largely used as a substrate by FAS for DNL. In contrast, ACC2 
is localized on the mitochondria and produces a local pool of malonyl-CoA. 
Malonyl-CoA resulting from de novo lipogenesis activation inhibits carnitine 
palmitoyl-transferse 1 (CPT1)215. Dorn et al. found that FAS mRNA 
expression was significantly higher in steatotic human livers samples than in 
normal liver tissue216. In accordance with Dorn et al., several authors have 
not only described an enhanced hepatic expression of FAS in NAFLD, but 
also of ACC1184–186. Moreover, in evidence supporting increased FA 
synthesis in NAFLD, Morgan et al. found that ACC1 and FAS mRNA 
expression were significantly higher in high-fat mice217.  
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6.3 Fatty acid oxidation  
The steady state of hepatic triglycerides is also controlled by 
consumption of fatty acids by oxidation. FA can be catabolized through 3 
distinct pathways of oxidation: α, ω, and β. ω-oxidation occurs exclusively in 
microsomes and α- and β-oxidation can occur in both peroxisomes and 
mitochondria. Mitochondrial β-oxidation is the primary catabolic pathway in 
the liver for most FA, but perixosomal β-oxidation is largely responsible for 
the initial oxidation of very long-chain FA (>20)215. 
 
Fatty acid β-oxidation in mitochondria is a process shortening the 
FA into acetyl-CoA, which can subsequently be converted into keton bodies 
or can be incorporated into the  tricarboxylic acid (TCA) cycle for the full 
oxidation163. To initiate the process, FA are activated by acyl-CoA-
synthetase to acyl-CoA in the cytosol to enable fatty acids to cross 
membranes. While short- and medium-chain FA pass the mitochondrial 
membrane without activation, activated long-chain fatty acids need to be 
transported across the membrane in a carnitine-dependent manner218. Fatty 
acyl-CoAs are converted to fatty acyl-carnitines by CPT1 in the outer mito-
chondrial membrane for the translocation into the intermembrane space. 
Fatty acyl-carnitines are then transported across the inner mitochondrial 
membrane by carnitine acylcarnitine translocase. Carnitine palmitoyl-
transferase 2 (CPT2), which is expressed on the inner mitochondrial 
membrane, converts fatty acyl-carnitines back to acyl-CoAs for fatty acid β-
oxidation inside the mitochondrial matrix163 (Figure 17).  
 
In the postprandial state, β-oxidation in the liver is suppressed. This 
occurs in part due to the antilipolytic effect of insulin on white adipose 
tissue, which reduces the flux of non-esterified fatty acids to the liver, and in 
part due to the direct control by glucose and insulin over the rate of fatty 
acid entry into the mitochondria219. As described previously, insulin 
facilitates DNL through the upregulation and activation of SREBP1c and 
induction of ACC. Malonyl-CoA produced by ACC activity inhibits the activity 
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of CPT1 (Figure 17), and thereby decreases the rate of β-oxidation by 
reducing fatty acid entry to mitochondria. Under fasting conditions, glucagon 
promotes fatty acid oxidation. Glucagon signaling activates AMP-activated 
protein kinase (AMPK), which in turn inactivates ACC1 and ACC2 by 
phosphorylation, resulting in the blockade of the synthesis of malonyl-
CoA220. Kohjima et al. showed that CPT1 expression in humans is reduced 
by 50% in NAFLD compared with levels in the normal liver221. 
 
6.3.1 PPARα 
peroxisome-proliferator-activated receptor α (PPARα) is a ligand-
activated transcription factor belonging to the NR1C nuclear receptor 
superfamily. Besides PPARα, the PPAR subfamily contains two other 
isotypes encoded by PPARδ (NR1C2) and PPARγ (NR1C3) genes222. 
PPARs form heterodimers with the retinoid X receptor (RXR), and activate 
transcription by binding to a specific DNA element, termed the perixosome 
proliferator response element (PPRE), in the regulatory region of genes 
encoding proteins that are involved in lipid metabolism and energy 
balance223. Binding agonists within the ligand-binding site of PPARs cause 
a conformational change, resulting in the transcriptional activation of their 
target genes. PPARα ligands are FA derivates formed during lipolysis, de 
novo lipogenesis or FA catabolism222. Activated PPARα promotes the 
expression of genes involved in perixosomal and mitochondrial β-oxidation, 
FA transport and hepatic glucose metabolism, with the latter being rodent-
specific224. In addition, PPARα negatively regulates pro-inflammatory and 
acute phase response signaling pathways, as seen in rodent models of 
systemic inflammation, atherosclerosis and NASH222,225. 
Studies in NAFLD patients have yielded mixed results in terms of 
alterations in rates of fatty acid oxidation. Impaired adenosisne triphosphate 
(ATP) production has been described in patients with NAFLD and insulin 
resistance226,227, while others have reported evidence for increased rates of 
fatty acid oxidation in NAFLD228,229. Interestingly, Francque S et al. have 
found that liver PPARα gene expression negatively correlates with NASH 
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severity, visceral adiposity and insulin resistance and positively with 
adiponectin. The histological improvement is associated with an increase in 
expression of PPARα and its target genes230. PPARα agonists may 
therefore potentially be useful in the management of NAFLD. Animal 
models have revealed that the administration of PPARα agonists not only 
prevents the development of steatohepatitis, but also reverses hepatic 
fibrosis by decreasing the expression of fibrotic markers and reducing the 
number of hepatic stellate cells231,232.  
 
Like PPARα, some studies have demonstrated a role in FA 
oxidation and inflammation for peroxisome-proliferator-activated receptor δ 
(PPARδ). Nagasawa et al. demonstrated that the administration of the 
PPARδ agonist GW501516 to mice with steatohepatitis decreased fat 
storage in liver mainly by activating the genes involved in FA oxidation, as 
well as reducing inflammatory gene expression233. Moreover, activation of 
PPARδ not only improved fatty acid oxidation in the liver of obese diabetic 
mice, but also suppressed de novo lipogenesis and glucose production234. 
Interestingly, animal models have also shown that PPARδ agonists were 
also able to improve hepatic inflammation by suppression of pro-
inflammatory cytokines synthesis235 and provided protection from liver 
fibrosis236. A dual PPARα/δ agonist was recently tested in animal models of 
NASH/NAFLD, resulting in improvement of steatosis, inflammation and 
fibrosis237. This agonist (GFT505) has already been tested in humans and 
initial studies in IR patients have shown that GFT505 improves hepatic and 
peripheral I sensitivity, liver function tests and systemic inflammation238,239 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
DEREGULATION OF FATTY ACID METABOLISM AND CANNABINOID RECEPTORS IN LIVER OF MORBIDLY 
OBESE WOMEN WITH NON-ALCOHOLIC FATTY LIVER DISEASE. 
Alba Berlanga Bustos 
Dipòsit Legal: T 1705-2015
II. INTRODUCTION 
 
77 
 
6.4 Triglyceride secretion 
The liver secretes triglycerides in the form of VLDL particles for 
delivery to peripheral tissues, including skeletal and cardiac muscle, and 
adipose tissue. VLDL consists of hydrophobic core lipids containing TG and 
cholesterol esters, which are covered by hydrophilic phospholipids and 
ApoB 10076. ApoB 100 is a liver-specific ApoB that is critical in VLDL as-
sembly, while apoB 48 in the intestine is associated with chylomicron 
formation. The VLDL assembly process initially occurs in the rough of ER 
during the translation and translocation of the ApoB 100 across the ER 
membrane, resulting in the formation of a partially lipidated ApoB 100, 
termed nascent VLDL. Nascent VLDL particles are then transported from 
ER to the Golgi for maduration, where they are lipidated by the activity of 
microsomal triglyceride transfer protein (MTP), and subsequently released 
from the liver via exocytosis240. The VLDL secretion rate depends not only 
on the availability of hepatic triglycerides, but also on the overall capacity for 
VLDL assembly. When the triglyceride availability is reduced, lipid-free 
apoB 100 is degraded by both proteasomal and non-proteasomal 
pathways241. Insulin is critical in the regulation of VLDL assembly. In 
response to postprandial insulin release, hepatic VLDL production is 
suppressed to limit plasma triglyceride excursion, by degradation of apoB 
100 and inhibition of MTP transcription241,242.  
 
Impaired VLDL assembly and secretion result in excessive lipid 
accumulation in the liver. Indeed, hepatic steatosis has been reported in 
subjects carrying mutations in apoB 100 (hypobetalipoproteinemia) and in 
MTP (abetalipoproteinemia)243. Moreover, ApoB 100 secretion is not 
increased in NAFLD, suggesting that ApoB 100 production limits the liver’s 
capacity to export hepatic triglycerides244,245. In this respect, prolonged 
exposure of the liver to non-esterified fatty acids, such as that occurring in 
the obesity and insulin resistance state, would promote excessive ER stress 
and other oxidative stress in the liver, leading to the degradation of ApoB 
100, thereby decreasing triglyceride secretion and worsening steatosis76,246. 
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Figure 18. Transcriptional regulation of mechanisms leading to TG 
accumulation in liver Fatty acid uptake: fatty acid transport protein (FATP) 
2, FATP5 and fatty acid translocase (CD36) mediate transport of non-
esterified fatty acids (NEFA) across the plasma membrane. Once taken up 
into cytosol, fatty acids (FA) are activated to form acyl-CoA. Fatty acid 
binding proteins (FABP) facilitate intracellular transport of FA. De novo 
lipogenesis: the conversion of glucose into FA through de novo lipogenesis 
is nutritionally regulated by glucose and insulin signalling pathways. Insulin 
activates the transcription factor sterol-regulatory-element-binding protein 
(SREBP1c), which is under the control of liver X receptor alpha (LxRα), 
while glucose activates the transcription factor carbohydrate response 
element binding protein (ChREBP), thereby stimulating the transcriptional 
activation of lipogenic enzymes, such as acetyl-CoA carboxylase 1 (ACC1) 
and fatty acis synthase (FAS), the two rate-limiting enzymes in the 
biosynthesis of FA. Interestingly, ChREBP has also been identified as a 
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direct target of LxRs, and glucose has been shown to activate LxRs and to 
induce their target genes, including ChREBP. Peroxisome-proliferator-
activated receptor γ (PPARγ) plays a role in promoting FA uptake into 
adipocytes, adipocyte differentiation, as well as in increasing insulin 
sensitivity through the transcriptional activation of adiponectin gene in 
adipocytes, resulting in a reduced delivery of FA to the liver. Meanwhile, 
several studies attribute a casual role of PPARγ in steatosis devolpment by 
activation of de novo lipogenesis. Fatty acid oxidation: acyl-CoAs are 
transported into mitochondria across the outer mitochondrial membrane 
(OMM) and inner mitochondrial membrane (IMM) by the activities of 
carnitine palmitoyl-transferase (CPT) 1, CPT2 and carnitine acylcarnitine 
translocase (CACT). Within mitochondria, acyl-CoAs are oxidized to form 
acetyl-CoA. Malonyl-CoA resulting from de novo lipogenesis inhibits the 
activity of CPT1, and thereby decreases the rate of β-oxidation by reducing 
fatty acid entry to the mitochondria. Activated peroxisome-proliferator-
activated receptor α (PPARα) promotes the expression of genes involved in 
mitochondrial β-oxidation. Hepatic farnesoid x receptor (FxR) activation 
inhibits FA synthesis by suppressing LxRα activation, and induces the 
expression of PPARα, which promotes mitochondrial FA β-oxidation. Some 
animal models have demonstrated a role for peroxisome-proliferator-
activated receptor δ (PPARδ) in decreased fat storage in the liver mainly by 
activating the genes involved in FA oxidation. Triglyceride secretion: 
triglycerides (TG) are packaged together with apolipoprotein B (ApoB) 100 
into very low density lipoprotein (VLDL) in the endoplasmic reticulum by the 
activity of microsomal triglyceride transfer protein (MTP) and released from 
the liver. Insulin inhibits VLDL assembly, degrading ApoB 100 and inhibiting 
the transcription of MTP. 
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7. THE ROLE OF ENDOCANNABINOID SYSTEM IN NAFLD  
 
 
The endocannabinoid system mainly consists of cannabinoid 
receptors type 1 (CB1) and type 2 (CB2), their endogenous ligands, known 
as endocannabinoids (EC), and the enzymes dedicated to EC biosynthesis 
and degradation247. It has been reported that the EC system plays an 
important role in NAFLD by modulating lipid metabolism248. In particular, 
CB1 and CB2 receptors in hepatocytes are increasingly being recognized 
as key mediators of fatty liver by regulating the expression of key enzymes 
of lipid synthesis and transport249,250. As said at the beginning of the 
introduction section, modulation of cannabinoid receptors is currently 
emerging as a potential novel therapeutic approach for management of 
NAFLD251.  
EC mimic the pharmacological actions of the psychoactive principle 
of marijuana, Δ9-tetrahydrocannabinol (Δ9-THC). They are endogenous 
lipid-signaling molecules, and are implicated in different physiological and 
pathological functions (regulation of food intake, immunomodulation, 
inflammation, analgesia, cancer, addictive behavior, epilepsy and others). 
The two most extensively studied endocannabinoids are 
arachidonoylethanolamine (anandamide or AEA) and 2-
arachidonoylglycerol (2-AG)252. Anandamide exhibits a higher affinity for 
CB1 than CB2 receptors, and 2-AG binds to CB1 and CB2 with similar 
affinities253,254. Both anandamide and 2-AG are synthesized from membrane 
phospholipid precursors, via parallel pathways involving phospholipase D 
for anandamide and diacylglycerol lipase for 2-AG255. It occurs “on demand” 
and they are released from cells immediately after production to activate the 
cannabinoid receptor to elicit a biological response, after which they are 
inactivated through reuptake247. The catabolism of 2-AG is catalysed by 
monoacyglycerol lipase (MAGL) and that of anadamide by fatty acid amide 
hydrolase (FAAH)255. 
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The cannabinoid receptors are membrane G-protein coupled 
receptors, first discovered as molecular targets of Δ9-THC. These receptors 
are involved in the physiological modulation various functions of the central 
nervous system (CNS) and various peripheral tissues after activation by 
their endogenous agonists. CB1 receptors are mainly expressed in CNS, 
but they are also located in liver and other peripheral tissues 
(gastrointestinal tract, pancreas, skeletal muscle, adipose tissue, heart and 
reproductive system). Meanwhile, CB2 receptors are primarily expressed in 
cells of the hematopoietic and immune system. However, the presence of 
CB2 have been also described in the brain and in peripheral tissues such as 
pancreas and liver253,254. Under physiological conditions, the EC system is 
silent, since CB1 and CB2 receptors are faintly expressed. By contrast, 
induction of CB receptors and/or increased levels of EC are common 
features of liver injuries of diverse origins. In particular, CB1 receptors are 
upregulated in hepatocytes, hepatic myofibroblasts and endothelial cells, 
whereas CB2 receptors are induced in Kupffer cells and hepatic 
myofibroblasts, but are not expressed by hepatocytes. During liver 
pathology, EC levels are increased with varying patterns depending on the 
nature of the liver insult, with anandamide produced mainly by Kupffer cells, 
and 2-AG by hepatic stellate cells and hepatocytes253. Table 5 provides a 
comparison between the two types of receptors and their role in fatty liver 
disease. 
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Table 5. Comparison between CB1 and CB2 receptors 
 
Saudi J Gastroenterol 2013;19:144-51247 
 
Several items of experimental evidence and clinical trials support 
the role of both CB1 and CB2 receptors in fatty liver disease 
 
7.1 Role of CB1 receptor in NAFLD 
CB1-mediated EC tone is enhanced in experimental diet-induced or 
genetic models of NAFLD, and is characterized by the upregulation of 
adipose tissue and hepatocyte CB1 receptors, and by increased liver 
synthesis of anandamide. The pathogenic role of CB1 receptors in NAFLD 
is supported by the resistance to steatosis of obese mice with a global or 
hepatocyte-specific CB1 deletion, and of rodents administered CB1 
antagonists256–258. Other studies further indicate that the steatogenic 
 CB1 CB2 
 
Distribution 
 
Throughout the body, 
highest density in the CNS 
 
Cells of the immune 
system 
Expression in 
normal liver 
Faint Faint/absent 
Expression in 
liver pathology 
Hepatocytes, endothelial 
cells, hepatic myofibroblast 
Kupffer cells, hepatic 
myofibroblasts 
Main roles Mood, appetite, emesis 
control, memory, spatial 
coordination muscle tone 
and analgesia 
Immune-modulatory,  
anti-inflammatory, 
pain, bone loss 
Role in fatty liver 
and MetS 
liver steatosis, food 
intake/body weight, insulin 
resistance, lipogenesis, 
splanchnic, vasodilation 
Inflammation,  
fibrogenesis 
Role in liver 
fibrosis 
Profibrogenic Antifibrogenic 
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properties of CB1 arise from altered hepatic lipid metabolism, consisting of 
a combination of hepatocyte activation of SREBP1c-mediated lipogenesis, 
the reduction of FA oxidation via inhibition of AMP kinase, and reduced 
release of TG-rich VLDL256,257,259,260.  In addition, the adipose tissue may 
largely contribute to the steatogenic process via the CB1-induced release of 
FFA by adipocytes261,262 (Figure 19).   
A potential impact of CB1 receptors on the inflammatory response 
associated with NASH has been suggested by experiments in obese rats 
showing that the CB1 antagonist Rimonabant reduces liver inflammation258. 
In addition, fat CB1 receptors reduce the production of adiponectin, an 
adipokine which reduces hepatic inflammation257,258. Chanda et al. 
demonstrated a novel mechanism of action of activated CB1 receptor 
signaling to induce hepatic gluconeogenesis in primary rat and human 
hepatocytes; this suggests a role for CB1 receptors activation in regulating 
the hepatic glucose metabolism263. With regard to fibrosis, hepatic CB1 
receptors have shown profibrogenic effects in NASH animal models. In 
these models, antagonism or blockade of CB1 receptors reduces 
fibrogenesis compared to control animals264,265. Finally, activation of CB1 
receptors has been also associated with liver regeneration, as well as with 
cardiovascular alterations associated with advanced cirrhosis266,267. 
In humans, enhanced EC tone has been reported in obese patients 
prone to developing fatty liver disease and metabolic syndrome. In several 
studies, obese individuals displayed higher serum levels of EC than lean 
individuals. There was a strong association between high plasma EC levels 
and visceral obesity, high TG, low high‑density lipoprotein (HDL) 
cholesterol, and IR in obese as well as T2DM patients268,269. More recently, 
a positive correlation between liver fat content and the arterial and hepatic 
venous concentrations of 2-AG has been reported, indicating that the 
human fatty liver takes up 2‑AG and overproduces TG containing saturated 
fatty acids, which might reflect increased de novo lipogenesis248. Clinical 
trials with Rimonabant in overweight and obese populations have shown 
UNIVERSITAT ROVIRA I VIRGILI 
DEREGULATION OF FATTY ACID METABOLISM AND CANNABINOID RECEPTORS IN LIVER OF MORBIDLY 
OBESE WOMEN WITH NON-ALCOHOLIC FATTY LIVER DISEASE. 
Alba Berlanga Bustos 
Dipòsit Legal: T 1705-2015
II. INTRODUCTION 
 
84 
 
clear benefits for weight reduction, abdominal obesity, liver steatosis and 
the improvement of other cardiometaboilc syndrome parameters, including 
improved insulin sensitivity, elevated plasma adiponectin and HDL 
cholesterol, and reduced plasma TG and low‑density lipoprotein (LDL) 
cholesterol levels270–276. However, the marketing approval for Rimonabant 
has been withdrawn by the European Regulatory Authorities due to the fact 
that this drug increases the incidence of psychiatric disorders: depression, 
anxiety, irritability, and aggression277,278. For this reason, in recent years, 
research in this area has focused on the development of compounds - 
either antagonists or inverse agonists - which do not cross the blood-brain 
barrier, and which block peripheral CB1 receptors279,280. 
 
Figure 19. Mechanisms of CB1 
involved in hepatic lipid 
accumulation.  
The activation of CB1 receptors in 
adipose tissue promotes lipoprotein 
lipase (LPL) activity, which results in 
an increased release of fatty acids 
(FA) into the liver. The activation of 
hepatic CB1 receptors contributes to 
liver fat accumulation by: 1. 
Increased de novo lipogenesis, 
inducing the expression of 
transcription factor SREBP1c and its 
target key enzymes such as ACC1 
and FAS; 2. Decreased fatty acid β-
oxidation; 3. Reduced secretion of 
triglycerides (TG) in the form of very 
low density lipoprotein (VLDL) 
particles.  
 
 
7.2 Role of CB2 receptor in NAFLD 
Unlike CB1 receptors, the role of CB2 receptors in the development 
of fatty liver is still under‑investigated. The potential role of CB2 in the 
pathogenesis of fatty liver has been supported by the finding that, in 
wild‑type (WT) mice fed with a high‑fat diet for 6 weeks, the administration 
De novo lipogenesis:
+ SREBP1c
+ ACC1 and FAS
TG
 β-oxidation
FA
-
FACB1
Dietary
fats
CPT1-
LPL
TG, VLDL
FA
+
VLDL-
TG
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of JWH‑133 (CB2 agonist) enhanced liver TG accumulation, IR and 
potentiated fat inflammation281. In contrast, genetic and pharmacological 
inactivation of CB2 receptors decreased adipose tissue macrophage 
infiltration, protected mice from both age‑related and diet‑induced IR282. In 
human studies, CB2 receptors are expressed in all liver samples from 
patients with steatosis and steatohepatitis283. Taken together, these results 
suggest that CB2 receptors have a potential role in liver steatogenesis and 
fat inflammatory response associated with insulin resistance. 
The role of CB2 receptors in fibrogenesis has not been 
well‑characterized. However, there is some evidence of a potential 
anti‑fibrogenic role of CB2 activation. Selective activation of hepatic CB2 
receptors significantly reduced hepatic collagen content in rats with 
pre‑existing cirrhosis and enhanced regenerative response to acute liver 
injury284. Furthermore, CB2–/– mice had enhanced response to fibrogenic 
stimuli and delayed liver regeneration in response to carbon tetrachloride 
CCl4‑induced injury285. However, treatment with a CB2 agonist, JWH‑133, 
in CCl4-treated WT mice reduced the injury and accelerated liver 
regeneration285. Moreover, in liver biopsy specimens from patients with 
active cirrhosis of various etiologies, CB2 receptors were highly 
up‑regulated in cirrhotic liver, and predominantly in hepatic fibrogenic cells. 
By contrast, they were not detected in normal human liver. Their activation 
triggered potent antifibrogenic effects – namely growth inhibition and 
apoptosis286. 
All these data support the hypothesis that an enhanced CB1 tone 
promotes liver fibrogenesis and cardiovascular alterations associated with 
cirrhosis, and contributes to the pathogenesis of NAFLD. However, 
upregulated CB2 signaling displays hepatoprotective effects, reducing liver 
inflammation, and improving liver fibrogenesis. Consequently, antagonism 
of CB1 and agonism of CB2 receptors have been identified as promising 
therapeutic strategies for the management of liver diseases78
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The work carried out in this doctoral thesis has focused on one of 
the main research lines of the GEMMAIR (Grup d'Estudi de Malalties 
Metabòliques i Insulin Resistència) Research Group. GEMMAIR has a track 
record of over 25 years’ experience in the study of liver and metabolic 
chronic diseases, and more than 15 years in the study of pathophysiology of 
obesity and its associated metabolic diseases.  
 
 
Due to the fact that: 
 
 NAFLD is an universal disorder which is now considered the most 
common liver disease in the western world 
 
 NAFLD not only affects the adult population, but also children 
 NAFLD can progress slowly from simple steatosis to non-alcoholic 
steatohepatitis, and subsequently to hepatic fibrosis, cirrhosis and 
hepatocellular carcinoma 
 
 NASH-related cirrhosis and hepatocellular carcinoma will be the major 
health care problem and the leading indication of liver transplantation 
in the near future 
 
 Most patients with NAFLD remain asymptomatic until they develop 
cirrhosis 
 
 There is no specific test that can predict the progression of simple 
steatosis to non-alcoholic steatohepatitis 
 
 Hepatic biopsy, an invasive diagnostic test, is still the gold standard for 
determining the staging and grading of NAFLD  
 
 There are currently no effective therapies for NAFLD apart from 
lifestyle modification, aimed at weight loss 
 
 
 
 
 
the study of pathophysiological mechanisms involved in the development 
and progression of NAFLD is of particular interest in order to develop 
therapeutic and preventive therapies.   
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The majority of the literature seems to point to the fact that lipid 
accumulation in the cytoplasm of hepatocytes seems to be the hallmark of 
NAFLD, and is the early and crucial step in NAFLD development. For this 
reason, an improved understanding of the underlying mechanisms leading 
to the initial lipid accumulation in the liver could be of great interest for 
controlling the progression of NAFLD. It has also been reported that the EC 
system, mediated mainly by CB1 and CB2 cannabinoid receptors, plays an 
important role in NAFLD pathogenesis by modulating lipid metabolism.  
 
We therefore hypothesized that in patients with NAFLD, the 
expression of genes and transcription factors involved in the regulation of 
hepatic fatty acid metabolism, as well as the expression of cannabinoid 
receptors could be altered; and this alteration may be related to the onset of 
liver damage. As a result, the main objectives of this thesis/study were to 
investigate the fatty acid metabolism in liver of morbidly obese (MO) women 
with NAFLD, and to study the association of cannabinoid receptors with the 
disease. To that end, six specific objectives were proposed: 
 
Study 1- Hepatic lipid metabolism 
1.1 To evaluate the hepatic mRNA expression of some key genes 
involved in the de novo synthesis of fatty acids (LxRα, SREBP1c, 
ACC1, FAS), fatty acid uptake and transport (PPARγ, CD36, 
FABP4), fatty acid oxidation (PPARα) and, finally, inflammation-
related genes (IL6, TNFα, CRP, PPARδ) of MO women according 
to their liver pathology (normal liver, NL; simple steatosis, SS; 
steatohepatitis, NASH). 
 
1.2 To assess the relationship between the expression of the genes 
studied and the presence of hepatic fat accumulation, classifying 
the SS group into different histological degrees: mild, moderate or 
severe SS. 
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1.3 To analyse the protein expression of the genes differentially 
expressed between each group of study by western blot analysis. 
 
1.4 To asses the relationship between the genes differentially 
expressed in each group of study and glucose metabolism 
parameters. 
 
Study 2- Cannabinoid receptors 
2.1 To evaluate the gene expression profiles of cannabinoid receptors 
(CB1 and CB2) in the liver of MO women according to their liver 
pathology. 
 
2.2 To asses the relationship between CB1 and CB2 gene expression 
and genes related to de novo synthesis of fatty acids (ChREBP, 
SREBP1c, LxRߙ, FxR, ACC1, and FAS), fatty acid oxidation 
(PPARߙ), fatty acid uptake and transport (PPARߛ, CD36, and 
FABP4), inflammation (IL6, TNFα, CRP, PPARδ), and adipokines 
(adiponectin and resistin) expression in the liver of MO women. 
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Abstract: Lipid accumulation in the human liver seems to be a crucial mechanism in the 
pathogenesis and the progression of non-alcoholic fatty liver disease (NAFLD). We aimed 
to evaluate gene expression of different fatty acid (FA) metabolism-related genes in 
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morbidly obese (MO) women with NAFLD. Liver expression of key genes related to de novo 
FA synthesis (LXRα, SREBP1c, ACC1, FAS), FA uptake and transport (PPARγ, CD36, 
FABP4), FA oxidation (PPARα), and inflammation (IL6, TNFα, CRP, PPARδ) were 
assessed by RT-qPCR in 127 MO women with normal liver histology (NL, n = 13),  
simple steatosis (SS, n = 47) and non-alcoholic steatohepatitis (NASH, n = 67). Liver FAS 
mRNA expression was significantly higher in MO NAFLD women with both SS and 
NASH compared to those with NL (p = 0.003, p = 0.010, respectively). Hepatic IL6 and 
TNFα mRNA expression was higher in NASH than in SS subjects (p = 0.033, p = 0.050, 
respectively). Interestingly, LXRα, ACC1 and FAS expression had an inverse relation with 
the grade of steatosis. These results were confirmed by western blot analysis. In conclusion, 
our results indicate that lipogenesis seems to be downregulated in advanced stages of SS, 
suggesting that, in this type of extreme obesity, the deregulation of the lipogenic pathway 
might be associated with the severity of steatosis. 
Keywords: insulin resistance; morbid obesity; fatty acid metabolism; non-alcoholic fatty 
liver disease; simple steatosis; non-alcoholic steatohepatitis 
 
1. Introduction 
Non-alcoholic fatty liver disease is characterized by an accumulation of triglycerides (TG) in 
hepatocytes and has frequently been associated with obesity, type 2 diabetes mellitus, hyperlipidemia, 
and insulin resistance (IR) [1]. NAFLD is an increasingly recognized condition associated with 
increased cardiovascular and liver-related mortality [2,3]. The pathogenesis of NAFLD has been 
interpreted by the “double-hit” hypothesis, comprising lipid accumulation as the primary insult or 
“first hit” in the liver [4,5], followed by a “second hit” in which proinflammatory mediators induce 
inflammation, hepatocellular injury and fibrosis [6]. Recently, however, some studies have shown that 
while hepatic TG accumulation seems to be a benign symptom of hepatic steatosis, fatty acid (FA) 
metabolites contribute to the progression of NAFLD to NASH. IR promotes the recruitment of free 
FAs from the serum pool as well as intrahepatic fatty acid accumulation, which induces apoptosis and 
the formation of reactive oxygen species (ROS). FAs themselves also promote hepatic insulin 
resistance via Toll-like receptor 4 (TLR4) activation that increases the release of inflammatory 
biomediators such as IL6, IL1β, and the TNFα receptor [7], indicating a vicious cycle of lipid 
accumulation, and IR as a crucial mechanism in the pathogenesis of NASH, among other mechanisms. 
In this regard, some authors have suggested a “multiple parallel hits hypothesis” to explain the 
pathophysiology of NAFLD [8,9]. 
Lipid accumulation in the human liver seems to be a crucial mechanism in NAFLD 
pathophysiology, so its regulatory mechanisms need to be understood in order to control the 
progression of NAFLD. It is known that hyperinsulinemia promotes de novo synthesis of fatty acids 
from glucose and increases free FA flux to the liver due to peripheral IR through the sterol regulatory 
element-binding protein-1c (SREBP1c) and inhibits fatty acid oxidation through the nuclear receptor 
peroxisome proliferators-activated receptor-α (PPARα). Then, insulin signalling and nuclear receptors 
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(including PPARs and LXRα) regulate both hepatic fatty acid and glucose metabolism. Both pathways 
are closely interrelated and share common regulatory elements and indistinguishably contribute to 
NAFLD [10]. Regarding that, some authors have described overexpression of genes involved in FA 
partitioning and binding, lipolysis and inflammation in the human fatty liver [11–15]. In addition,  
more recently, Ahn et al. found that LXRα expression correlated with the degree of hepatic fat 
deposition, as well as with hepatic inflammation and fibrosis in NAFLD patients [16]. 
In a previous study we demonstrated that lipogenesis and FA oxidation were downregulated in 
subcutaneous adipose tissue (SAT) samples from morbidly obese women, suggesting that SAT works 
to limit any further development of fat mass [17]. Based on that data, we wished to further investigate 
the fatty acid metabolism in the liver of MO women with NAFLD by evaluating the expression of 
some key genes involved in de novo synthesis of fatty acids (LXRα, SREBP1c, ACC1, FAS),  
fatty acid uptake and transport (PPARγ, CD36, FABP4), fatty acid oxidation (PPARα) and, finally, 
inflammation related genes (IL6, TNFα, CRP, PPARδ). Furthermore, as the lipid accumulation in the 
cytoplasm of hepatocytes seems to be the hallmark of NAFLD, we assessed the relationship between 
the expression of these genes and the presence of hepatic fat accumulation in this cohort. 
2. Results 
2.1. Baseline Characteristics of Subjects 
The cohort of morbidly obese women was classified according to the liver pathology into normal 
liver (NL), simple steatosis (SS) and non-alcoholic steatohepatitis (NASH) (Table 1). Age and 
anthropometrical measurements were not significantly different between the three morbidly obese 
groups. However, insulin and HbA1c levels were significantly higher in both SS and NASH groups 
than in the NL group. Glucose levels were significantly higher in SS and tended to be higher in NASH 
(p = 0.05), compared with the NL group. Also, IL6 levels were significantly higher in NASH than in 
the NL group. Our results indicated that ALT and ALP activity was higher in both SS and NASH 
groups than in obese women with normal liver histology. Furthermore, AST levels tended to be higher 
in SS (p = 0.05) and were significantly higher in NASH, compared with the NL group. 
Table 1. Anthropometric and metabolic variables of the study cohort classified according 
to the liver pathology. 
Variables 
NL (n = 13) SS (n = 47) NASH (n = 67) 
Mean ± SEM Mean ± SEM p-Value 1 Mean ± SEM p-Value 1 p-Value 2 
Age (years) 44.5 ± 3.2 47.7 ± 1.5 n.s 47.1 ± 1.3 n.s n.s 
Weight (kg) 122.9 ± 4.3 121.6 ± 2.4 n.s 119.4 ± 1.8 n.s n.s 
WC (cm) 131.5 ± 6.2 128.7 ± 1.6 n.s 130.8 ± 1.7 n.s n.s 
BMI (kg/m2) 49.1 ± 1.9 48.3 ± 1.1 n.s 46.5 ± 0.5 n.s n.s 
Glucose (mg/dL) 100.8 ± 6.8 128.1 ± 6.2 0.026 128.8 ± 6.0 0.05 n.s 
Insulin (mUI/L) 13.7 ± 2.6 20.4 ± 1.7 0.048 23.4 ± 3.1 0.04 n.s 
HbA1c (%) 5.1 ± 0.3 6 ± 0.3 0.031 6.3 ± 0.2 0.028 n.s 
HOMA2-IR 2.1 ± 0.5 2.7 ± 0.2 n.s 2.9 ± 0.5 n.s n.s 
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Table 1. Cont. 
Variables 
NL (n = 13) SS (n = 47) NASH (n = 67) 
Mean ± SEM Mean ± SEM p-Value 1 Mean ± SEM p-Value 1 p-Value 2 
HDL-C (mg/dL) 43.3 ± 2.6 39.4 ± 1.8 n.s 39.6 ± 1 n.s n.s 
LDL-C (mg/dL) 96 ± 6.9 99.7 ± 4.3 n.s 100.7 ± 3.7 n.s n.s 
Triglycerides 
(mg/dL) 
142.7 ± 13 197.2 ± 15 n.s 156.6 ± 7.9 n.s n.s 
AST (U/L) 25.6 ± 4 45.6 ± 5.3 0.05 43.2 ± 3.5 0.042 n.s 
ALT (U/L) 24.6 ± 2.4 44.3 ± 4.6 <0.001 43.2 ± 3.3 <0.001 n.s 
GGT (U/L) 23.3 ± 6.9 28.6 ± 3.2 n.s 36.2 ± 5.2 n.s n.s 
ALP (U/L) 57.8 ± 3.2 68.3 ± 2.4 0.028 71.4 ± 2.6 0.032 n.s 
Adipo/Cytokine Circulating Levels 
HMW adiponectin 
(µg/mL) 
3.8 ± 1.7 3.3 ± 0.7 n.s 3 ± 0.4 n.s n.s 
IL6 (pg/mL) 2.1 ± 0.3 2.7 ± 0.5 n.s 3.3 ± 0.5 0.031 n.s 
TNFRI (ng/mL) 2.8 ± 0.3 3.1 ± 0.2 n.s 3 ± 0.2 n.s n.s 
TNFRII ng/mL 4.2 ± 0.7 5.2 ± 0.5 n.s 5.7 ± 0.4 n.s n.s 
CRP (mg/dL) 2.2 ± 2.1 1.4 ± 0.3 n.s 3 ± 0.8 n.s 0.046 
FABP4 (ng/mL) 56.8 ± 16.9 62.6 ± 4.6 n.s 56.4 ± 5.1 n.s n.s 
NL, morbidly obese subjects with normal liver; SS, morbidly obese subjects with simple steatosis;  
NASH, morbidly obese subjects with steatohepatitis; ALT, alanine aminotransferase; ALP, alkaline 
phosphatase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C reactive protein; FABP4, 
fatty acid binding protein 4; GGT, gamma-glutamyltransferase; HbA1c, glycosylated haemoglobin; HDL-C, 
high density lipoprotein cholesterol; HOMA2-IR, homeostatic model assessment 2-insulin resistance;  
IL6, interleukin 6; LDL-C, low density lipoprotein cholesterol; TNFRI and II, tumour necrosis factor receptor 
I and II; WC, waist circumference. ANOVA test was used to compare the gene expression in the different 
groups. p-Value 1 indicates significant differences respect NL group (p < 0.05); p-Value 2 indicates 
significant differences respect SS group (p < 0.05). n.s indicates no significant differences. Data are 
expressed as mean ± SEM. 
2.2. Evaluation of the Expression of Genes Related to Lipid Metabolism and Inflammation in Liver and 
Their Protein Expression 
We analysed liver expression, in our cohort of morbidly obese women, of some key genes related to 
the de novo synthesis of fatty acids (LXRα, SREBP1c, ACC1, FAS), fatty acid (FA) uptake and 
transport (PPARγ, CD36, FABP4), FA oxidation (PPARα), and related to inflammation (IL6, TNFα, 
CRP, PPARδ). 
We first classified the whole cohort into NL, SS, and NASH (Table 2). The results indicate that 
among the key genes related to the novo fatty acid synthesis, only FAS mRNA expression was 
significantly higher in MO NAFLD women with both SS and NASH compared to those with normal 
liver histology. Regarding inflammation, IL6 hepatic mRNA expression was significantly higher in 
NASH than in the SS group. Hepatic TNFα mRNA expression tended to be higher in NASH compared 
with the SS group (p = 0.05). No more significant differences were found regarding the other studied 
fatty acid metabolism-related genes (Table 2). 
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Table 2. Hepatic expression of genes related to de novo fatty acid synthesis, fatty acid 
uptake and transport, fatty acid oxidation, and inflammation in morbidly obese women 
according to the liver pathology. 
Gene Expression 
NL (n = 13) SS (n = 47) NASH (n = 67) 
Mean ± SEM Mean ± SEM p-Value 1 Mean ± SEM p-Value 1 p-Value 2 
De novo lipogenesis 
LXRα 9.5 ± 2.6 10.4 ± 1.4 n.s 8.5 ± 1.1 n.s n.s 
SREBP1c 8.1 ± 1.3 10.2 ± 1 n.s 8.7 ± 0.9 n.s n.s 
ACC1 4.4 ± 1.0 6.7 ± 1.7 n.s 7.6 ± 2.1 n.s n.s 
FAS 5.9 ± 1.1 13.9 ± 2.3 0.003 16.8 ± 2.8 0.001 n.s 
Fatty acid uptake and transport 
PPARγ 2.9 ± 0.5 4.6 ± 0.7 n.s 4.8 ± 1.1 n.s n.s 
CD36 6.1 ± 0.9 6.3 ± 0.7 n.s 5.8 ± 0.7 n.s n.s 
FABP4 1.1 ± 0.4 3.3 ± 0.8 n.s 3.5 ± 1.3 n.s n.s 
Fatty acid oxidation 
PPARα 26.1 ± 4.5 26.6 ± 3.6 n.s 21.2 ± 3 n.s n.s 
Inflammation 
IL6 1.1 ± 0.7 0.5 ± 0.1 n.s 1.5 ± 0.4 n.s 0.033 
TNFα 0.8 ± 0.6 0.4 ± 0.1 n.s 1 ± 0.2 n.s 0.050 
CRP 117.4 ± 19.9 167.4 ± 30 n.s 165.4 ± 26.4 n.s n.s 
PPARδ 3.6 ± 0.8 4.9 ± 0.7 n.s 3.7 ± 0.5 n.s n.s 
NL, morbidly obese subjects with normal liver; SS, morbidly obese subjects with simple steatosis; NASH, 
morbidly obese subjects with steatohepatitis. ANOVA test was used to compare the gene expression in the 
different groups. p-Value 1 indicates significant differences respect NL group (p < 0.05); p-Value 2 indicates 
significant differences respect SS group (p < 0.05). n.s indicates no significant differences. Data are 
expressed as mean ± SEM. 
Then, in order to add to the current knowledge about the role of lipid metabolism alterations in 
simple steatosis, we assessed the relationship between the expression of the studied genes and the 
presence of hepatic fat accumulation, classifying the SS group into different grades: mild, moderate or 
severe SS (Table 3). 
Table 3. Hepatic expression of genes related to de novo fatty acid synthesis, fatty acid 
uptake and transport, fatty acid oxidation, and inflammation in morbidly obese women 
diagnosed with different degrees of simple steatosis (SS). 
Gene 
Expression 
MILD SS (n = 18) MODERATE SS (n = 16) SEVERE SS (n = 13) 
Mean ± SEM Mean ± SEM p-Value 1 Mean ± SEM p-Value 1 p-Value 2 
De novo lipogenesis 
LXRα 12.5 ± 3.1 11 ± 1.8 n.s 4.8 ± 2.2 0.05 0.05 
SREBP1c 10.9 ± 2.3 11.8 ± 1.6 n.s 8.7 ± 2.0 n.s n.s 
ACC1 6.6 ± 1.9 6.4 ± 1.3 n.s 2.4 ± 0.4 0.042 0.008 
FAS 15.2 ± 4.4 16.3 ± 3.8 n.s 7.4 ± 1.6 n.s 0.047 
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Table 3. Cont. 
Gene 
Expression 
MILD SS (n = 18) MODERATE SS (n = 16) SEVERE SS (n = 13) 
Mean ± SEM Mean ± SEM p-Value 1 Mean ± SEM p-Value 1 p-Value 2 
Fatty acid uptake and transport 
PPARγ 6.1 ± 1.6 4.7 ± 1.2 n.s 2.9 ± 0.9 n.s n.s 
CD36 5.4 ± 1.4 8.4 ± 0.9 n.s 5.3 ± 1.2 n.s n.s 
FABP4 1.7 ± 0.6 4.7 ± 1.4 n.s 4.9 ± 2.3 n.s n.s 
Fatty acid oxidation 
PPARα 31.5 ± 7.9 24.5 ± 4.9 n.s 23.1 ± 6.2 n.s n.s 
Inflammation 
IL6 0.6 ± 0.2 0.5 ± 0.1 n.s 0.4 ± 0.2 n.s n.s 
TNFα 0.3 ± 0.1 0.4 ± 0.1 n.s 0.5 ± 0.2 n.s n.s 
CRP 129.9 ± 63.7 132.7 ± 34.5 n.s 139 ± 64.1 n.s n.s 
PPARδ 5.7 ± 1.2 5.6 ± 1 n.s 4.3 ± 2.2 n.s n.s 
NL, morbidly obese subjects with normal liver; MILD SS, morbidly obese subjects with mild simple 
steatosis; MODERATE SS, morbidly obese subjects with moderate simple steatosis; SEVERE SS, morbidly 
obese subjects with severe simple steatosis. ANOVA test was used to compare the gene expression in the 
different groups. p-Value 1 indicates significant differences respect MILD SS group (p < 0.05); p-Value 2 
indicates significant differences respect MODERATE SS group (p < 0.05). n.s indicates no significant 
differences. Data are expressed as mean ± SEM. 
Regarding de novo synthesis of fatty acids, liver ACC1 mRNA expression was down regulated in 
severe SS compared to both mild and moderate SS groups. In addition, LXRα mRNA expression 
tended to be lower in severe SS compared to both mild and moderate SS groups (p = 0.05). Hepatic 
FAS mRNA expression levels were significantly lower in severe SS compared to the moderate SS 
group. Regarding SREBP1c, despite we did not find any significant difference, its mRNA expression 
seem to be lower in severe SS compared to both mild and moderate SS groups (Table 3). 
In order to confirm these results regarding lipogenic gene expression, we also analyzed the protein 
expression of the key genes related to the de novo fatty acid synthesis by western blot analysis. There 
were similar results with respect to its protein expression and those obtained in the gene expression 
analysis. LXRα, SREBP1c precursor form, ACC1 and FAS protein expression was significantly lower 
in morbidly obese women with severe SS compared to those with moderate SS (p < 0.05). We also 
determined the activated SREBP1c form by Western blot analysis. Our results show that, although  
we did not find any significant difference between groups, activated SREBP1c protein has a similar 
profile of both ACC1 and FAS mRNA and protein expression, two well known target genes of 
SREBP1c (Figure 1). 
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Figure 1. Liver expression of lipogenic transcription factors and enzymes in morbidly 
obese patients diagnosed with different degree of simple steatosis. Representative Western 
blot analysis showing LXRα, SREBP1c-precursor form (SREBP1c-p), SREBP1c-active 
form (SREBP1c-a), ACC1, FAS and β-actin protein expression and bar graphs showing the 
quantification of bands normalized by values of β-actin bands (n = 28: 6 NL, 8 MILD SS,  
8 MOD SS, 6 SEV SS). Results are shown as mean ± SD. p < 0.05 are considered 
statistically significant. NL, morbidly obese subjects with normal liver; MILD SS, 
morbidly obese subjects with mild simple steatosis; MOD SS, morbidly obese subjects with 
moderate simple steatosis; SEV SS, morbidly obese subjects with severe simple steatosis. 
 
We also studied the genes related to FA oxidation, FA uptake and transport, and related to 
inflammation in the SS cohort classified into different grades of simple steatosis. In this case, we did 
not find any significant difference on its mRNA expression levels (Table 3). 
2.3. Correlations between the Expression of Genes Related to Lipid Metabolism and Inflammation 
with Glucose Metabolism Parameters 
Our results showed that liver FAS expression correlated positively with glucose circulating levels in 
the morbidly obese cohort (Table 4). 
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Regarding FA uptake and transport, hepatic CD36 expression correlates positively with insulin 
circulating levels, and also with HOMA2-IR in the morbidly obese group. In addition, we found a 
positive correlation between FABP4 expression and glucose, insulin, HbA1c and HOMA2-IR (Table 4). 
Interestingly, when we classify the morbidly obese cohort into NL, SS and NASH, we observed that 
both CD36 and FABP4 correlations with glucose metabolism parameters became stronger in NASH 
(CD36: Insulin r = 0.550, p = 0.010; HOMA2-IR r = 0.546, p = 0.010) (FABP4: Glucose r = 0.801,  
p < 0.001; Insulin r = 0.833, p < 0.001; HbA1c r = 0.893, p < 0.001; HOMA2-IR r = 0.838, p < 0.001). 
Finally, liver IL6 expression correlated positively with insulin circulating levels and with HOMA2-IR 
in the morbidly obese group (Table 4). 
Table 4. Significant correlations between the expression of genes related to lipid metabolism 
and inflammation with glucose metabolism parameters in the morbidly obese cohort. 
Variables 
FABP4 FAS CD36 IL6 
r p-Value r p-Value r p-Value r p-Value 
Glucose (mg/dL) 0.465 0.001 0.185 0.035 −0.055 0.697 0.014 0.925 
Insulin (mu/L) 0.710 <0.001 0.008 0.933 0.357 0.013 0.371 0.011 
Homa2-IR 0.714 <0.001 0.079 0.514 0.354 0.014 0.369 0.012 
Hba1c (%) 0.742 <0.001 0.118 0.24 0.155 0.325 0.185 0.252 
HbA1c, glycosylated haemoglobin; HOMA2-IR, homeostatic model assessment 2-insulin resistance. 
3. Discussion 
The novelty of this study lies in the fact that it establishes a clear relationships between NAFLD and 
genes related to de novo synthesis of fatty acids, FA uptake and transport, FA oxidation, and related to 
inflammation, in an extensive cohort of women with morbid obesity (BMI > 40 kg/m2). Moreover,  
this design provides a comparison of gene expression and protein levels between different degrees of 
simple steatosis according to the percentage of liver fat deposition (mild, moderate or severe SS). 
The present study demonstrates that FAS, well known as an important lipogenic enzyme,  
is overexpressed in the liver of MO NAFLD patients with both simple steatosis and non-alcoholic 
steatohepatitis, in agreement with other authors [13,14,18]. Other studies have shown enhanced 
expression of LXRα and SREBP1c in NAFLD [13–15,18,19]. However, we were unable to find any 
other significant difference in other related genes to the de novo lipogenesis pathway. These 
discrepancies might be explained by differences in the cohort of the patients studied. Higuchi et al. [13] 
included normal weight patients with NAFLD and Lima-Cabello et al. [14] included patients with 
NAFLD and with steatosis related to chronic hepatitis C virus infection in mildly overweight men  
and women. Finally, Nakamuta et al., who included a cohort of obese patients, observed that the 
expression of LXRα and ACC1 was upregulated in NAFLD and it was more noticeable in non-obese 
than in obese patients [19]. 
In order to add to the current knowledge about the role of lipid metabolism alterations in simple 
steatosis, we evaluated the expression of these genes in morbidly obese patients with different 
histopathology types of SS according to the hepatic fat deposition. The most outstanding finding of the 
present study is that the liver expression of key genes related to de novo fatty acid synthesis (LXRα, 
ACC1 and FAS) have an inverse relationship with the grade of steatosis, that is to say, it diminishes 
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when the grade of steatosis increases. This novel finding was confirmed evaluating the protein 
expression, obtaining similar results with respect to LXRα, ACC1, FAS levels, and also with respect to 
SREBP1c. Our findings indicate that, in this type of extreme obesity, the hepatic lipogenic pathway 
seems to be downregulated in advanced stages of simple steatosis. The explanation for these results are 
complex, however experimental studies have shown that in mice with total insulin resistance in liver, 
insulin fails to stimulate the synthesis of fatty acids and triglycerides [20,21]. In this context, the liver 
of an extremely obese patient with severe steatosis might behave as if there were total insulin 
resistance, which could be responsible for the downregulation of the lipogenic pathway shown in the 
liver of these patients. However, in the present study we did not perform hyperinsulinemic euglycemic 
clamp to measure hepatic insulin sensitivity in order to confirm this hypothesis. 
We also found that IL6 and TNFα, two important proinflammatory adipocytokines hugely expressed 
in the adipose tissue of obese human subjects and patients with IR [22,23], were overexpressed in the 
liver of NAFLD MO women with NASH compared to those with simple steatosis. These results are in 
agreement with the literature, which supports that they correlate with histological severity in obese 
patients. For instance, Crespo et al. reported increased hepatic expression of TNFα in patients with 
NASH compared to SS patients [24]. Moreover, Wieckowska et al. demonstrated markedly increased 
IL6 expression in the liver of NAFLD patients with NASH compared to those with SS or normal liver [25]. 
Insulin resistance is known to be an intrinsic defect in NAFLD that is closely associated with 
steatosis, inflammation and disease progression in NASH. Moreover, IR has been described as the main 
factor associated with NASH development, as well as genetic and environmental factors [12,26,27].  
In this regard, we found correlations between some important genes related to the hepatic uptake and 
transport of fatty acids (CD36 and FABP4) and the presence of IR and insulin circulating levels in our 
cohort of MO NAFLD women, becoming stronger in those with NASH. These findings are in 
agreement with Miquilena-Colina et al. who observed a significant correlation between hepatic CD36 
expression and plasma insulin levels and insulin resistance (HOMA-IR) in patients with NASH [28]. 
Furthermore, we observed the same correlation regarding IL6 gene expression. These results indicate 
that hepatic fatty acid accumulation, as well as inflammation, might be contributing to NAFLD 
progression in relation with insulin resistance. 
In addition, we found a positive correlation between glucose circulating levels and liver FAS 
expression in the MO cohort. This finding supports the reported observation that glucose binds and 
activates LXRs transcription factors and induces their target genes, including SREBP1c, ACC1 and 
FAS [29,30]. 
Our cohort of severely obese women has made it possible to establish clear relationships between 
NAFLD and fatty acid metabolism-related genes without the interference of such confounding factors 
as gender or age. These results cannot be extrapolated to other obesity groups, normal-weight or  
over-weight women or men. Further studies, including these cohorts, would be useful in order to 
validate our findings. Another limitation is that we did not assess the hepatic insulin sensitivity by 
hyperinsulinemic euglycemic clamp. 
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4. Materials and Methods 
4.1. Subjects 
The study was approved by the institutional review board (Comitè d’Ètica d’Investigació Clínic, 
Hospital Sant Joan de Reus, 09-06-25/6proj2). All participants gave written informed consent for 
participation in medical research. We included 127 morbidly obese women (BMI > 40 kg/m2) of 
Western European descent. Liver biopsies were obtained during planned laparoscopic bariatric surgery. 
All biopsies were performed for clinical indications.  
The diagnosis of NAFLD was made using the following criteria: (1) liver pathology; (2) an intake 
of less than 10 gr. of ethanol/day; and (3) appropriate exclusion of other liver diseases. 
The weight of all subjects was stable with no fluctuation in body weight greater than 2% for at least 
3 months prior to surgery. The exclusion criteria were: (1) concurrent use of medications known to 
produce hepatic steatosis; (2) patients using lipid-lowering medications including PPARα or -γ agonists; 
(3) diabetic women who were receiving insulin or on medication likely to influence endogenous 
insulin levels; (4) menopausal and post-menopausal women and subjects receiving contraceptive 
treatment; (5) patients who had an acute illness, current evidence of acute or chronic inflammatory or 
infectious diseases or end-stage malignant diseases. 
4.2. Liver Pathology 
Liver samples were stained with hematoxylin and eosin, and Manson’s trichrome stains and scored 
by two experienced hepatopathologists using the methods described before [31,32]. Simple steatosis (SS) 
was graded as follows: grade 1 or mild SS: more than 5% and less than 33% of hepatocytes affected; 
grade 2 or moderate SS: 33% to 66% of hepatocytes affected; or grade 3 or severe SS: more than 66% 
of hepatocytes affected. In addition to steatosis, the minimum criteria for the diagnosis of steatohepatitis 
included the presence of lobular inflammation and either ballooning cells or perisinusoidal/pericellular 
fibrosis in zone 3 of the hepatic acinus. 
According to their liver pathology [30,31], patients were sub-classified into the following groups: 
(1) normal liver (NL) histology (n = 13); (2) simple steatosis (SS) (micro/macrovesicular steatosis 
without inflammation or fibrosis, n = 47); (3) non-alcoholic steatohepatitis (NASH) (Brunt grade 1–3, 
n = 67). 
4.3. Biochemical Analyses 
A complete anthropometrical, biochemical, and physical examination was carried out on each 
patient. Body height and weight were measured with the patient standing in light clothes and shoeless. 
Body mass index was calculated as body weight divided by height squared (kg/m2). The subjects’ 
waist circumference was measured with a soft tape midway between the lowest rib and the iliac crest. 
Laboratory studies included glucose, insulin, glycated haemoglobin, high-density lipoprotein cholesterol, 
low-density lipoprotein cholesterol, triglycerides and transaminases, all of which were analysed  
using a conventional automated analyser. Insulin resistance was estimated using homeostasis model 
assessment of IR (HOMA2-IR) [33]. 
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We determined the circulating levels of several molecules related to inflammation including 
adipokines (HMW adiponectin), acute phase proteins (CRP) and proinflammatory cytokines  
(IL6, TNFRI and TNFRII). Circulating levels of HMW adiponectin (EMD Millipore, St. Charles, MO, 
USA), CRP (Dade Behring, Marburg, Germany), IL6 (Quantikine, R&D Systems, Minneapolis, MN, 
USA), FABP4 (Biovendor, Modrice, Czech Republic), TNFRI and TNFRII (AssayPro, St. Charles, MO, 
USA) were measured in duplicate using enzyme-linked immunosorbent assays (ELISA) following the 
manufacturer’s instructions. 
4.4. RNA Isolation and Real-Time PCR 
Liver samples were conserved in RNAlater (Sigma, Barcelona, Spain) for 24 h at 4 °C and then 
stored at −80 °C. Total RNA from liver was isolated according to the manufacturers’ protocols RNeasy 
mini kit (Qiagen, Barcelona, Spain). RNA was digested with DNase I (RNase-Free DNase set; 
Qiagen). First-strand cDNA was synthesized using an equal amount of total RNA with the High 
Capacity RNA-to-cDNA Kit (Applied Biosystems, Madrid, Spain). Real-time quantitative PCR was 
carried out in a final volume of 20 μL, which contained 10 ng of reverse-transcribed cDNA, 10 μL of 
2× TaqMan Fast Universal PCR Master Mix (Applied Biosystems) and 1 μL TaqMan Assay 
predesigned by Applied Biosystems for the detection of LXRα, SREBP1c, ACC1, FAS, PPARγ, 
CD36, FABP4, PPARα, IL6, TNFα, CRP, PPARδ, and 18S ribosomal RNA, which was used as the 
housekeeping gene. The mRNA expression for each gene and sample was calculated using the 
recommended 2−ΔΔCt method. All reactions were carried out in duplicate in 96-well plates using the 
7900HT Fast Real-Time PCR systems (Applied Biosystems). 
4.5. Western Blot Analysis 
Protein levels were evaluated in a subgroup of 28 subjects (6 MO women with NL, 8 with mild SS, 
8 with moderate SS and 6 with severe SS), for whom enough tissue was available. Liver samples were 
homogenized in a medium containing 50 mM HEPES, 150 mM NaCl, 1 mM DTT, 0.1% SDS and 1% 
protease inhibitor cocktail (Thermo Scientific, Madrid, Spain). Protein concentrations were determined 
by using a BCA assay Kit (Thermo Scientific). For Western blot analysis, equal amounts of protein (50 µg) 
were separated by SDS/PAGE (7% acrylamide) and transferred onto nylon membranes. Non-specific 
binding was blocked by preincubation of the membranes with 5% (w/v) non-fat milk powder in 0.1% 
PBS-Tween for 1 h. Specific protein expression was detected by incubating with goat anti-LXRα 
(Santa Cruz Biotechnology, Inc., Heidelberg, Germany), rabbit anti-SREBP1c (Thermo Scientific), 
rabbit anti-ACC1 (Cell Signaling Technology, Inc., Barcelona, Spain) and rabbit anti-FAS (Cell 
Signaling Technology) antibodies overnight at 4 °C, followed by an incubation with anti-mouse IgG 
(GE Healthcare, Freiburg, Germany), anti-goat IgG (Santa Cruz Biotechnology, Inc.) or anti-rabbit 
IgG (GE Healthcare) antibodies for 2 h at room temperature and developed with SuperSignal West 
Pico Chemiluminescent or SuperSignal Femto Maximum Sensitivity Substrate (Thermo Scientific). 
The density of specific bands was determined by densitometry and quantified by the Phoretix 1D 
software from TotalLab. The expression pattern of all proteins was normalized by β-actin (Sigma) 
liver expression. 
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4.6. Statistical Analysis 
All the values reported were analyzed using the SPSS/PC+ for windows statistical package (version 
19.0; SPSS, Chicago, IL, USA). One-way ANOVA with post-hoc Tukey test was used to compare 
continuous variables between groups. The strength of association between variables was calculated 
using Pearson’s method for parametric variables and Spearman’s ρ-correlation test for non-parametric 
contrasts. p-Values <0.05 were considered to be statistically significant. 
5. Conclusions 
In conclusion, although it was not possible to determine the causality that leads to the 
downregulation of de novo fatty acid synthesis in advanced stages of simple steatosis, our results 
suggest that, in NAFLD patients with this type of extreme obesity, the deregulation of the lipogenic 
pathway might be associated with the severity of simple steatosis. Prospective studies are needed in 
order to better understand the alteration of fatty acid metabolism-related pathways in morbidly obese 
subjects with NAFLD. 
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Background. Recent reports suggest a role for the endocannabinoid system in the pathology of nonalcoholic fatty liver disease
(NAFLD).The aim of this study was to investigate the relationship between liver expression of cannabinoid (CB) receptor subtypes,
CB1 and CB2, in morbidly obese (MO) women with different histological stages of NAFLD.Methods. We analysed hepatic CB1 and
CB2mRNA expression, and the expression of genes involved in lipid metabolism in 72MOwomen, subclassified by liver histology
into MO with normal liver (NL, 𝑛 = 16), simple steatosis (SS, 𝑛 = 28), and nonalcoholic steatohepatitis (NASH, 𝑛 = 28) by
enzyme-linked immunosorbent assay andRT-PCR.Results.We found that CB1mRNA expressionwas significantly higher inNASH
compared with SS and correlated negatively with PPAR𝛼. Regarding CB2, CB2 mRNA expression correlated positively with ACC1,
PPAR𝛾, IL6, TNF𝛼, resistin, and adiponectin. Conclusions. The increased expression of CB1 in NASH and the negative correlation
with PPAR𝛼 suggest a deleterious role of CB1 in NAFLD. Regarding CB2, its positive correlation with the anti-inflammatory
molecule adiponectin and, paradoxically, with inflammatory genes suggests that this receptor has a dual role. Taken together, our
results suggest that endocannabinoid receptors might be involved in the pathogenesis of NAFLD, a finding which justifies further
study.
1. Introduction
Obesity, as part of the metabolic syndrome, is one of the
major risk factors in the development of fatty liver [1, 2].
Nonalcoholic fatty liver disease (NAFLD) has become the
most common liver disorder in developed countries, affecting
over one-third of the population [3, 4]. NAFLD has fre-
quently been associated with obesity, type 2 diabetes mellitus,
hyperlipidemia, and insulin resistance [5]. The spectrum of
the disease ranges from simple steatosis to steatohepatitis,
a condition that associates steatosis, liver inflammation,
hepatocellular injury, and activation of fibrogenic pathways
with a 10–20% risk of developing cirrhosis within 10 to 20
years [6]. The transition from steatosis (SS) to nonalcoholic
steatohepatitis (NASH) is not completely understood and
appears multifactorial. Recent studies have revealed a role of
lipotoxic fatty acid metabolites originating from the adipose
tissue or from de novo lipogenesis in the development of
hepatocellular injury [7]. Increasing evidence suggests that
a fatty liver is more vulnerable to factors that lead to
inflammation and fibrosis [8, 9]. Different studies confirm
that de novo lipogenesismight be upregulated inNAFLD [10–
12]. Recent reports have shown that endogenous cannabi-
noids (EC) are related to fatty liver metabolism [13, 14]
although the molecular mechanism by which EC modulates
the metabolism within hepatocytes is still not clear.
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EC are lipid mediators that produce similar effects to
those of marijuana by acting on membrane-bound receptors
and regulating appetite behaviour [15]. Cannabinoid recep-
tors are mainly localized in the brain, but are also present in
small amounts in liver and other peripheral tissue (CB1) and
in immune and haematopoietic cells (CB2) [16, 17]. EC may
also regulate peripheral energy metabolism, as demonstrated
by their CB1-mediated effect on lipoprotein lipase activity
in adipocytes [18] and their ability to stimulate lipogenesis
in hepatocytes [13, 14]. In agreement with that data, other
studies have shown that CB1 receptor antagonists represent
an important therapeutic target, owing to beneficial effects on
lipid metabolism and in light of its antifibrogenic properties.
Unfortunately, the brain-penetrant CB1 antagonist rimona-
bant was withdrawn because of an alarming adverse effect
on mood. However, the efficacy of peripherally-restricted
CB1 antagonists with limited brain penetration has now been
validated in preclinical models of NAFLD [19].
Taken together, these findings indicate that CB1 receptors
mediate metabolic steatogenesis in the liver by central and
peripheral effects. Regarding CB2, results of recent studies
have suggested that this receptor could be a promising anti-
inflammatory and antifibrogenic target [19, 20], although
clinical development of its agonists is still awaited.
In order to investigate the associations of CB1 and CB2
with NAFLD we aimed to (1) find out the gene expression
profiles of CB1 and CB2 in liver of morbidly obese women
with or without NAFLD, (2) assess the relationship between
its gene expressions and the presence of hepatic fat and
inflammation, and (3) study the relationship between liver
CB1 and CB2 mRNA expression and liver mRNA expression
of key genes involved in lipid metabolism: genes involved in
de novo synthesis of fatty acids (ChREBP, SREBP1c, LxR𝛼,
FxR, ACC1, and FAS), fatty acid oxidation (PPAR𝛼), uptake
and transport (PPAR𝛾, CD36, and FABP4), and inflamma-
tory related genes (PPAR𝛿, IL6, TNF𝛼, and CRP).
2. Patients and Methods
2.1. Subjects. The institutional review board approved the
study. All participants gave written informed consent for
participation in medical research. This study included 72
morbidly obese (MO) women (body mass index, BMI >
40Kg/m2) of Western European descent.
We analysed 72 liver samples from MO women. Liver
biopsies were obtained during planned bariatric surgery. All
biopsies were carried out under clinical indications.
NAFLD was diagnosed by the following criteria: (1) liver
pathology, (2) an intake of less than 10 gr of ethanol/day, and
(3) appropriate exclusion of other liver diseases. Liver samples
were scored by two experienced hepatopathologists using the
methods described before [21, 22].
According to their liver pathology, patients were sub-
classified into the following groups: (1) MO with normal
liver (NL) histology (𝑛 = 16), (2) MO with simple steatosis
(SS) (micro/macrovesicular steatosis without inflammation
or fibrosis, 𝑛 = 28), and (3) MO with nonalcoholic steato-
hepatitis (NASH) (Brunt grade 1–3, 𝑛 = 28).
Subjects’ weight was stable, with no fluctuation greater
than 2% of body weight for at least 3 months prior to surgery.
The exclusion criteria were (1) concurrent use of medication
known to produce hepatic steatosis, (2) patients using antidi-
abetics or lipid-lowering medications, including PPAR𝛼 or
-𝛾 agonists, (3) diabetic women that were receiving insulin
or on medication likely to influence endogenous insulin
levels, (4) menopausal and postmenopausal women and
subjects receiving contraceptive treatment, and (5) patients
who had an acute illness, current evidence of acute or chronic
inflammatory or infectious diseases, or end-stage malignant
diseases.
2.2. Anthropometrical and Biochemical Analysis. A complete
anthropometrical examination and a biochemical analysis
were carried out on each patient. Height and weight were
measured with the patient standing in light clothes and
shoeless. BMI was calculated as body weight divided by
height squared (kg/m2). Laboratory studies included glucose,
insulin, glycated haemoglobin, total cholesterol, high-density
lipoprotein cholesterol, low-density lipoprotein cholesterol,
triglycerides, and transaminases, all of which were analysed
using a conventional automated analyser. Insulin resistance
(IR) was estimated using homeostasis model assessment of
IR (HOMA2-IR) [23]. Serum levels of adiponectin (Linco
Research, Inc., St. Charles, USA), resistin (Biovendor, Mod-
rice, Czech Republic), interleukin 6 (IL6) (Quantikine, R&D
Systems,Minneapolis, USA), tumour necrosis factor receptor
2 (TNFRII) (AssayPro, St. Charles, USA), and C-reactive
protein (CRP) (Dade Behring, Marburg, Germany) were
measured in duplicate using ELISA, following the manufac-
turer’s instructions.
2.3. RNA Isolation and Real Time PCR. Liver samples were
conserved inRNAlater (Sigma, Barcelona, Spain) for 24 hours
at 4∘C and then stored at −80∘C. Total RNA from liver tissue
was isolated using the RNeasy mini kit (Qiagen, Barcelona,
Spain), according to the manufacturers’ protocols. RNA was
digestedwithDNase I (RNase-FreeDNase set; Qiagen). First-
strand cDNA was synthesized using an equal amount of
total RNA with High Capacity RNA-to-cDNA Kit (Applied
Biosystems, Madrid, Spain). The Real-time quantitative PCR
was carried out in a final volume of 20 𝜇L, which contained
10 ng of reverse-transcribed cDNA, 10 𝜇L of 2X TaqMan Fast
Universal PCR Master Mix (Applied Biosystems), and 1 𝜇L
TaqMan Assay predesigned by Applied Biosystems for the
detection of CB1, CB2, ChREBP, SREBP1c, FxR, LxR𝛼, ACC1,
FAS, PPAR𝛼, PPAR𝛾, CD36, FABP4, PPAR𝛿, IL6, TNF𝛼,
CRP, adiponectin, and resistin gene and for GAPDH, which
was used as the housekeeping gene.ThemRNAexpression for
each gene and sample was calculated using the recommended
2
−ΔΔCt method. All reactions were carried out in duplicate in
96-well plates using the 7900HTFast Real-Time PCR systems
(Applied Biosystems).
2.4. Statistical Analysis. All the values reported are expressed
as mean ± SD (standard deviation) and were analysed
using SPSS/PC+ for windows statistical package (version
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20.0; SPSS, Chicago, IL). Differences between groups were
calculated using the Student’s 𝑡-test or one-way ANOVA
analysis. The strength of association between variables was
calculated using Pearson’s method for parametric variables
and Spearman’s 𝜌-correlation test for nonparametric con-
trasts. A multiple linear regression analysis was carried out.
The predictors for stepwise linear regression analysis were
based on correlation analysis and selected from the variables
known to be associated with the dependent variable. 𝑃 values
<0.05 were considered to be statistically significant.
3. Results
3.1. Baseline Characteristics and General Laboratory Data of
the Subjects in the Study. Morbidly obese women were class-
ified according to the presence of NAFLD (Table 1). Age,
anthropometrical measurements, glucose, HbA1c, insulin,
HDL and LDL-Cholesterol, and triglycerides were not sig-
nificantly different among morbidly obese women in the NL,
SS, or NASH groups. However, our results indicated that AST
and ALT activity were higher in both the SS and the NASH
groups than in obese women with normal liver histology
(SS: AST 𝑃 = 0.05, ALT 𝑃 < 0.001; NASH: AST 𝑃 =
0.042, ALT 𝑃 < 0.001). ALP activity was higher in the NASH
group than in NL (𝑃 = 0.032). Moreover, the levels of
adipocytokines determined were not significantly different
between the morbidly obese with NL, SS, or NASH (Table 1).
3.2. Evaluation of CB1 and CB2 mRNA Expression in Liver.
We analysed hepatic CB1 and CB2 mRNA expression in the
MO cohort in relation to the presence of NAFLD. When
we subclassified that cohort into NL, SS, and NASH, we
observed that CB1mRNA expression was significantly higher
in NASH compared with SS (SS: 0.09 ± 0.07; NASH: 0.14 ±
0.03; 𝑃 < 0.010) (Figure 1(a)). However, CB2 gene expression
was similar among the three groups (Figure 1(b)).
Additionally, we studied the relationship between the
grade of steatohepatitis and CB1 and CB2 gene expression.
When we subclassified the MO cohort into those with NASH
Brunt 1 and with NASH Brunt 2/3, we found that both CB1
and CB2mRNA expression were similar in both groups (data
not shown).
3.3. Correlations between the Gene Expression of CB1 and
CB2 and Genes Related to Fatty Acid Synthesis (ChREBP,
SREBP1c, LxR𝛼, FxR, ACC1, and FAS), Fatty Acid Oxidation
(PPAR𝛼), Uptake and Transport (PPAR𝛾, CD36, and FABP4),
Inflammation (PPAR𝛿, IL6, TNF𝛼, and CRP), and Adipokines
(Adiponectin and Resistin) in Liver from MO Cohort. We
found a negative correlation between CB1 and PPAR𝛼 gene
expression. We also found that CB2 mRNA expression cor-
related positively with ACC1 and PPAR𝛾 mRNA expression
(Table 2).
Regarding inflammation and adipokines, we did not find
any correlation between CB1 gene expression and inflamma-
tory genes expression, nor with adipokines expression. How-
ever, we found positive correlations between CB2 and IL6,
TNF𝛼, resistin, and adiponectin geneexpression (Table 2).
In addition, we performed a stepwise multiple linear
regression analysis, which included age, BMI, triglycerides,
PPAR𝛼, and the presence of NASH as independent variables,
and CB1 expression as a dependent variable. The results
indicated that NASH and PPAR𝛼 (inverse) were the only
variables associated with CB1 expression (𝑅2 = 0.255, 𝑃 =
0.002; 𝑅2 = 0.129, 𝑃 = 0.014, resp.).
4. Discussion
The present study demonstrates that in morbidly obese
women with NAFLD, liver CB1 gene expression is signifi-
cantly higher at the histological stage of NASH compared
to SS. This finding might agree with experimental studies
in obese rats, which showed that rimonabant, a selective
CB1 receptor antagonist used as an adjunctive treatment of
obesity, reduces liver inflammation [24, 25]. The underlying
mechanism has not yet been delineated but in hepatocytes
CB1 receptors might contribute to the acute phase response
via activation of ChREBP, a liver-specific transcription factor
that upregulates acute phase response genes [26]. In our
case, we were not able to demonstrate a positive relationship
between CB1 and ChREBP mRNA expression, nor with
mRNA expression of inflammatory genes.
Studies in cultured hepatocytes and in animal models
have observed steatogenic properties of CB1 as a result of
hepatic lipogenesis activation, reduction of fatty acid oxida-
tion, and decreased release of TG-rich VLDL, combined to
CB1-dependent release of free fatty acids from the adipose
tissue [24, 25, 27]. Our cohort did not demonstrate any
relationship between the hepatic CB1 gene expression and
simple steatosis. However, we did find a negative correlation
between CB1 and PPAR𝛼 gene expression. PPAR𝛼 plays a
pivotal role in fatty acid (FA) catabolism by upregulating the
expression of numerous genes involved in mitochondrial FA
oxidation, peroxisomal FA oxidation, and other aspects of FA
metabolism [28]. Furthermore, PPAR𝛼 is related to adipoR2.
Activation of adipoR2 can increase PPAR𝛼 levels and activate
PPAR𝛼 pathways, leading to increased fatty acid oxidation
and a reduction in oxidative stress [29, 30]. Recently in
experimental studies the adipoR agonist (AdipoRon) bound
to both adipoR1 and AdipoR2 in vitro. AdipoRon showed
very similar effects to adiponectin inmuscle and liver, such as
an activation of AMK and PPAR𝛼 pathways, and ameliorated
IR and glucose intolerance in mice fed a high-fat diet, which
was completely obliterated in adipoR1 and AdipoR2 double-
knockout mice [31]. In conclusion, the higher expression
of CB1 in NASH and the negative correlation with PPAR𝛼
suggest a deleterious role of CB1 in NAFLD.
Regarding hepatic CB2 expression, we did not find any
differences betweenMOwithNL, SS orNASH. It is important
to note that the role of CB2 in liver diseases is controversial.
Some authors have reported that CB2 receptors display
protective properties during liver injury. These effects largely
depend on anti-inflammatory and antifibrogenic signals
generated by CB2-expressing hepatic immune cells and/or
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Table 1: Characteristics of study cohort classified according to the liver pathology.
Morbidly Obese (𝑛 = 72)
NL (𝑛 = 16) SS (𝑛 = 28) NASH (𝑛 = 28)
Mean ± SD Mean ± SD Mean ± SD
Age (years) 44.0 ± 3.2 47.4 ± 1.5 45.9 ± 1.4
Weight (kg) 121.0 ± 12.1 121.8 ± 16.3 123.8 ± 14.3
WC (cm) 129.5 ± 6.4 132.1 ± 10.7 135.1 ± 9.9
BMI (kg/m2) 48.6 ± 2.6 48.1 ± 7.8 47.5 ± 5.4
Glucose (mg/dL) 101.8 ± 18.9 125.4 ± 38.2 119.0 ± 30.0
Insulin (mUI/L) 11.4 ± 3.1 21.2 ± 11.5 23.1 ± 28.1
HbA1c (%) 4.3 ± 0.3 5.9 ± 1.7 5.8 ± 1.7
HOMA2-IR 1.5 ± 0.5 2.9 ± 1.4 3.0 ± 3.4
HDL-C (mg/dL) 43.6 ± 7.6 39.3 ± 9.5 41.5 ± 9.0
LDL-C (mg/dL) 102.0 ± 31.7 104.7 ± 24.6 102.5 ± 32.6
Triglycerides (mg/dL) 144.4 ± 51.9 178.4 ± 68.5 183.1 ± 86.6
AST (U/L) 25.8 ± 8.5 43.7 ± 34.4∗ 44.9 ± 29.3∗
ALT (U/L) 25.4 ± 10.5 45.6 ± 31.6∗ 46.3 ± 28.3∗
GGT (U/L) 18.3 ± 13.8 30.6 ± 22.2 36.1 ± 31.7
ALP (U/L) 58.2 ± 12.6 66.3 ± 16.0 71.9 ± 15.2∗
Adipocytokine levels
Adiponectin (𝜇g/mL) 10.1 ± 2.0 6.8 ± 3.5 6.7 ± 2.4
IL6 (pg/mL) 2.1 ± 0.6 2.9 ± 2.5 3.3 ± 2.0
Resistin (ng/mL) 5.1 ± 2.1 4.6 ± 2.0 4.5 ± 1.6
TNFRII (ng/mL) 4.2 ± 1.4 5.5 ± 2.5 5.6 ± 1.7
CRP (mg/dL) 1.0 ± 0.8 0.9 ± 0.7 1.1 ± 0.7
NL: morbidly obese subjects with normal liver; SS: morbidly obese subjects with simple steatosis; NASH: morbidly obese subjects with steatohepatitis; ALT:
alanine aminotransferase; ALP: alkaline phosphatase; AST: aspartate aminotransferase; BMI: body mass index; CRP: C-reactive protein; GGT: gamma-
glutamyltransferase; HbA1c: glycosylated haemoglobin; HDL-C: high density lipoprotein; HOMA2-IR: homeostatic model assessment 2-insulin resistance;
IL6: interleukin 6; LDL-C: low density lipoprotein; TNFRII: tumour necrosis factor receptor II; WC: waist circumference. ∗indicates significant differences
respect NL group (𝑃 < 0.05).
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Figure 1: Liver CB1 and CB2 mRNA expression in morbidly obese women classified according to the liver pathology.NL: with normal liver
histology; SS: simple steatosis; NASH: nonalcoholic steatohepatitis. Results are shown as mean ± SD. 𝑃 < 0.05 is considered statistically
significant.
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Table 2: Correlations between the expression of CB1 and CB2 and genes related to fatty acid synthesis, to fatty acid oxidation, uptake and
transport, inflammation, and adipokines in liver from morbidly obese women.
CB1 CB2
𝑟 𝑃 value 𝑟 𝑃 value
De novo synthesis of Fatty acids
ChREBP 0.185 0.198 0.072 0.603
SREBP1c 0.074 0.590 0.031 0.816
LxR𝛼 0.052 0.709 0.126 0.346
FxR 0.079 0.571 0.095 0.482
ACC1 0.207 0.126 0.257 0.047
FAS 0.164 0.232 0.182 0.167
Fatty acid oxidation
PPAR𝛼 −0.354 0.037 0.155 0.347
Fatty acid uptake and transport
PPAR𝛾 0.161 0.240 0.600 <0.001
CD36 −0.028 0.846 0.157 0.257
FABP4 0.105 0.460 0.040 0.776
Inflammation
IL6 0.116 0.431 0.288 0.040
TNF𝛼 −0.018 0.902 0.293 0.033
CRP −0.210 0.140 −0.002 0.988
PPAR𝛿 −0.077 0.576 0.126 0.342
Adipokines
Adiponectin 0.031 0.846 0.625 <0.001
Resistin −0.058 0.701 0.506 <0.001
𝑃 < 0.05 are considered statistically significant.
hepatic myofibroblasts, with paracrine impact on hepatocy-
tes, which do not express CB2 [19, 32]. The endogenous or
exogenous activation of CB2 receptors has been described as
a protective pathway in several models of acute liver injury
in which CB2 receptors undergo early induction in nonpar-
enchymal cells [16, 20, 33, 34].
We found that CB2 liver expression correlated positively
with hepatic ACC1 gene expression, a gene related to fatty
acid synthesis. In fatty acid synthesis process, ACC1 converts
acetyl-CoA, an essential substrate of fatty acids, to malonyl-
CoA. Fatty acids as well as acyl-CoA and acetyl-CoA have
been identified as potential causes of lipotoxicity [35]. Fur-
thermore, we found that CB2 liver expression correlated
positively with PPAR𝛾 gene expression. In NAFLD, PPAR𝛾 is
upregulated in liver tissue and liver-specific PPAR𝛾 knockout
mice are protected from diet-induced steatosis [36, 37].
However, these isolated correlations do not clarify the role of
CB2 in lipogenic and uptake and transport pathways.
Other studies provide additional evidence that supports
the potential involvement of CB2 receptors in inflammatory
liver diseases [38]. However, in our study, we found a
positive correlation between liver CB2 and adiponectin gene
expression, which is a molecule with an anti-inflammatory
role. Taken together, all of this suggests that CB2 seems to be
a molecule with a dual action.
Our cohort of morbidly obese women has made it pos-
sible to establish clear relationships between NASH and CB1
liver expressionwithout the interference of such confounding
factors as gender or age. However, the results of our study
cannot be extrapolated to other obesity groups, to men, or
to normal-weight subjects.
The main results of our study demonstrate that liver CB1
mRNA expression is induced in nonalcoholic steatohepatitis
and correlates negatively with hepatic PPAR𝛼 expression,
which suggests a deleterious role of CB1 in NAFLD. Further-
more, liver CB2mRNA expression is related to the expression
of key genes involved in hepatic lipid metabolism. With
regard to inflammation, CB2 seems to act as a dual molecule
because it correlates positively with the anti-inflammatory
molecule adiponectin and, paradoxically, also with inflam-
matory genes. Our results suggest that endocannabinoid
receptors might be involved in the physiopathological pro-
cesses of NAFLD and justify the need for further study.
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In the first study of this doctoral thesis, we have analysed the liver 
expression of some key genes related to the de novo synthesis of fatty 
acids (LxRα, SREBP1c, ACC1, FAS), fatty acid uptake and transport 
(PPARγ, CD36, FABP4), fatty acid oxidation (PPARα), and related to 
inflammation (IL6, TNFα, CRP, PPARδ) in an extensive cohort of 127 
morbidly obese (MO) women with a body mass index greater than 40 kg/m2. 
We first classified the cohort according to their liver histology into normal 
liver, SS or NASH. We found that, in liver of both MO women with SS and 
MO women with NASH, the main lipogenic enzyme fatty acid synthase 
(FAS) is over expressed (p<0.05). For inflammation, we found that IL6 gene 
expression is significantly higher in NASH patients compared to those with 
SS (p<0.05). TNFα, another important inflammatory molecule, tended to be 
higher in NASH (p=0.05). We did not find any more significant differences 
for the other fatty acid metabolism-related genes studied. We then 
assessed the relationship of the hepatic expression of fatty acid metabolism 
and inflammation-related genes with the presence of hepatic lipid 
accumulation. In order to do so, we classified the steatotic patients 
according to mild, moderate or severe degree of SS. Our results showed 
that the liver expression of key genes related to de novo fatty acid synthesis 
(ACC1, FAS and LxRα) had an inverse relationship with the degree of 
steatosis; their mRNA expression diminished when the degree of simple 
steatosis increased: liver ACC1 mRNA expression was down-regulated in 
severe SS compared to both mild and moderate SS groups (p<0.05); 
hepatic FAS mRNA expression levels were significantly lower in severe SS 
compared to the moderate SS group (p<0.05); LxRα mRNA expression 
tended to be lower in severe SS compared to both mild and moderate SS 
groups (p=0.05). For SREBP1c, although we did not find any significant 
difference, its mRNA expression seemed to be lower in severe SS MO 
women compared to those with mild or moderate SS. In order to confirm 
these results, we also analysed LxRα, SREBP1c (precursor and active 
form), ACC1, and FAS protein expression according to the degree of simple 
steatosis. Interestingly, these results were similar for its protein expression 
and those obtained in the gene expression analysis. For FA oxidation, FA 
UNIVERSITAT ROVIRA I VIRGILI 
DEREGULATION OF FATTY ACID METABOLISM AND CANNABINOID RECEPTORS IN LIVER OF MORBIDLY 
OBESE WOMEN WITH NON-ALCOHOLIC FATTY LIVER DISEASE. 
Alba Berlanga Bustos 
Dipòsit Legal: T 1705-2015
V. SUMMARY RESULTS 
 
 
126 
 
uptake and transport, and inflammation–related genes, we found no 
significant difference in its mRNA expression levels according to the grade 
of simple steatosis. Finally, we also assessed the correlations of hepatic 
expression of fatty acid metabolism and inflammation -related genes with 
glucose metabolism parameters in our cohort of morbidly obese women. 
Liver FAS expression correlated positively with glucose circulating levels; 
CD36 and IL6 with insulin circulating levels, and also with HOMA2-IR; and 
FABP4 with glucose, insulin, HbA1c and HOMA2-IR. Interestingly, both 
CD36 and FABP4 correlations with glucose metabolism parameters 
became stronger in NASH.  
 
Meanwhile, in order to add to the current knowledge about the role 
of the endocannabinoid system in physiopathology of non-alcoholic fatty 
liver disease, in the second study of this thesis, we analysed the gene 
expression of cannabinoid receptor 1 (CB1) and 2 (CB2) in the liver of 72 
MO women according to their liver histology. We observed that CB1 was 
over expressed in liver of MO women with NASH (p<0.05). Unlike CB1, 
CB2 gene expression in the liver of MO women was similar for those with 
normal liver, simple steatosis or NASH histology. We also assessed the 
correlations of CB1 and CB2 hepatic gene expression with de novo 
synthesis of FA, FA oxidation, FA uptake and transport, and inflammation–
related genes, as well as with resistin and adiponectin adipokines in the 
cohort of MO women. We found that CB1 hepatic gene expression 
correlated negatively with PPARα gene expression levels, while CB2 
correlated positively with ACC1, PPARγ, IL6, TNFα, adiponectin and 
resistin gene expression levels. Finally, we performed a stepwise multiple 
linear regression analysis, which included age, BMI, triglycerides, PPARߙ, 
and the presence of NASH as independent variables, while CB1 hepatic 
gene expression was included as dependent variable. The results indicated 
that NASH and PPARߙ (inverse) were the only variables associated with 
CB1 gene expression in the liver of the MO women cohort. 
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As mentioned in the introduction to this thesis, NAFLD 
encompasses a histological spectrum from simple steatosis to non-alcoholic 
steatohepatitis, with the latter being more frequently progressive.  Although 
the disease is asymptomatic most of the time, in a subset of patients it can 
lead to progressive liver disease such as cirrhosis, liver failure and 
hepatocellular carcinoma, which has led to NAFLD becoming a serious 
public health concern. NAFLD is now the most common cause of chronic 
liver disease in Western countries, and its prevalence worldwide has risen 
as more cultures have adopted a western lifestyle and diet1,19. It is now 
predicted to be the most common indication of liver transplantation in the 
near future30. Metabolic risk factors such as obesity, IR, dyslipidaemia, 
metabolic syndrome and diabetes, which are also well known risk factors for 
cardiovascular disease, have been associated to NAFLD11. In fact, the 
majority of deaths among NAFLD patients are attributable to CVD8,9. While 
simple steatosis does not affect mortality, patients with NASH are at 
increased risk of cardiovascular death as well as liver-related 
mortality27,287,288. It is therefore especially important distinguish NASH 
patients from those with simple steatosis, not only because of the risk of 
progression to cirrhosis and HCC, but also of risk of cardiovascular death. 
However, although clinical scoring methods, laboratory tests, and imaging 
techniques are being developed, liver biopsy - an invasive procedure - is 
still the gold standard for reliably distinguishing NASH from simple 
steatosis289. Moreover, management of NAFLD patients largely depends on 
the stage of the disease, with emphasis on the importance of careful risk 
stratification38. Although a number of pharmacological therapies have been 
evaluated in NASH, and agents such as vitamin E and thiazolidinediones 
have shown some promise, there are currently no effective therapies for 
NAFLD apart from lifestyle modification, aimed at weight loss and increased 
physical activity. As a result, a better understanding of the underlying 
mechanisms in NAFLD pathogenesis could be of great interest for 
controlling the progression of NAFLD, and it might help in the development 
of non-invasive diagnostic and optimal therapeutic interventions. In this 
context, as lipid accumulation in the human liver seems to be the early and 
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crucial step in NAFLD development91, we wished to further investigate the 
hepatic fatty acid metabolism of morbidly obese women with NAFLD and 
normal liver histology, by evaluating the expression of key genes involved in 
the molecular mechanisms that cause the initial hepatic lipid accumulation.  
It has been reported that, in NAFLD, the mechanisms leading to 
excessive hepatic lipid accumulation arise from an imbalance between lipid 
acquisition and removal, with an increased delivery of non-esterified fatty 
acids from peripheral expanded adipose tissue to the liver, and/or an 
increased intake of dietary fats and sugars, enhanced de novo lipid 
synthesis via the lipogenic pathway, and decreased hepatic clearance 
capacity by means of fatty acid oxidation or triglyceride export78,90,91. We 
therefore decided to investigate the expression levels of hepatic genes that 
play significant roles in the metabolism of fatty acids in an extensive cohort 
of women with morbid obesity (BMI > 40 Kg/m2). Their roles include the de 
novo synthesis (LxRα, SREBP1c, ACC1, and FAS), uptake and transport 
(PPARγ, CD36, and FABP4) and oxidation (PPARα) of fatty acids. We first 
classified the cohort according to their liver histology into normal liver, 
simple steatosis or NASH. Donnelly et al. have shown that in NAFLD 
patients, although several pathways are involved in hepatic lipid 
accumulation, elevated peripheral fatty acids and de novo lipogenesis 
predominantly contribute to the accumulation of hepatic fat. A recent study 
has confirmed that increased de novo lipogenesis is a distinct characteristic 
of subjects with NAFLD181. In this context, and in agreement with other 
authors184–186,216, we found that FAS, the enzyme that catalyzes the last 
step in FA biosynthesis and which is considered a major determinant of the 
maximal hepatic capacity to generate FA by de novo lipogenesis 
pathway216, is over-expressed in the liver of both morbidly obese women 
simple steatosis and morbidly obese women with NASH. These authors184–
186, in accordance with other studies180,187, have also shown enhanced 
expression of LxRα and SREBP1c, the major transcriptional factors in 
lipogenic gene expression183,189 in NAFLD patients. However, apart from 
FAS, we were unable to find any other significant difference in other genes 
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related to the de novo lipogenesis pathway. These discrepancies might be 
explained by differences in the cohort of patients studied. It is important to 
note that we studied a homogenous cohort of MO women, while the authors 
of these studies included normal weight184, mildly over weight185 or obese187 
patients with NAFLD, as well as men and women in the same cohort of 
patients, or patients with steatosis related to other etiologies, such as 
chronic hepatitis C virus infection185. In addition, Nakamuta et al. found that 
the hepatic expression of LxRα was significantly higher in non-obese 
NAFLD than in obese patients187. 
In order to add to current knowledge of the role of lipid metabolism 
alterations, we then evaluated the hepatic expression of fatty acid 
metabolism-related genes according to the hepatic fat deposition, 
classifying the steatotic patients in different histopathology types of simple 
steatosis (SS): mild, moderate or severe. The most interesting finding was 
that liver expression of key genes related to de novo lipogenesis (LxRα, 
ACC1 and FAS) has an inverse relationship with the degree of SS, i.e it 
diminishes when the degree of steatosis increases. This novel finding was 
confirmed by evaluating the protein expression. Interpreting these findings 
is extremely complicated. Under normal conditions, dietary glucose 
stimulates insulin secretion from the pancreas, which travels directly to the 
liver via the portal vein and elicits two key actions at the gene transcription 
level. In order to keep blood glucose low, insulin first stimulates the 
phosphorylation of the transcription factor FOXO1, preventing it from 
entering the nucleus290, which results in the downregulation of genes 
required for gluconeogenesis. Insulin then also activates the transcription 
factor SREBP1c, which enhances the transcription of genes required for 
fatty acid and triglyceride biosynthesis, and particularly ACC and FAS189,291. 
In the liver, intact insulin signaling is therefore required for lipogenesis 
activation and for gluconeogenesis suppression. Paradoxically, in liver of 
animal models of insulin-resistant type 2 diabetes139 as well as in humans 
with mutations in the insulin receptor137, insulin fails to suppress 
gluconeogenesis but continues to activate lipogenesis, leading to a clear 
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relationship between insulin resistance and hepatic steatosis. To resolve 
this paradox, Brown and Goldstein139 introduced the concept of “selective 
insulin resistance”, according to which although the effect of insulin in both 
gluconeogenic and lipogenic pathways requires the insulin receptor, at 
some distal point, the FOXO1 pathway becomes insensitive to insulin, 
whereas the SREBP1c pathway remains sensitive. Li S, et al.140 suggested 
that mTORC1 is the responsible branch point and an essential component 
in the insulin-regulated pathway for hepatic lipogenesis, but not for 
gluconeogenesis. Surprisingly, our results show a down-regulated 
lipogenesis in the liver of morbidly obese women exhibiting a severe simple 
steatosis. In this context, Biddinger et al. showed that in mice with total 
insulin resistance in liver, insulin fails to stimulate both gluconeogenesis and 
synthesis of fatty acids and triglycerides292. We could thus assume that the 
liver of an extremely obese patient with severe steatosis might behave as if 
there were total insulin resistance, which could be responsible for the 
downregulation of the lipogenic pathway in the liver of these patients. 
However, because we did not use any hyperinsulinemic euglycemic clamp 
technique to measure hepatic insulin sensitivity, we are unable to confirm 
this hypothesis.  
Obesity, which  is commonly observed in NAFLD,  is associated 
with a chronic low-grade inflammatory state characterized by abnormal 
cytokine production, increased synthesis of acute-phase reactants and 
activation of inflammatory signaling pathways91,293. Adipose tissue, and 
especially white adipose tissue, has been recognized as a crucial site in this 
state, due to the fact that many of the interactions between metabolism and 
the immune system are mediated by a complex network of soluble 
mediators derived mainly from adipocytes, known as adipokines 294. In the 
obese state, a dysregulated adipokine secretion is observed, characterized 
by increased pro-inflammatory and decreased anti-inflammatory adipokine 
secretion73. According to the “portal theory”, in obese individuals, the 
increasing pro-inflammatory citokines released from visceral fat, as well as 
increasing amounts of free fatty acids, reach the liver via the portal system, 
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promoting the development of hepatic insulin resistance and liver steatosis 
295. In fact, serum levels of pro-inflammatory adipokines such as leptin, 
resistin, visfatin, TNFα and IL6 has been reported are significantly higher in 
NAFLD/NASH patients, while levels of anti-inflammatory cytokines such as 
adiponectin are significantly reduced103. Moreover, it is important to 
recognize that although the majority of adipokines are secreted by adipose 
tissue, they are also produced by other organs, such as the liver91. Because 
various studies have reported adipokines and pro-inflammatory cytokines as 
having a key role in the pathogenesis of NAFLD, as well as in obesity-
related insulin resistance91,103,293, we also decided to investigate the 
expression levels of hepatic genes that play a significant role in 
inflammation. When we classified our cohort of morbidly obese women 
according to their liver histology, we found that IL6 gene expression is over-
expressed in the liver of NASH patients compared to those with simple 
steatosis, while the gene expression of TNFα also tends to be higher in 
NASH. These results are consistent with the literature, which supports the 
theory that these two pro-inflammatory cytokines are correlated with 
histological NAFLD severity in obese patients. For instance, Crespo et al. 
reported increased hepatic TNFα and TNFRI expression in the liver of 
obese patients with NASH compared to those without NASH107. For IL6, 
Wieckowska et al. demonstrated a marked increase in hepatic IL6 
expression in NASH patients compared to those with hepatic steatosis or 
normal liver histology, and its expression positively correlated with the 
degree of inflammation, stage of fibrosis and systemic insulin resistance108.  
The generally accepted dogma in NAFLD pathogenesis is that 
hepatic lipid accumulation occurs when hyperinsulinemia and IR is 
present74. Hyperinsulinemia is widely considered a consequence of IR 
where β-cells, as a compensatory response to the insulin resistant state, 
produce and secrete increased levels of insulin, resulting in elevated insulin 
basal levels. However, there is increasing data to suggest that 
hyperinsulinemia is often both a result and a driver of insulin resistance296, 
and that hyperinsulinemia is an independent risk factor for the development 
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of perturbed glucose tolerance, type 2 diabetes mellitus and NAFLD297–299. 
In this regard, in a recent study, Steneberg et al. presented in vivo and ex 
vivo data providing evidence that increased insulin circulating levels trigger 
hepatic steatosis development and IR, by stimulating hepatic expression of 
the FA transporter CD36300. In accordance with this theory, we found that 
not only hepatic gene expression of CD36, but also the FA transporter 
FABP4, correlate positively with circulating insulin levels and the presence 
of insulin resistance (HOMA2-IR) in our cohort of morbidly obese women, 
becoming stronger in those with NASH. Moreover, in agreement with our 
results, Miquelina-Colina et al. observed significant correlations between 
CD36 expression and insulin resistance, and plasma insulin levels in 
patients with NASH170. In addition, we found that the expression of the pro-
inflammatory IL6 cytokine in the liver of MO women also correlates with 
insulin circulating levels and HOMA2-IR. Taken together, these results 
indicate that hepatic fatty acid accumulation, as well as inflammation, might 
be contributing to NAFLD progression in relation to the presence of insulin 
resistance. Finally, we also found that the glucose circulating levels of 
morbidly obese women correlate positively with liver FAS expression, 
supporting the observation that glucose binds and activates LXRs 
transcription factors, there by inducing their target genes, including 
SREBP1c, ACC1 and FAS196,301. 
 
The endocannabinoid system, mediated mainly by CB1 and CB2 
cannabinoid receptors, has recently been reported as playing an important 
role in NAFLD by modulating lipid metabolism248. Although traditionally 
associated with the central nervous system, increasing energy intake by 
stimulating the appetite261, cannabinoid receptors in hepatocytes are 
increasingly being recognized as key mediators of fatty liver by regulating 
the expression of key enzymes of lipid synthesis and transport249,250, and 
associated insulin resistance258,263 caused by high-fat diet256, viral 
hepatitis302 or ethanol intake303. Modulation of cannabinoid receptors, and 
specially antagonism of CB1 receptors and CB2 receptor agonism, is thus 
emerging as a potential novel therapeutic approach for the management of 
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NAFLD247,251,253. Consequently, in order to further investigate the role of the 
endocannabinoid system in the physiopathology of NAFLD and its 
relationship with lipid metabolism, for this doctoral thesis, we also studied 
the gene expression profiles of both CB1 and CB2 in the liver of morbidly 
obese women with NAFLD and normal liver histology, as well as the 
correlations between them and the hepatic gene expression of the de novo 
synthesis of FA, FA oxidation, FA uptake and transport, and inflammation–
related genes, and resistin and adiponectin adipokines. Our results show 
that CB1 hepatic gene expression is significantly higher at the histological 
stage of NASH, suggesting that CB1 might have a role in the progression of 
NAFLD. M. Gary-Bobo et al. found that Rimonabant, a selective CB1 
receptor antagonist, decreased the high level of local hepatic TNFα, 
currently associated with steatohepatitis, in obese rats258. However, we 
were  unable to find significant correlations between CB1 gene expression 
and the pro-inflammatory cytokine TNFα, which has been shown to be a 
key mediator of the progression of liver diseases to more serious 
forms304,305. On the other hand, studies in cultured hepatocytes and in 
animal models have observed steatogenic properties of CB1 as a result of 
hepatic lipogenesis activation, reduction of fatty acid oxidation, and 
decreased release of TG-rich VLDL, combining to produce a CB1-
dependent release of free fatty acids from the adipose tissue256,257,259–262. 
Although our cohort of MO women did not demonstrate a relationship 
between the hepatic CB1 gene expression and de novo synthesis of fatty 
acids, we did find that CB1 hepatic gene expression correlates negatively 
with PPARα in the liver of these women. It is well known that PPARα plays 
a pivotal role in FA catabolism by upregulating the expression of numerous 
genes involved in FA oxidation, as well as other aspects of FA 
metabolism306. In addition, it has been demonstrated that PPARα gene 
expression negatively correlates with NASH severity in NAFLD patients230. 
The induced liver gene expression of CB1 in NASH and the negative 
correlation with PPARߙ therefore suggest that CB1 might be playing a 
deleterious role in the physiopathological process of NAFLD. 
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Unlike to CB1, our results show that CB2 gene expression in liver of 
morbidly obese women is similar among those with normal liver, simple 
steatosis and NASH histology. It is important to note that the role of CB2 in 
liver disease is controversial. Some authors have reported that CB2 
receptors have a potential role in liver steatogenesis and fat inflammatory 
response associated with IR281,282, while others have reported that CB2 
receptors exert hepatoprotective effects, reduce liver inflammation, and 
display antifibrogenic propierties (review in Mallat et al.253 and Khalid et 
al.247). As for the steatogenic role of CB2, we found that it correlates 
positively with ACC1 gene expression, a rate-limiting enzyme during the 
fatty acid biosynthesis process by de novo lipogenesis in liver, and with 
PPARߛ gene expression, which has been found to be increased in steatotic 
livers, and several studies attribute a causal role to PPARγ in steatosis 
development by mechanisms involving the activation of lipogenic genes and 
de novo lipogenesis174,177,307. Accordingly, targeted deletion of PPARγ in 
hepatocytes and in macrophages protected mice against diet-induced 
hepatic steatosis175, suggesting a pro-steatotic role for PPARγ. Moreover, 
Paulina Pettinelli et al. showed that PPARγ is up-regulated in the liver of 
obese patients with simple steatosis and NASH, and significantly correlates 
with SREBP1c mRNA levels, acting as an additional reinforcing lipogenic 
mechanism in the development of hepatic steatosis178. However, these 
isolated correlations do not fully clarify the role of CB2 in liver 
steatogenesis. With regard to inflammation, we found that CB2 hepatic 
gene expression correlates positively with the anti-inflammatory molecule 
adiponectin and paradoxically, also with the pro-inflammatory cytokines 
TNFα, IL6 and resistin, suggesting that CB2 is a molecule with a dual action 
in NAFLD. 
  
To summarize, the major finding in this doctoral thesis is that in our 
cohort of morbidly obese women who were diagnosed with isolated simple 
steatosis, de novo fatty acid synthesis appears to be down-regulated in 
advanced histological stages of simple steatosis. We were unable to 
determine the casuality that leads to a down-regulated lipogenesis in a 
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severe steatotic liver, but these results suggest that the deregulation of the 
lipogenic pathway may be associated with the severity of simple steatosis. 
Regarding the role of the endocannabinoid system, our results suggest a 
deleterious role of CB1 in NAFLD, while the role of CB2 is not fully clarified; 
which justifies the need for further study of cannabinoid receptors and its 
relationship with the physiopathological processes of non-alcoholic fatty 
liver disease. Finally, I would like to emphasize that our cohort of MO 
women made it possible to establish relationships between NAFLD and fatty 
acid metabolism-related genes and the CB1 receptor, with no interference 
by confounding factors such as gender or age. However, these results 
cannot be extrapolated to other obesity groups, normal-weight or male 
gender subjects. Further studies including these cohorts would be useful in 
order to validate our results. 
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1. The main lipogenic enzyme fatty acid synthase (FAS) is over-
expressed in the liver of morbidly obese NAFLD women, and its 
hepatic gene expression is positively correlated with glucose circulating 
levels. 
 
2. Gene and protein expression of key genes related to de novo fatty acid 
synthesis has an inverse relationship with the histological degree of 
simple steatosis in the liver of morbidly obese NAFLD women with 
simple steatosis. They diminish when the degree of steatosis 
increases.  
 
3. The inflammatory molecules IL6 and TNFα are over-expressed in the 
liver of morbidly obese NAFLD women with NASH compared to those 
with simple steatosis.  
 
4. Gene expression of the inflammatory molecule IL6, as well as the fatty 
acid transporters CD36 and FABP4 in liver of morbidly obese women is 
positively correlated with glucose metabolism parameters. 
 
5. Cannabinoid receptor 1 (CB1) mRNA expression is significantly higher 
in the liver of morbidly obese NASH women compared to those with 
simple steatosis, and is negatively correlated with hepatic PPARα gene 
expression, suggesting that it might have a deleterious role in NAFLD. 
 
6. Cannabinoid receptor 2 (CB2) mRNA expression in the liver of 
morbidly obese women is similar in those with normal, simple steatosis 
and NASH histology.  
 
7. CB2 mRNA expression in liver of morbidly obese NAFLD women 
correlates positively with both ACC1 and PPARγ hepatic gene 
expression. However, these isolated correlations do not fully clarify the 
role of CB2 in liver steatogenesis. 
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8. CB2 seems to act as a dual molecule in NAFLD due to the fact that its 
hepatic mRNA expression is positively correlated with the hepatic gene 
expression of the anti-inflammatory molecule adiponectin and 
paradoxically, also with inflammatory molecules such as IL6, TNFα and 
resistin.   
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Abstract: Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological change character-
ized by the accumulation of triglycerides in hepatocytes and has frequently been associated with 
obesity, type 2 diabetes mellitus, hyperlipidemia, and insulin resistance. It is an increasingly 
recognized condition that has become the most common liver disorder in developed countries, 
affecting over one-third of the population and is associated with increased cardiovascular- and 
liver-related mortality. NAFLD is a spectrum of disorders, beginning as simple steatosis. In 
about 15% of all NAFLD cases, simple steatosis can evolve into non-alcoholic steatohepatitis, 
a medley of inflammation, hepatocellular injury, and fibrosis, often resulting in cirrhosis and 
even hepatocellular cancer. However, the molecular mechanism underlying NAFLD progression 
is not completely understood. Its pathogenesis has often been interpreted by the “double-hit” 
hypothesis. The primary insult or the “first hit” includes lipid accumulation in the liver, followed 
by a “second hit” in which proinflammatory mediators induce inflammation, hepatocellular 
injury, and fibrosis. Nowadays, a more complex model suggests that fatty acids (FAs) and their 
metabolites may be the true lipotoxic agents that contribute to NAFLD progression; a multiple 
parallel hits hypothesis has also been suggested. In NAFLD patients, insulin resistance leads to 
hepatic steatosis via multiple mechanisms. Despite the excess hepatic accumulation of FAs in 
NAFLD, it has been described that not only de novo FA synthesis is increased, but FAs are also 
taken up from the serum. Furthermore, a decrease in mitochondrial FA oxidation and secre-
tion of very-low-density lipoproteins has been reported. This review discusses the molecular 
mechanisms that underlie the pathophysiological changes of hepatic lipid metabolism that 
contribute to NAFLD.
Keywords: non-alcoholic fatty liver disease, molecular pathways, insulin resistance, fatty acid 
metabolism
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a major public health issue due to its 
high prevalence worldwide, and ranges widely from 11% to 46%,1–3 and has potentially 
serious sequelae.4 The prevalence increases to 58% in overweight individuals and can 
be as high as 98% in non-diabetic obese individuals.5
NAFLD is an inclusive term that takes in a spectrum of liver pathologies from simple 
steatosis (SS) to non-alcoholic steatohepatitis (NASH). NASH involves hepatocellular 
injury and inflammation of the liver.6
Whereas SS is characterized by a relatively favorable clinical course, NASH much 
more frequently progresses to cirrhosis and hepatocellular carcinoma.7,8 NAFLD should 
be suspected in individuals who are either obese, diabetic, or have metabolic syndrome.9 
Moreover, NAFLD is considered a hepatic manifestation of metabolic syndrome and 
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a risk factor for type 2 diabetes mellitus, dyslipidemia, and 
hypertension.10,11 The majority of patients with NAFLD are 
asymptomatic and the disease may be detected via routine 
blood tests showing elevated liver enzymes or when an 
ultrasound is performed for various reasons and detects liver 
steatosis. Secondary causes of hepatic steatosis or elevated 
liver enzymes, such as excess alcohol consumption, medica-
tions, toxins, lipodystrophy, autoimmune and inflammatory 
diseases, nutrition (malnutrition, total parenteral nutrition, 
severe weight loss, and refeeding syndrome), viral hepatitis, 
and metabolic liver disease should be excluded by reviewing 
the patient’s history and proper investigation.9,12
Although it is still not possible to diagnose NAFLD based 
solely on blood work, elevated transaminases can be used as 
a first step.13 An aspartate aminotransferase–alanine amino-
transferase ratio ,1 is also seen in NAFLD14 and supports 
NASH. However, it is important to note that patients with 
normal transaminases and liver steatosis on imaging may also 
have NASH.15 Ultrasonography is a noninvasive tool that is 
used in the detection of liver steatosis. Other imaging tech-
niques such as computed tomography and nuclear magnetic 
resonance imaging can also detect liver steatosis, but neither 
of these more expensive techniques provide more informa-
tion than ultrasonography,16,17 except for fat quantification.18 
Diagnosis for NASH is confirmed when a liver biopsy shows 
the presence of perilobular inflammation, or the presence 
of hepatocyte ballooning, Mallory’s hyaline, and acidophil 
bodies with or without fibrosis. Noninvasive tests such as 
Fatty Liver Index, NAFLD fibrosis score, FibroMeter, and 
Fibroscan19 may suggest the presence of NASH by detecting 
fibrosis. Research is ongoing to assess surrogate markers for 
NASH such as CK18, but this remains experimental.20,21
Regarding the management of NAFLD, weight manage-
ment through improvements in diet and increased physical 
activity can help to improve liver histology as well as delay 
disease progression.22–24 Lifestyle interventions may not be 
effective in certain cases, and thus other approaches must 
be considered. Pharmacological treatment has been studied 
in this population, specifically insulin-sensitizing agents 
(metformin and thiazolidinediones [TZDs]); however, there 
are conflicting results. Clinical studies could not demonstrate 
the effectiveness of metformin in the treatment of NAFLD.25 
On the other hand, TZDs that are peroxisomal proliferator-
activated receptor γ (PPARγ) agonists promote hepatic fatty 
acid (FA) oxidation and decrease hepatic lipogenesis.26,27 
In NAFLD patients, TZDs have been shown to decrease 
hepatic fat and decrease cellular injury. However, discon-
tinuing TZD therapy resulted in NASH recurrence and 
long-term use of TZDs can result in medical complications 
such as edema, congestive heart failure, osteoporosis, and 
weight gain.28,29 The use of statins in NAFLD patients with 
dyslipidemia can improve liver function tests,30 as well as 
steatosis.31  Furthermore, statins seem to be safe in NAFLD/
NASH patients with dyslipidemia.32 However, there is a lack 
of evidence for the use of statins in the treatment of NASH 
patients without dyslipidemia.33 Further research is necessary 
to document the effect of other strategies, such as bariatric 
surgery, antioxidants, and fish oil in NAFLD.
Because there are currently no effective therapies for 
NAFLD apart from weight loss, ongoing research efforts 
are focused on understanding the underlying pathobiology 
of hepatic steatosis with the intention of identifying novel 
therapeutic targets. In this sense, this review analyses some 
of the molecular mechanisms that underlie the pathophysio-
logical changes of hepatic lipid metabolism in NAFLD: the 
contribution of lipid metabolism, the influence of inflamma-
tion, and the role of lipotoxicity and cannabinoid receptors 
in NAFLD.
Contribution of lipid  
metabolism to NAFLD
The liver plays a major role in lipid metabolism, importing 
free FAs (FFAs) and manufacturing, storing, and exporting 
lipids; derangements in any of these processes can lead to 
the development of NAFLD.34 FAs are involved in many 
important cellular events, such as synthesis of cellular mem-
branes, energy storage, and intracellular signaling pathways. 
 However, chronically elevated FFAs can disturb diverse met-
abolic pathways and induce insulin resistance (IR) in many 
organs. Hepatic fat accumulation has been strongly associ-
ated with IR.35,36 IR in the peripheral adipose tissue enhances 
lipolysis and increases the delivery of adipose-derived FFAs 
to the liver. In particular, obesity increases tumor necrosis 
factor α (TNFα) production in adipocytes, facilitates adipo-
cyte IR, and increases lipolysis rate.37 Thus, the circulating 
pool of FFAs is increased in obese individuals and accounts 
for the majority of liver lipids in NAFLD.38
Under physiological conditions, triglyceride (TG) syn-
thesis is stimulated to dispose of the excess of FFAs. The 
TGs can then be stored as lipid droplets within hepatocytes 
or secreted into the blood as very-low-density lipoprotein 
(VLDL).39 Rodent studies have shown that the mechanisms 
leading to the excessive accumulation of hepatic TGs are 
associated with an increased supply of FFAs from peripheral 
adipose tissue to the liver and an enhanced de novo lipid syn-
thesis via the lipogenic pathway. Conversely, liver disposal 
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via β-oxidation and VLDL export are moderately affected.40 
At the cellular level, defects in the insulin signaling pathways 
contribute to the increase of FFA flux in the liver, which in 
turn activates a series of signaling cascades and leads to the 
phosphorylation of several substrates.41 Despite TGs being 
the main lipids stored in the liver of patients with NAFLD, 
large epidemiological studies suggest that they might exert 
protective functions. TG synthesis seems to be an adap-
tive, beneficial response in situations where hepatocytes 
are exposed to potentially toxic TG metabolites.42–44 FFAs 
and cholesterol, especially when accumulated in the mito-
chondria, are considered the “aggressive” lipids leading to 
TNFα-mediated liver damage and reactive oxygen species 
(ROS) formation.45,46 These lipids could also be present in 
a non-steatotic liver and act as early “inflammatory” hits, 
leading to the whole spectrum of NAFLD pathologies. The 
concept of lipotoxicity and involved lipid species has been 
introduced: abundant FAs cause lipotoxicity via the induction 
of ROS release, which causes inflammation, apoptosis, and 
thus, the progression to NASH and fibrogenesis.46–48
In summary, TG accumulation in the cytoplasm of 
hepatocytes, as the hallmark of NAFLD, arises from an 
imbalance between lipid acquisition (FA uptake and de 
novo  lipogenesis) and removal (mitochondrial FA oxidation 
and export as a component of VLDL particles) and accom-
panies multiple pathophysiological mechanisms in NASH 
(Figure 1). In order to control the progression of NAFLD, 
it is important to understand the regulatory mechanisms of 
lipid accumulation in the human liver.
Hepatic FA uptake
One of the sources for hepatic FAs is FFA recruitment from 
the blood stream. FFAs are derived from lipolysis in adipo-
cytes, which usually occurs in the fasting state, promoted by 
catecholamines, natriuretic peptides, and glucagon, and are 
usually repressed by insulin.49 However, the IR state (obesity, 
metabolic syndrome) goes along with increased adipocyte 
lipolysis, leading to abundant FFAs in the plasma pool inde-
pendently from the nutritional status.50 FFAs are then taken 
up by the hepatocytes in a facilitated fashion rather than by 
passive processes.51 FA uptake into the liver contributes to 
the steady balance of hepatic TGs, as well as the pathogen-
esis of NAFLD. The rate of FA uptake from plasma into 
cells depends on the FA concentration in the plasma and the 
hepatocellular capacity for FA uptake, which also depends 
on the number and activity of transporter proteins on the 
sinusoidal plasma membrane of the hepatocyte. The main 
plasma membrane transporters for FFAs are FA transporter 
protein (FATP), caveolins, FA translocase (FAT)/CD36, and 
FA-binding protein (FABP).52–56
FATP
Six FATP isoforms have been identified in mammalian cells, 
which contain a common motif for FA uptake and fatty acyl-
CoA synthetase function.57 Of these isoforms, FATP2 and 
FATP5 are highly expressed in the liver, and are utilized as 
major FATPs for the normal physiological context. In mouse 
hepatocytes, adenovirus-mediated knockdown of FATP2 or 
genetic deletion of FATP5 significantly decreases the rates 
of FA uptake.58 Indeed, FATP5 knockout mice have shown 
resistance to diet-induced obesity and hepatic TG accumu-
lation.58 In humans, a promoter polymorphism in the liver-
specific FATP5 is associated with features of the metabolic 
syndrome and steatosis.59
Caveolins
Caveolins consist of three protein family members termed 
caveolins 1, 2, and 3. They are found in the membrane 
structures called caveolae, which are important for protein 
trafficking and the formation of lipid droplets. Caveolin 1 
knockout mice exhibited lower TG accumulation in the liver 
and showed resistance to diet-induced obesity, showing the 
importance of this protein in TG synthesis.60 Some authors 
Insulin Glucose
FFAs
 FFAs
Triglycerides
ApoB
De novo lipogenesis
Chylomicron
VLDL
β-oxidation
Figure 1 Hepatic steatosis.
Notes: The hallmark of NAFLD is triglyceride accumulation in the cytoplasm 
of hepatocytes as a result of an imbalance between lipid input and output: 1) an 
increase in FFAs uptake derived from the circulation due to increased lipolysis from 
adipose tissue and/or from the diet in the form of chylomicrons; 2) an increase in 
glucose and insulin levels in response to carbohydrate intake that promotes de novo 
lipogenesis; 3) a decrease in FA mitochondrial oxidation; 4) a decrease in triglyceride 
hepatic secretion by packaging with ApoB into vLDLs. in NAFLD patients, enhanced 
acquisition of FAs through uptake and de novo lipogenesis are not compensated by 
FA oxidation or production of vLDL particles.
Abbreviations: ApoB, apolipoprotein B; FFAs, free fatty acids; FA, fatty acid; 
NAFLD, non-alcoholic fatty liver disease; vLDL, very-low-density lipoprotein.
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suggest there is an involvement of caveolin 1 in abnormal 
lipogenesis and mitochondrial function typical of steatotic 
hepatocytes in NAFLD.61
FAT/CD36
It is well-known that FFAs are taken up into cells by passive 
diffusion and by protein-mediated mechanisms involving a 
number of FA transporters, of which FAT/CD36 is the best 
characterized. FAT/CD36 is expressed in a wide variety 
of cells including macrophages, adipocytes, myocytes, 
enterocytes, and hepatocytes. This transmembrane pro-
tein plays an important role in facilitating the uptake and 
intracellular trafficking of FFAs, as well as esterification 
into TGs in heart and skeletal muscle cells; this function 
is largely dependent on its translocation from intracellular 
depots to the plasma membrane. Insulin, muscular contrac-
tions, and the transcription factor Forkhead box protein 
O1 (FoxO1) induce FAT/CD36 translocation and enhance 
FFA uptake.62
Hepatic FAT/CD36 expression is normally weak, but 
its expression is enhanced in rodents with fatty liver.63 
Moreover, some authors have demonstrated that FAT/CD36 
mRNA levels increase concomitantly with hepatic TG con-
tent in different animal models of liver steatosis.64,65 Further 
studies have shown that FAT/CD36 is a common target gene 
of liver X receptor (LXR), pregnane X receptor, and PPARγ 
in promoting hepatic steatosis in a murine model.66 However, 
little is known about the significance of FAT/CD36 in human 
liver diseases. In morbidly obese patients with NAFLD, 
Greco et al showed that hepatic FAT/CD36 mRNA levels 
were positively related to liver fat content67 and Bechmann 
et al found a significant correlation between hepatic FAT/
CD36 mRNA and apoptosis in patients with NASH.68 Other 
authors have described that hepatic FAT/CD36 upregulation 
is significantly associated with IR, hyperinsulinemia, and 
increased steatosis in patients with NASH.62
FABPs
The FABPs are a group of molecules that coordinate inflam-
matory and metabolic responses in cells.69 These proteins are 
a family of 14- to 15-kDa proteins that bind with high affinity 
to hydrophobic ligands such as saturated and unsaturated long-
chain FAs (LCFAs).70 Two isoforms of FABPs, aP2 (FABP4) 
and mal1 (FABP5) are the isoforms coexpressed in adipocytes 
and macrophages.71 The expression of these FABP isoforms 
is controlled transcriptionally during adipocyte differentia-
tion and is regulated by PPARγ agonists, insulin, and FAs. 
The functions of cytoplasmic FABPs include  enhancement of 
FFA solubility and transport to specific enzymes and  cellular 
 compartments (to the mitochondria and peroxisomes for 
oxidation; to the endoplasmic reticulum [ER] for reesterifica-
tion; into lipid droplets for storage; or to the nucleus for gene 
expression regulation).71,72 Disruption or pharmacological 
blockade of FABP4 protects mice from dyslipidemia, athero-
sclerosis, IR, and fatty liver in the context of either a high-fat 
diet or genetically induced obesity.73 The definitive biology 
and function of FABPs in human physiology and disease 
are still not fully clarified.69,73 Few studies have assessed the 
involvement of hepatic FABP4 expression in NAFLD. Greco 
et al and Taskinen et al have described FABP4 as being upregu-
lated in subjects with high liver fat content.67,74 The expression 
of FABP4 and FABP5 in the liver was correlated with hepatic 
fatty infiltration in NAFLD patients.75
Recent studies have also suggested that hepatic FA uptake 
via FATPs can be a novel therapeutic strategy for NAFLD. 
Adenovirus-mediated knockdown of FATP2 or FATP5 
reduced hepatic TG accumulation in high-fat fed mice.76,77 
Moreover, both deoxycholic and ursodeoxycholic acid have 
shown promise as inhibitors of FATP5-mediated FA uptake, 
suggesting that they may improve hepatic steatosis in high-
fat fed mice.78
PPARγ
PPARγ is a master transcriptional regulator of adipogenesis 
and plays an important role in the process of lipid storage.79 
Thus, PPARα and PPARγ have opposing functions in the 
regulation of fat metabolism; PPARα promotes utilization, 
while activation of PPARγ promotes storage. Indeed, as 
increased PPARγ expression has been found in steatotic 
livers, it has been suggested that the role of PPARγ in the 
activation of lipogenic genes may contribute to the develop-
ment of steatosis. Nevertheless, several studies have shown 
that PPARγ overexpression can prevent the progression of 
hepatic steatosis in murine models, and treatment with the 
PPARγ agonist rosiglitazone has been shown to have simi-
lar effects. The protective effects of PPARγ could be due 
to higher insulin sensitivity in adipose tissue and skeletal 
muscle leading to a reduction in FFA deposition in the liver. 
Adiponectin has also been shown to be increased by PPARγ, 
which also contributes to insulin sensitivity as well as upregu-
lating PPARα expression, which leads to further hepatic FA 
oxidation. Furthermore, PPARγ expression has been shown 
to have anti-inflammatory and anti-fibrotic effects in stellate 
cells, macrophages, and epithelial cells. Westerbacka et al 
have described that PPARγ was overexpressed in the fatty 
liver of obese human subjects.75
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Activation of PPARγ in adipose tissue has been proposed 
to promote the relocalization and storage of fat in adipose 
tissue, protecting peripheral tissues from lipotoxicity.
Regarding this, the TZDs have proven to be effective 
drugs for improving insulin sensitivity and treating type 2 
diabetes. Moreover, pioglitazone and rosiglitazone are highly 
effective in improving NAFLD outcomes in patients.80 
 Unfortunately, the clinical use of TZDs against NAFLD has 
been hampered by side effects.
De novo lipogenesis
The process in which the liver synthesizes endogenous FAs is 
called de novo lipogenesis. This includes de novo synthesis of 
FAs through a complex cytosolic polymerization in which glu-
cose is converted to acetyl-CoA by glycolysis and the oxidation 
of pyruvate. Acetyl-CoA carboxylase (ACC1) then converts 
acetyl-CoA into malonyl-CoA. Finally, FA synthase (FAS) 
catalyzes the formation of palmitic acid from malonyl-CoA 
and acetyl-CoA.81–83 Depending on the metabolic state, FAs are 
then processed to TGs and stored or rapidly metabolized.
Dietary fats are packed in chylomicrons and hydrolyzed, 
releasing FAs of which approximately 20% are delivered 
to the liver.7 In the fasting state, a decline of insulin levels 
stimulates adipocyte TG hydrolase, thereby releasing FFAs 
that are transported to the liver. In the liver, FFAs derived 
from peripheral tissue, endogenous synthesis, or diet, can 
be used for: 1) energy and ketone body production via 
mitochondrial β-oxidation; 2) sterified and stored as TGs 
in lipid droplets; or 3) packaged with apolipoprotein B into 
VLDL that is secreted into the circulation.83,84 In NAFLD 
patients, enhanced acquisition of FAs through uptake and 
de novo lipogenesis are not compensated by FA oxidation 
or production of VLDL particles (Figure 1).
The rate of de novo lipogenesis is regulated primarily at 
the transcriptional level. Several nuclear transcription factors 
are involved such as LxRα, sterol regulatory element-binding 
protein 1c (SREBP1c), carbohydrate-responsive element-
binding protein (ChREBP), and farnesoid X receptor (FxR); 
and enzymes (ACC1, FAS, and steroyl CoA desaturase 1 
[SCD1]). Postprandially, plasma glucose and insulin levels 
rise, which promote activation of lipogenesis through the acti-
vation of ChREBP and SREBP1c, respectively.34,85 In humans, 
NAFLD has been associated with increased hepatic expres-
sion of several genes involved in de novo lipogenesis.86,87
LXRs
LXRs are ligand-activated transcription factors that belong 
to the nuclear receptor (NR) superfamily.88 There are two 
LXR isoforms termed α and β. LxRα is mainly expressed 
in the liver, adipose tissue, and intestine, whereas LxRβ is 
ubiquitously expressed.89 In addition to modulating choles-
terol metabolism, LXRs have been characterized as major 
regulators of hepatic FA biosynthesis.90 A major function of 
LxRα in the liver is the stimulation of de novo lipogenesis, 
through the induction of SREBP1c, ACC1, FAS, and SCD1 
(Figure 2).91–93
Several authors have described an enhanced expression 
of LxRα and SREBP1c in NAFLD.87,94,95
SREBP1c
SREBPs are a family of membrane-bound transcription 
factors. SREBPs are synthesized as 125 kD precursors 
embedded in the ER. Proteolytic cleavage then allows the 
accumulation of active SREBP in the nucleus.
There are different SREBP isoforms: SREBP1c and 
SREBP2 are expressed in the liver, while SREBP1a is 
expressed only at very low levels in the liver of adult mice, 
rats, and humans.96 SREBP1c, the predominant isoform in 
the liver, preferentially affects the transcription of genes that 
regulate de novo lipid synthesis, although SREBP2 regulates 
Insulin
FxR
LXR
SREBP1c
PPARα
ChREBP
ACC, FAS, SCD1
G6PC, GCKR
Glucose
SFA
MUFA
FAs/TGs
β-oxidation
Figure 2 Transcriptional control of lipogenesis and glycolysis.
Notes: The conversion of glucose into FAs through de novo lipogenesis is 
nutritionally regulated by glucose and insulin signaling pathways, which induce the 
expression of glycolytic and lipogenic genes synergistically in response to dietary 
carbohydrates. insulin activates the transcription factor SREBP1c, which induces 
lipogenic enzymes (ACC1, FAS, SCD1), while glucose activates the transcription 
factor ChREBP, which induces both lipogenic (ACCl, FAS, SCD1) and glycolytic 
(G6PC, GCKR) enzymes. ChREBP is also a direct target of LXRs, and modifies the 
ratio of MUFA/SFA in favor of MUFA by stimulating SCD1 activity. Recently, glucose 
was also identified as activating LXR’s genes. Hepatic FxR activation inhibits FA/TG 
synthesis by suppressing SREBP1c and LXRα activation, and inducing the expression 
of PPARα, which promotes mitochondrial oxidation of FAs.
Abbreviations: ACC, acetyl-CoA carboxylase; ChREBP, carbohydrate-responsive 
element-binding protein; FA, fatty acid; FAS, fatty acid synthase; FFAs, free fatty 
acids; FxR, farnesoid X receptor; G6PC, glucose 6-phosphatase; GCKR, glucokinase 
regulatory protein; LXR, liver X receptor; MUFA, monosaturated fatty acids; PPARα, 
peroxisomal proliferator-activated receptor alpha; SCD1, steroyl CoA desaturase 1; 
SFA, saturated fatty acids; SREBP1c, sterol regulatory element-binding protein 1c; 
TG, triglyceride.
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genes involved in cholesterol biosynthesis and metabolism. 
The SREBP1a isoform, despite its very low levels in the liver, 
transactivates both lipogenic and cholesterol genes.97
To date, the main regulation demonstrated for SREBP1c 
is at the transcriptional level. SREBP1c transcription is 
induced by two quite disparate stimuli: insulin, a hormone 
released in response to carbohydrate intake and leading to a 
parallel increase in both the membrane-bound precursor and 
the mature nuclear form, and LxRα, a transcription factor that 
acts as a cholesterol sensor.92,93,98–100 In response to feeding, 
SREBP1c binds to its lipogenic genes, such as ACC1, FAS, 
and SCD1, and to its own gene, thereby stimulating hepatic 
lipogenesis (Figure 2).96,101–105
Different authors have described an enhanced expres-
sion of SREBP1c and LxRα in NAFLD.87,94,95 However, 
Nagaya et al demonstrated the downregulation of the hepatic 
SREBP1c-mediated lipogenic pathway in advanced NASH 
patients; SREBP1c mRNA levels were inversely correlated 
with the fibrosis stage.106 These discrepancies might be 
explained by differences in the cohort of studied patients. 
For example, Higuchi et al94 included normal weight patients 
with NAFLD and Lima-Cabello et al95 included patients 
with NAFLD and with steatosis related to chronic hepatitis 
C virus infection in mildly overweight men and women. 
Moreover, Higuchi et al did not evaluate either histological 
findings nor protein levels or intracellular localization of 
SREBP1c.94
ChREBP
De novo lipogenesis is regulated by glucose and insulin 
signaling pathways in response to dietary carbohydrate 
intake to induce glycolytic and lipogenic gene expression. 
SREBP1c has emerged as a major mediator of insulin action 
on lipogenic genes. However, SREBP1c activity alone is 
not sufficient for the stimulation of glycolytic and lipogenic 
gene expression.107,108 Over recent years, it has been reported 
that the liver transcription factor ChREBP is required for 
the induction of glycolytic gene expression by glucose and 
that it acts together with SREBP1c to stimulate lipogenic 
genes.109–111 Interestingly, ChREBP was also identified as a 
direct target of LXRs, which are an important regulator of 
the lipogenic pathway through the transcriptional control 
of SREBP1c, ACC1, FAS, and SCD1.112–117 Oxysterols are 
known as ligands of LXRs, but glucose was also shown to 
activate LXRs and to induce their target genes, including 
ChREBP (Figure 2).107,118
Postprandial hyperglycemia raises the hepatic concentra-
tions of phosphorylated intermediates, causing activation 
of ChREBP, which binds to the promoter of its target genes 
as a heterotetramer with its ubiquitously expressed partner 
Max-like protein X (Mlx). ChREBP target genes include not 
only enzymes of glycolysis and lipogenesis that predispose 
to hepatic steatosis, but also glucose 6-phosphatase (G6PC), 
which catalyzes the final reaction in glucose production, 
and glucokinase regulatory protein (GCKR), which inhibits 
hepatic glucose uptake.119,120 Transcriptional induction of 
G6PC and GCKR manifests as hepatic glucose intolerance 
or IR.121 Studies using a dominant negative variant of Mlx 
identified target genes of ChREBP–Mlx that promote hepatic 
glucose intolerance when overexpressed.120
Study results of the role and impact of ChREBP in 
glucose and lipid metabolism have been confusing. Global 
ChREBP deficiency in C57BL/6J mice results in IR.122 On 
the other hand, ChREBP deficiency123,124 or expression 
of a dominant negative Mlx isoform125 in an obese ob/ob 
background decreases hepatic steatosis and other related 
metabolic alterations, including IR. Benhamed et al126 
hypothesized that these opposite phenotypes in these two 
murine models may reside in the fact that ChREBP controls 
both glycolysis and lipogenesis, and that the beneficial 
effect of ChREBP deficiency may only be apparent in the 
context of lipid overload. The authors showed that mice 
overexpressing ChREBP, on a standard diet, remained 
insulin sensitive, despite increased lipogenesis resulting in 
hepatic steatosis. However, mice that overexpress ChREBP, 
on a high-fat diet, showed normal insulin levels and 
improved insulin signaling and glucose tolerance compared 
with controls, despite having greater hepatic steatosis. This 
effect seems to be mediated by the fact that ChREBP modi-
fies the monounsaturated FAs/saturated FAs (MUFA/SFA) 
balance in favor of MUFA, by stimulating SCD1 activity. 
Taken together, these results demonstrated that increasing 
ChREBP, by buffering detrimental FAs and favoring lipid 
partitioning, can dissociate hepatic steatosis from IR, with 
beneficial effects on both glucose and lipid metabolism. 
Interestingly, ChREBP expression in liver biopsies from 
patients with NASH was higher when steatosis was greater 
than 50% and lower in the presence of severe IR,126 sup-
porting this conclusion.
Furthermore, because insulin induces enzymes of 
 lipogenesis by activation of SREBP1c and represses G6PC 
through other transcriptional regulators, a mechanism of 
“selective IR” has been proposed to explain the simulta-
neous elevation of hepatic glucose production (or G6PC 
 expression) and lipogenesis in human type 2 diabetes or 
models of IR.127
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FxR
The FxR is a member of the NR superfamily and a receptor 
for bile acids. FxR activation leads to alterations in pathways 
involved in energy metabolism. It is mainly expressed in 
the liver, intestine, kidneys, and the adrenal glands, with 
less expression in adipose tissue and heart.128–130 FxR has 
emerged as a master regulator of lipid and glucose homeo-
stasis in the liver and of inflammatory processes at hepatic 
and extrahepatic sites. Also, a number of synthetic FxR 
agonists are being used for the treatment of different hepatic 
and metabolic disorders, resulting in a lower inflammatory 
and fibrogenic process.131,132
The generation of FxR knockout mice showed a clear role 
for FxR as the master regulation of bile acid homeostasis.133,134 
However, FxR knockout mice also revealed elevated levels 
of cholesterol and TGs in both the plasma and liver, sug-
gesting a key role for FxR lipid metabolism as well. In fact, 
it was demonstrated that FxR needs to be activated in order 
to reduce the expression of SREBP1c.135 More recently, in 
addition to bile acid and lipid metabolism, it has been shown 
that FxR also plays an important role in glucose metabolism, 
improving insulin sensitivity and glucose tolerance in a dia-
betic mice model.136,137
Regarding its role in lipid metabolism, the majority of 
literature seems to point to the fact that FxR activation is ben-
eficial in situations of excess, such as obesity and diabetes. 
FxR activation seems to reduce TGs levels by: 1) reducing 
FA synthesis in the liver, through the reduction of SREBP1c 
and LxR expression;138 2) inducing the expression of PPARα, 
which promotes FFA catabolism via β-oxidation; 3) increas-
ing TG clearance; and 4) increasing adipose tissue storage 
and altering adipokine patterns (Figure 2).139,140
Another hepatic protective mechanism of FxR activation 
has been shown to be maintenance of gut integrity against 
gut-derived endotoxins through the induction of antibacte-
rial factors such as angiogenin, inducible NO synthase, and 
interleukin-18 (IL18).131,132
Patients with NAFLD have lower protein and mRNA FxR 
levels, which has been attributed to higher TG synthesis and 
induced expression of SREBP1c and LxRα.138
ACC1 and FAS
In the process of FA synthesis, ACC1 converts acetyl-CoA, an 
essential substrate of FAs, to malonyl-CoA. FAS then utilizes 
both acetyl-CoA and malonyl-CoA to form palmitic acid 
(C16:0). Both are highly regulated by a transcriptional factor, 
SREBP1c, and play important roles in the energy metabolism 
of FAs. They are currently considered an attractive target for 
regulating the human diseases of obesity, diabetes, cancer, 
and cardiovascular complications. Dorn et al found that FAS 
expression was impaired in SS, while the absence of SS in 
hepatic inflammation did not affect FAS expression.141 In 
agreement with Dorn et al, several authors have described 
an enhanced expression of FAS in NAFLD.142 These authors 
have also described that ACC1 mRNA expression was higher 
in NAFLD. In support of increased FA synthesis in NAFLD, 
Morgan et al found that ACC1 and FAS mRNA expression 
were significantly higher in high-fat mice.143 All these find-
ings suggest that ACC1 and FAS might be a new diagnostic 
marker or therapeutic target for NAFLD.
FoxO1
FoxO1 is a transcription factor with an important role not 
only in glycogenolysis and gluconeogenesis, but also in lipid 
metabolism.
With regard to lipid metabolism, liver-specific transgenic 
expression of active FoxO1 induces the expression of genes 
involved in lipid transport and decreases the expression of 
important genes for glycolysis and lipid/sterol synthesis, 
resulting in lower postprandial TG concentrations compared 
to in wild-type mice.144 However, using a similar murine 
model, another group observed enhanced lipogenesis and 
liver steatosis.145 Similarly, adenoviral delivery of an active 
FoxO1 variant to the liver results in lipogenesis, hepatic 
steatosis, and reduced FA oxidation. These increases in 
lipogenesis result from a feedback loop that enhances insu-
lin signaling, thereby modulating lipid metabolism through 
SREBP1c in a FoxO1-independent manner.146
FoxO1 not only inhibits SREBP1c expression but also 
suppresses the expression of genes directly involved in FA 
synthesis, including FAS and adenosine triphosphate (ATP) 
citrate lyase.144
With regard to glucose metabolism, under fasting 
conditions, the liver provides energy by releasing glucose 
into the bloodstream. Initially, this results from the break-
down of liver glycogen stores (glycogenolysis), whereas 
with prolonged fasting, the primary source of glucose is 
 gluconeogenesis. Studies with adenoviral vectors in isolated 
hepatocytes confirm that FoxO1 stimulates the expression of 
gluconeogenic genes and suppresses the expression of genes 
involved in glycolysis, the shunt pathway, and lipogenesis, 
including glucokinase and SREBP1c. Taken together, these 
results indicate that FoxO1 proteins promote hepatic glucose 
 production through multiple mechanisms and contribute 
to the  regulation of other important metabolic pathways 
in adapting to fasting and feeding in the liver, including 
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 glycolysis, the pentose phosphate shunt, and lipogenic and 
sterol synthetic pathways.144
Chronic expression of an active FoxO1 mutant in the liver 
leads to increased expression of genes involved in gluconeo-
genesis, resulting in elevated plasma glucose and insulin lev-
els, which are not able to maintain normal  glycemia.144 Valenti 
et al suggest that increased FoxO1 activity may play a role in 
the pathogenesis of hepatic IR associated with NAFLD.147
Reduction of FoxO1 in both liver and white adipose tis-
sue using an antisense oligonucleotide-mediated approach 
improves glucose tolerance and both hepatic and peripheral 
insulin action in mice with diet-induced obesity.148  Consistent 
with these studies, FoxO1 haploinsufficiency is able to 
rescue the loss of insulin sensitivity in insulin receptor– 
haploinsufficient mice partly by reducing the hepatic expres-
sion of gluconeogenic genes.149
FA oxidation
Oxidation of FAs occurs within the mitochondria, peroxi-
somes, and the ER. It facilitates the degradation of activated 
FAs to acetyl-CoA. FAs are activated by acyl-CoA-synthetase 
to acyl-CoA in the cytosol, which is indispensable for enabling 
FAs to cross membranes and enter organelles. Short- and 
medium-chain FAs pass the mitochondrial membrane without 
activation. However, activated LCFAs are shuttled across 
the membrane via carnitine palmitoyltransferase-1 (CPT1). 
Malonyl-CoA, an early intermediate of de novo lipogenesis, 
is an inhibitor of CPT1. In the fed state, FA oxidation is 
inhibited and de novo lipogenesis promoted, allowing for 
storage and distribution of lipids. In general, short-, medium-, 
and long-chain FAs are oxidized within mitochondria 
(β-oxidation), while toxic, very-long-chain FAs are oxidized 
within peroxisomes. In diabetes or FA overload, cytochrome 
P450 (CYP4A)-dependent ω-oxidation of LCFAs occurs in 
the ER and induces ROS and lipid peroxidation. During the 
process of β-oxidation, electrons are indirectly donated to the 
electron transport chain to drive ATP synthesis. Acetyl-CoA 
can be further processed via the tricarboxylic acid cycle, or in 
the case of FA abundance, be converted into ketone  bodies. 
PPARα and insulin signaling are again involved in the regu-
lation of FA oxidation and the formation of ketone bodies 
via transcriptional regulation of mitochondrial 3-hydroxy-3-
methylglutaryl (HMG)-CoA synthase.82
PPARα
In the liver, PPARα plays a pivotal role in FA metabolism 
by upregulating the expression of numerous genes involved 
in mitochondrial FA and peroxisome FA oxidation, as well 
as numerous other aspects of FA metabolism in the cell.150 
As a consequence, activation of PPARα can prevent and 
decrease hepatic fat storage.151–154 When PPARα sensing is 
inefficient, overnight or prolonged fasting leads to severe 
hepatic steatosis, as seen in PPAR-α-/- mice.155,156 PPARα-/- 
mice fail to upregulate FA oxidation systems in the liver and 
cannot oxidize the influxed FAs, and thus develop severe 
hepatic steatosis. PPARα-/- mice also develop severe steato-
hepatitis when maintained on a diet deficient in methionine 
and choline.153,157,158 Also of importance is that administering 
PPARα agonists to rats not only prevents the development of 
methionine- and choline-deficient diet-induced steatohepatitis 
by preventing intrahepatic lipid and lipoperoxide accumula-
tion, but also reverses hepatic fibrosis by decreasing the expres-
sion of fibrotic markers and reducing the number of stellate 
cells.153,157–159 The efficacy of these agonists in the treatment of 
NAFLD in human subjects has not yet been studied in depth. 
From the available data, no definitive conclusion can be made 
on the efficacy of PPARα agonists on NAFLD due to study 
limitations, such as small sample size, incomplete data, and the 
use of agonists in combination with other strategies.160
Besides governing metabolic processes, PPARα also reg-
ulates inflammatory processes, mainly by inhibiting inflam-
matory gene expression. Hepatic PPARα activation has been 
repeatedly shown to reduce hepatic inflammation elicited by 
acute exposure to cytokines and other compounds.161–165
In conclusion, PPARα activation plays a role in the 
modulation of hepatic steatosis due to its effects: upregulation 
of FA oxidation systems and the ensuing burning of energy, 
reduction in the toxicity of FAs, and its anti-inflammatory 
effect (Figure 3).153,155,156,158
CPT1
CPT1 is a regulatory enzyme in the mitochondria that 
transfers FAs from the cytosol to the mitochondria prior to 
β-oxidation (Figure 3). Inhibition of CPT1 has been shown to 
prevent IR induced by a high-fat diet, partly due to a reduction 
in some of the deleterious intermediates generated by incom-
plete FA oxidation and partly to a shift toward increased 
glucose oxidation for energy production.166 Kohjima et al 
showed that CPT1 expression in humans is reduced by 50% 
in NAFLD compared with that in the normal liver.142
Inflammation and NAFLD
It is well-known that the balance between pro- and anti-
inflammatory acting cytokines is fundamental in the control 
of systemic and hepatic insulin action, and as a consequence, 
in the development of NAFLD. IR is an important feature 
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Figure 3 Fatty acid oxidation.
Notes: in the liver, mitochondrial, peroxisomal, and microsomal FA oxidation are regulated by PPARα and metabolize energy. increased sensing of PPARα results in energy 
burning and reduced fat storage. Decreased sensing of PPARα leads to a reduction in energy utilization and increased lipogenesis, resulting in steatosis and steatohepatitis.
Abbreviations: CPT1, carnitine palmitoytransferase-1; FA, fatty acid; PPARα, peroxisomal proliferator-activated receptor alpha.
NAFLD
Adipose tissue inflammation
ADIPOR2
Adiponectin
TNFα
TNFR
IL6RIL6
Figure 4 Cytokines and NAFLD.
Notes: The balance/imbalance of pro- and anti-inflammatory cytokines secreted by 
adipose may profoundly affect the liver. Hepatic adiponectin mRNA expression was 
lower in individuals with NAFLD. However, TNFα and iL6 mRNA expression were 
higher in these patients. NALFD is associated with more proinflammatory cytokines 
and with fewer anti-inflammatory cytokines.
Abbreviations: ADiPOR2, adiponectin receptor type 2; iL6, interleukin-6; NAFLD, 
non-alcoholic fatty liver disease; TNFα, tumor necrosis factor alpha; TNFR, tumor 
necrosis factor receptor; iL6R, interleukin-6 receptor.
of NAFLD and is caused by a variety of factors, including 
soluble mediators derived from adipose tissue and/or immune 
cells: the adipocytokines (Figure 4).167
Adiponectin
Adiponectin, one of the major products of adipocytes, is a 
prototypic anti-inflammatory and anti-diabetic adipocytokine, 
the actions of which are mainly exerted by the activation of 
adenosine monophosphate (AMP)-activated kinase and 
PPARα. Adiponectin has two specific receptors: adiponectin 
receptor type 1 and 2 (ADIPOR1 and 2). ADIPOR1 is widely 
expressed, whereas ADIPOR2 can be mainly observed in the 
liver.168 Serum levels of adiponectin are lower in individu-
als with obesity, type 2 diabetes, and in conditions of IR,169 
whereas adiponectin synthesis is induced by weight loss and 
PPARγ activation by its ligands, TZDs.28 In general, studies 
have suggested that adiponectin exerts anti-inflammatory 
effects, stimulates secretion of anti-inflammatory cytokines 
such as IL10 or IL1 receptor antagonist (IL1Ra), blocks 
nuclear factor κB (NF-κB) activation, and inhibits the release 
of TNFα, IL6, and chemokines.170,171
The liver is not a relevant source of circulating adiponec-
tin, but it is a major target organ for many of its effects. In 
mice with alcoholic and non-alcoholic fatty liver disease, 
administering recombinant adiponectin ameliorated necroin-
flammation and steatosis, partly via inhibition of the hepatic 
production of TNFα and the decrease in plasma concentration 
of this proinflammatory cytokine.172
In humans, adiponectin serum levels were lower in 
patients with NASH in comparison to matched controls and 
to patients with SS, independently of IR or the waist–hip 
ratio. IR and low adiponectin serum levels were associated 
with increased steatosis and necroinflammation, but not 
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with severe fibrosis, which was predicted only by IR.173 
Another study has shown that morbidly obese patients with 
IR undergoing bariatric surgery have lower mRNA adiponec-
tin expression in adipose tissue and lower serum levels of 
adiponectin than those without IR. This low expression of 
adiponectin may predispose patients to the progressive form 
of NAFLD or to NASH.174
Low mRNA expression of adiponectin and ADIPOR2 
was found in the liver of patients with NASH compared with 
those with SS. Moreover, ADIPOR2 expression was inversely 
related to alanine aminotransferase and the fibrosis stage.175 
More recently, Moschen et al demonstrated in a prospective 
study that rapid weight loss after bariatric surgery results in 
a significant improvement of both histological and biochemi-
cal liver parameters, which is accompanied by an increase 
of adiponectin serum levels, as well as hepatic mRNA adi-
ponectin expression.176
Altogether, there is now strong evidence that circulating 
adiponectin levels are lower in obesity and related human 
disorders, including NAFLD.176,177
TNFα and iL6
TNFα and IL6 are two important proinflammatory adipocy-
tokines and the expression of both is hugely increased in the 
fat cells of obese human subjects and patients with IR.178,179 
In patients with severe obesity, the mRNA expression of IL6 
and TNFα is clearer in adipose compared to liver tissue.180
TNFα was identified more than two decades ago as the 
first inflammatory molecule linked with IR.181 Higher serum 
levels of TNFα and soluble TNFα receptor 2 (TNFR2) have 
been found in patients with NASH compared with healthy 
subjects and these differences were independent of higher 
IR. However, no significant differences in TNFα and TNFR2 
were found between SS and NASH patients.173
Enhanced TNFα hepatic expression was recently dem-
onstrated in a group of obese patients with NAFLD. Crespo 
et al reported increased hepatic expression of TNFα and 
TNFR2 in patients with NASH compared to patients with SS. 
In these patients, more advanced fibrosis was also accompa-
nied by the increased hepatic expression of TNFα.182 In line 
with these results, TNFα plasma levels have been shown to 
correlate positively with the grade of liver fibrosis assessed 
by ultrasound-guided liver biopsy in patients with advanced 
stages of NAFLD.183
Furthermore, certain TNFα polygenetic polymorphisms 
have been found to have higher IR indices, a higher preva-
lence of impaired glucose tolerance, and higher susceptibility 
to the development of NAFLD and NASH.184,185
IL6 is a pleiotropic cytokine expressed in many inflam-
matory cells in response to different types of stimuli, regu-
lating a number of biological processes including IR and 
the regulation of inflammation. It is known to be the main 
stimulating factor for hepatocyte synthesis and the secretion 
of C-reactive protein in humans,186 and for this reason, it has 
been proposed as a potential mediator leading to NAFLD. 
However, the true mechanisms driving IL6 induced NAFLD 
remain unclear. 
Preliminary studies have found that IL6 plays a protective 
role in liver fibrosis by promoting hepatocyte proliferation 
and by protecting against oxidative stress and mitochon-
drial dysfunction.187 On the other hand, Wieckowska et al 
 demonstrated markedly increased IL6 expression in the liver 
of patients with NASH compared to those with SS or normal 
liver. Hepatic IL6 expression also correlated positively with 
the severity of inflammation and fibrosis. IL6 plasma levels 
that were measured in parallel in this study correlated well 
with liver IL6 expression.6 In another study, IL6 was evalu-
ated among several serum markers in NAFLD patients, and 
IL6 circulating levels were significantly increased in patients 
with NAFLD as compared to healthy controls, but not in 
NASH compared to SS.188
Weight loss resulted in a dramatic decrease of IL6 subcu-
taneous and hepatic expression with a subsequent reduction in 
expression of the hepatic suppressor of cytokine signaling 3 
(SOCS3) and improved insulin sensitivity. On the other hand, 
TNFα expression after weight loss only decreased in adipose 
tissue, not in hepatic tissue.180 This would suggest that the 
liver might be a key organ for adipose tissue-derived IL6 
and TNFα because continuous TNFα/IL6 exposure affects 
hepatic IR.189
visfatin
Visfatin, also termed pre-B cell colony enhancing factor 
(PBEF) or nicotinamide phosphoribosyltransferase (NAMPT) 
was first identified in 1994 as a protein secreted by activated 
lymphocytes, synergizing with IL7 and stem cell factor in 
early B cell formation.190 Although the first discovery of 
this molecule suggested primarily a cytokine function, its 
rediscovery as the key enzyme in generating nicotinamide 
adenine dinucleotide has considerably widened its biological 
perspective.191 Its extracellular functions (cytokine-like) are 
mainly proinflammatory as it potently induces various other 
proinflammatory cytokines such TNFα and IL6. Its intracel-
lular functions concentrate on regulating the activity of NAD-
consuming enzymes such as various sirtuins, thereby also 
affecting TNFα biosynthesis, cell lifespan, and longevity.
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Only a few reports have so far addressed the role of this 
adipocytokine in human NAFLD. In patients with NAFLD, 
visfatin shows higher serum concentrations and weight 
loss is associated with both a decrease in serum levels and 
a reduction in liver mRNA expression, suggesting that the 
fatty liver might indeed contribute to an observable increase 
in serum visfatin levels.176 In the same study, immunohis-
tochemistry staining for visfatin was carried out in 18 paired 
liver biopsies. The staining showed that visfatin was abun-
dantly expressed in hepatocytes; weight loss decreased this 
expression dramatically. Another report has demonstrated 
the correlation of visfatin serum levels with liver histology 
in NAFLD, and such high circulating levels could predict the 
presence of portal inflammation in NAFLD patients.192
A protective role of visfatin against hepatocyte inflam-
matory damage was suggested by Jarrar et al.193 In that study, 
serum visfatin circulating levels in NAFLD patients were 
higher than in healthy control individuals, both lean and 
obese without NAFLD. Furthermore, when NASH occurred, 
visfatin concentration decreased significantly compared with 
SS, but was still significantly higher than in obese or lean 
healthy subjects without NAFLD.
Our findings are in line with data reporting that circulat-
ing levels and hepatic expression of visfatin are significantly 
higher in a group of morbidly obese women compared to 
lean controls and morbidly obese women with normal liver 
histology. Moreover, serum visfatin correlated well with IL6 
and C-reactive protein.194
All these findings suggest that visfatin is a molecule 
with an important role in the pathophysiology of NAFLD 
and indicate that the liver could be a major source for this 
cytokine.
PPARδ
The PPARs family consists of three members: namely, 
PPARα, PPARβ/δ, and PPARγ. These receptors act as 
FA sensors that control many metabolic programs that are 
essential for systematic energy homeostasis. Today, due to 
its ubiquitous profile, much less is known about PPARδ than 
the other two in relation to human obesity and NAFLD.195
Oliver et al showed that IR obese rhesus monkeys nor-
malized fasting glucose and insulin, increased high-density 
lipoprotein cholesterol and reduced low-density lipoprotein 
(LDL) cholesterol after treatment with a potent and specific 
PPARδ agonist, the GW501516.196 Other studies in an animal 
model of adenovirus-mediated hepatic PPARδ overexpres-
sion showed that PPARδ regulates lipogenesis and glucose 
utilization for glycogen synthesis. These effects could result 
in hepatic protection from FFA-mediated damage, possibly 
due to the generation of protective MUFA and the lowering 
of lipotoxic SFA levels.197
Overweight and obese men subjected to the PPARδ 
agonists, GW501516 or MBX-8025, exhibited improved 
insulin sensitivity and decreased fasting plasma TGs, non-
esterified FAs, apolipoprotein B-100, and LDL-cholesterol, 
with diminished liver fat content quantified by magnetic 
resonance imaging.198,199
However, the final mechanisms underlying PPARδ effects 
in the liver of NAFLD patients still need further study.
NAFLD and lipotoxicity
The pathogenesis of NAFLD is often interpreted by the 
“double-hit” hypothesis. The primary insult or the “first hit” 
is lipid accumulation in the liver,8,200 followed by a “second 
hit” in which proinflammatory mediators induce inflamma-
tion, hepatocellular injury, and fibrosis.201 This paradigm 
suggested TG accumulation to be the “first hit” that predis-
poses to further liver damage in the pathogenesis of NASH, 
but has recently been replaced by a more complex model as 
emerging evidence points to FAs and their metabolites as the 
true lipotoxic agents.202 Interestingly, lipid accumulation and 
altered composition of phospholipids within ER membranes 
further promotes ER stress and IR in obese mice.203 Cytosolic 
TGs are therefore now considered to be inert, and in fact, 
lipid droplet accumulation seems to be hepatoprotective.204 
 However, TG accumulation and lipid droplet formation go 
hand in hand with pathophysiological mechanisms in NASH. 
FAs, as well as acyl-CoA and acetyl-CoA, have been iden-
tified as potential causes of lipotoxicity.205 FAs have been 
found to initiate the extrinsic apoptosis cascade and also to 
interfere with NR signaling, which might influence the extent 
of hepatocyte damage and further promote IR and ER stress.206 
Accordingly, β-oxidation of LCFA within peroxisomes and 
ω-oxidation within the ER are upregulated in NASH and 
contribute to lipotoxicity and ROS formation.142 This might 
be secondary to inhibition of mitochondrial β-oxidation due to 
an accumulation of malonyl-CoA and the inhibition of CPT1. 
In fact, recent studies indicate that activation of mitochondrial 
FA oxidation protects from steatosis and IR.207
It is known that FAs induce the production of TNFα. 
Hepatic TNF receptor expression correlates with the severity 
of NAFLD disease.182 Also, TNF receptor activation increases 
expression of SREBP1c, which induces hepatic lipogenesis 
and lipid accumulation.208 TNFα activation is further paral-
leled by death-receptor expression, which facilitates activa-
tion of the extrinsic apoptosis cascade. Apoptosis is indeed 
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the predominant form of hepatocellular injury in NASH. In 
fact, apoptotic activity within the unhealthy liver correlates 
with disease severity, and thus, cleaved cytokeratin-18 frag-
ments in the serum of NAFLD could effectively be utilized 
as surrogate markers for the progression of NAFLD.209 As 
previously mentioned, FA accumulation also leads to the 
induction of ER stress and ROS formation, which again 
promotes hepatic injury.210
On the other hand, other studies indicate that metabolic 
oxidative stress, autophagy, and inflammation are hallmarks 
of NASH progression. In this sense, CYP2E1, the principal 
isoform of the CYP450 enzyme, seems to be critically 
important in NASH development by promoting oxidative/
nitrosative stress, protein modifications, inflammation, and 
IR.211,212  Moreover, Das et al suggest that purinergic  receptor 
X7 (P2X7), upregulated by CYP2E1, might have a key 
role in autophagy induced by metabolic oxidative stress in 
NASH.213
In summary, while hepatic TG accumulation seems to 
be a benign symptom of hepatic steatosis, FA metabolites 
contribute to the progression of NAFLD to NASH. IR pro-
motes the recruitment of FFAs from the serum pool as well 
as intrahepatic FA accumulation, which induces apoptosis 
and ROS formation. FAs themselves also promote hepatic 
IR via TNF receptor activation, indicating a vicious cycle 
of lipid accumulation (Figure 1D). Other mechanisms could 
also contribute to liver damage. Regarding that, some authors 
have even suggested a “multiple parallel hits hypothesis” to 
explain the pathophysiology of NAFLD.41
Cannabinoid receptors  
(CB1, CB2) in NAFLD
The endocannabinoid (EC) system consists of cannabinoid 
receptors, endogenous cannabinoid ligands, and their biosyn-
thetic and degradative enzymes, and has recently emerged 
as a ubiquitous system with key functions in a variety of 
physiological settings. Over the last decade, the EC system 
has emerged as a pivotal mediator of acute and chronic liver 
injury. ECs regulate appetite behavior and are lipid mediators 
that produce similar effects to those of marijuana by acting 
on membrane-bound receptors.214 Cannabinoid receptors are 
localized mainly in the brain, but are also present in minor 
amounts in the liver and some other peripheral tissues (CB1) 
and in immune and hematopoietic cells (CB2).215,216
ECs may also regulate peripheral energy metabolism, as 
demonstrated by their CB1-mediated effect on lipoprotein 
lipase activity in adipocytes217 and their ability to stimulate 
lipogenesis in hepatocytes.218,219 Cannabinoids exert their 
effects through two different cannabinoid receptors: CB1 
and CB2. Under physiological conditions, the EC system is 
silent, since CB1 and CB2 receptors are faintly expressed. 
In contrast, induction of CB receptors and/or increased lev-
els of ECs are common features of liver injuries of diverse 
origins.220 Both receptors have been implicated in the devel-
opment of liver fibrosis secondary to various  etiologies. 
CB1-mediated EC tone is enhanced in experimental diet-
induced or genetic models of NAFLD, and is characterized 
by upregulation of adipose tissue and hepatocyte CB1 recep-
tors, and by increased liver synthesis of anandamide. The 
pathogenic role of CB1 receptors in NAFLD is supported by 
the resistance to steatosis of obese mice bearing a global or 
hepatocyte-specific CB1 deletion, or of rodents administered 
rimonabant or AM6545, a CB1 antagonist.221–223 Studies with 
cultured hepatocytes and liver slices further indicate that 
the steatogenic properties of CB1 arise from altered hepatic 
lipid metabolism, consisting of a combination of hepatocyte 
activation of SREBP1c-mediated lipogenesis, reduction of 
FA oxidation via inhibition of AMP kinase, and decreased 
release of TG-rich VLDL.221,222,224 In addition, the adipose 
tissue may largely contribute to the steatogenic process via 
CB1-induced release of FFAs by adipocytes (Figure 5).225
CB1
CB1
CB1
↓
−CPT1
VLDL
-TGs
TGs
+LPL
FFAs
FFAs
FFAs
TGs
De novo lipogenesis:
+ SREBP1c
+ ACC1 and FAs
β-oxidation
Dietary fats
Figure 5 Mechanisms of CB1 involved in hepatic lipid accumulation.
Notes: The activation of CB1 receptors in adipose tissue promotes LPL activity, 
which results in increased FFA release into the liver. The activation of hepatic 
CB1 receptors contributes to liver fat accumulation by increased de novo hepatic 
lipogenesis, decreased FA oxidation, and decreased secretion of TG-rich vLDL.
Abbreviations: ACC1, acetyl-CoA carboxylase; CB, cannabinoid; CPT1, carnitine 
palmitoyltransferase-1; FA, fatty acid; FAS, fatty acid synthase; FFA, free fatty acid; 
LPL, lipoprotein lipase; SREBP1c, sterol regulatory element-binding protein 1c; TG, 
triglyceride; vLDL, very-low-density lipoprotein.
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and ROS formation. Better understanding of the molecular 
pathways of liver injury should promote the development of 
diagnostic and therapeutic interventions aimed at reducing 
the morbidity and mortality associated with NAFLD.
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Resumen  La  enfermedad  del  hígado  graso  no  alcohólico  (EHGNA)  se  ha  convertido  en  el  tras-
torno  hepático  más  común  en  los  países  desarrollados,  que  abarca  condiciones  patológicas
que van  desde  la  esteatosis  simple  a  la  esteatohepatitis  no  alcohólica,  cirrosis  y  hepatocar-
AT ROVIRA I VIRGILI 
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cinoma. A  menudo  la  patogenia  de  la  EHGNA  ha  sido  interpretada  por  la  hipótesis  del  «doble
impacto»,  donde  tras  la  acumulación  de  lípidos  hepáticos  tendría  lugar  la  aparición  de  mediado-
res  proinﬂamatorios  que  inducirían  inﬂamación,  lesión  hepatocelular  y  ﬁbrosis.  Actualmente,  el
modelo  propuesto  sugiere  que  la  constante  exposición  de  los  hepatocitos  a  ácidos  grasos  libres
Abreviaturas: ATP: adenosín trifosfato; AG: ácidos grasos; AGL: ácidos grasos libres; AGPAT: acil-glicerol-fosfato-acil transferasa; APOC3:
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glucógeno sintasa 3; GLUT: transportador de glucosa; IL-6: interleucina 6; NADH: nicotinamida adenina dinucleótido; OAS: oligonucleótidos
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proteína cinasa C; PI(3)K: fosfatidilinositol 3; PNPLA3: Patatin-like phospholipase domain-containing protein 3; PPAR: receptor gamma
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y  sus  metabolitos,  agentes  potencialmente  lipotóxicos,  estarían  contribuyendo  al  desarrollo  de
EHGNA  y  resistencia  hepática  a  la  insulina;  sugiriendo  así  un  papel  primordial  para  las  lipasas
metabólicas  intracelulares  en  este  proceso.
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Role  of  metabolic  lipases  and  lipotoxicity  in  the  development  of  non-alcoholic
steatosis  and  non-alcoholic  steatohepatitis
Abstract  Non-alcoholic  fatty  liver  disease  (NAFLD)  has  become  the  most  common  liver  disease
in  developed  countries,  covering  a  spectrum  of  pathological  conditions  ranging  from  single  stea-
tosis  to  non-alcoholic  steatohepatitis,  cirrhosis  and  hepatocellular  carcinoma.  Its  pathogenesis
has  been  often  interpreted  by  the  ‘‘double-hit’’  hypothesis,  where  the  lipid  accumulation  in
the  liver  is  followed  by  proinﬂammatory  mediators  inducing  inﬂammation,  hepatocellular  injury
and  ﬁbrosis.  Nowadays,  a  more  complex  model  suggests  that  free  fatty  acids  and  their  meta-
bolites  could  be  the  true  lipotoxic  agents  that  contribute  to  the  development  of  NAFLD  and
hepatic  insulin  resistance,  suggesting  a  central  role  for  metabolic  lipases  in  that  process.
©  2015  Sociedad  Espan˜ola  de  Arteriosclerosis.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.
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a  enfermedad  del  hígado  graso  no  alcohólica  (EHGNA)
e ha  convertido  en  el  trastorno  hepático  más  común  en
os países  desarrollados,  afectando  aproximadamente  a  un
0%  de  adultos  y  a  un  10%  de  nin˜os1,2.  Esta  enfermedad
barca un  espectro  anatomopatológico  de  condiciones  que
an desde  la  simple  acumulación  de  triglicéridos  (TG)  hepá-
icos (esteatosis  simple)  a  la  esteatosis  con  inﬂamación
esteatohepatitis),  cirrosis  e  incluso  hepatocarcinoma2,3.
proximadamente el  20%  de  los  pacientes  con  esteatohepa-
itis progresan  hacia  cirrosis  e  insuﬁciencia  hepática4,5.  De
echo, la  esteatohepatitis  asociada  a  cirrosis  es  actualmente
a tercera  causa  más  frecuente  de  trasplante  hepático  en  los
stados Unidos6.
La EGHNA  es  considerada  como  la  manifestación  hepática
el síndrome  metabólico  (SM)  y  se  encuentra  fuertemente
sociada a  la  diabetes  mellitus  tipo  2  (DM2)  y  la  obesidad.
anto la  obesidad  como  la  DM2  son  consecuencias  del  estilo
e vida  moderno,  que  se  caracteriza  por  el  aumento  de  la
ngesta de  ácidos  grasos  (AG)  saturados,  trans-insaturados  y
ructosa en  la  dieta,  así  como  el  sedentarismo7.
Aunque  los  mecanismos  implicados  en  la  patogénesis  y
rogresión de  la  EHGNA  no  son  del  todo  conocidos3,  la  resis-
encia a  la  insulina  (RI)  en  el  músculo,  tejido  adiposo  y  en
l hígado  parece  desempen˜ar  un  papel  central8,9.  El  dete-
ioro en  la  sen˜alización  de  la  insulina  en  el  tejido  adiposo
rovoca un  aumento  de  la  lipólisis,  generando  así  un  ﬂujo
e AG  hacia  el  hígado  que  promueven  la  RI  hepática,  con
l consiguiente  aumento  de  la  lipogénesis  de  novo  y acumu-
ación de  TG  en  este  órgano10,11.  Aproximadamente  el  60%Cómo  citar  este  artículo:  Berlanga  A,  et  al.  Papel  de  las  lipasas  m
hepática  y  esteatohepatitis  no  alcohólica.  Clin  Invest  Arteriosc
e los  AG  que  participan  en  el  cúmulo  de  TG  hepáticos  en
a EHGNA  proceden  de  la  lipólisis  del  tejido  adiposo,  el  15%
irectamente de  la  dieta  (ingesta  excesiva  de  grasa  e  hidra-
os de  carbono)  y  el  25%  restante  proceden  del  incremento
e
d
i
ee  la  ratio  de  la  lipogénesis  de  novo  controlada  por  factores
e transcripción  como  SREBP1c  (proteína  de  unión  al  ele-
ento regulador  de  esterol),  ChREBP  (proteína  de  unión  al
lemento de  respuesta  a  hidratos  de  carbono),  LxR  (recep-
or X  hepático)  y  PPAR  (receptor  gamma  activado  por  el
actor proliferador  de  perixosomas).  Muchos  son  los  estudios
ue han  demostrado  el  incremento  de  la  expresión  hepática
e genes  involucrados  en  la  lipogénesis  de  novo  en  pacientes
on EHGNA12--16.  En  este  sentido,  nuestro  grupo,  al  estu-
iar la  expresión  de  genes  involucrados  en  el  metabolismo
ípidico hepático  en  mujeres  obesas  mórbidas  con  EGHNA,
bservó que  la  expresión  hepática  de  FAS  (sintasa  de  áci-
os grasos),  importante  enzima  lipogénica  bajo  el  control
e LxR17,  estaba  signiﬁcativamente  aumentada  en  muje-
es con  esteatosis/esteatohepatitis  no  alcohólica,  respecto
 aquellas  con  histología  hepática  normal18.
Recientemente  se  ha  observado  que  la  constante
xposición de  los  hepatocitos  a metabolitos  lipídicos  poten-
ialmente tóxicos,  tales  como  AG,  ácido  fosfatídico,  ácido
isofosfatídico, ceramidas  y  diacilgliceroles  (DAG),  pue-
en dar  lugar  a  efectos  «lipotóxicos»3,  caracterizados  por
strés en  el  retículo  endoplásmico,  inﬂamación,  apop-
osis, necrosis,  ballooning  y  formación  de  cuerpos  de
allory-Denk, características  histopatológicas  propias  de  la
steatohepatitis19.  Estas  observaciones  refuerzan  la  hipóte-
is de  que  los  metabolitos  derivados  de  los  TG  serían  los
erdaderos agentes  tóxicos20,21,  y  que  la  hidrólisis  de  los  TG
epáticos a  través  de  lipasas  metabólicas  estarían  contribu-
endo al  desarrollo  de  la  EHGNA19.
Dado  que  actualmente  no  existen  terapias  efectivas  para
a EHGNA,  a  excepción  de  la  pérdida  de  peso,  los  esfuerzosetabólicas  y la  lipotoxicidad  en  el  desarrollo  de  esteatosis
l.  2015.  http://dx.doi.org/10.1016/j.arteri.2015.03.003
n la  investigación  actual  se  centran  en  la  comprensión
e la  patogenia  de  esta  enfermedad,  con  la  ﬁnalidad  de
dentiﬁcar nuevas  dianas  terapéuticas.  En  este  sentido,
sta revisión  pretende  actualizar  los  conocimientos  sobre
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Lipasas  metabólicas,  lipotoxicidad  y  esteatosis  hepática  
la  contribución  de  las  lipasas  metabólicas  hepáticas  y
mediadores lipotóxicos  en  el  desarrollo  de  la  esteatosis
y esteatohepatitis  no  alcohólica.
Rol de las lipasas metabólicas
en  la  patogénesis y progresión de la
enfermedad  del  hígado graso no alcohólico
Debido  a  que  la  EHGNA  se  caracteriza  principalmente  por
la acumulación  hepática  de  lípidos22,  las  lipasas  metabóli-
cas se  han  involucrado  en  la  patogénesis  y  progresión  de  la
enfermedad y  se  encuentran  actualmente  en  el  centro  de
interés.
Los AG  liberados  del  tejido  adiposo  son  transportados
hacia el  hígado  y  captados  mediante  transportadores  celu-
lares especíﬁcos  como  clúster  de  diferenciación  36  (CD36)
y proteína  transportadora  de  ácidos  grasos  (FATP)  o por
difusión pasiva23.  Una  vez  dentro  de  los  hepatocitos  son  este-
riﬁcados y  almacenados  en  forma  de  TG.  Estudios  en  ratones
modiﬁcados genéticamente  que  sobreexpresan  diacilglicerol
aciltransferasa 2  en  el  hígado,  enzima  que  cataliza  el  último
paso en  la  formación  de  TG,  han  objetivado  un  aumento  de
la acumulación  hepática  de  TG  sin  inﬂamación  o  RI  hepática.
Sin embargo,  la  silenciación  de  la  expresión  de  diacilglicerol
aciltransferasa 2  previene  el  cúmulo  hepático  de  TG,  pero
causa dan˜o  lipotóxico  debido  al  exceso  de  AG  libres19. Estos
hallazgos sugieren  que  los  TG  podrían  estar  protegiendo
contra la  lesión  hepática  mediada  por  lípidos.  Sin  embargo,
las propiedades  antilipotóxicas  de  los  TG  se  ven  limitadas
debido a  que  las  lipasas  metabólicas  pueden  actuar  sobre
ellos liberando  AG  libres,  generando  así  una  nueva  fuente
de intermediarios  lipotóxicos19.
Diacilgliceroles,  resistencia  a  la  insulina  hepática  y
enfermedad del  hígado  graso  no  alcohólico
La  acción  de  la  insulina  en  las  células  hepáticas  requiere
un conjunto  de  sen˜ales  intracelulares  coordinadas,  que  se
basan sobre  todo  en  procesos  de  fosforilación  y  desfos-
forilación. Durante  este  proceso,  la  insulina  se  une  a  su
receptor y  activa  la  vía  de  la  PI(3)K  y  Akt2,  suprimiendo
la producción  hepática  de  la  glucosa  mediante  2  mecanis-
mos principales:  primero,  la  disminución  de  la  expresión  de
las enzimas  gluconeogénicas  mediante  la  fosforilación  y  la
exclusión nuclear  del  factor  de  transcripción  FOXO1,  y  en
segundo lugar,  el  aumento  de  la  actividad  glucógeno  sintasa
(GS), mediante  la  fosforilación  e  inactivación  de  la  cinasa
glucógeno sintasa  3  (GSK3)24--26 (ﬁg.  1  A).
El  desarrollo  de  la  EHGNA  se  encuentra  fuertemente
asociado a  la  resistencia  a  la  insulina  hepática.  Esta  relación
ha sido  demostrada  en  ratas  sometidas  a  una  dieta  rica  en
grasa durante  3  días,  las  cuales  desarrollaron  esteatosis  y  RI
hepática, sin  cambios  en  el  peso  corporal,  adiposidad  o  RI
en el  músculo  esquelético27.  Curiosamente,  en  el  hígado  de
estos animales  se  observó  un  aumento  de  DAG.  La  conexión
entre la  acumulación  de  DAG  y  RI  hepática  podría  atribuirse
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a la  activación  de  la  proteína  quinasa  C  (PKC),  altamente
expresada en  el  hígado.  Estos  cambios  se  han  asociado  con
reducciones en  la  fosforilación  del  receptor  de  la  insulina
y en  la  actividad  Akt2.  Por  lo  tanto,  en  este  modelo,  la
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ctividad  de  la  insulina  para  inducir  la  síntesis  de  glucógeno
 inhibir  la  gluconeogénesis  se  ve  disminuida  debido  a
a activación  de  PKC  mediada  por  DAG,  promoviendo  la
nión de  PKC  en  el  dominio  intracelular  del  receptor  de  la
nsulina (ﬁg.  1  B).
PKC es  un  miembro  de  la  familia  PKC,  compuesta  por  3
rupos diferentes:  convencional  (,  I,  II,  y  ),  novel  (,
, , y  ) y  atípico  (	  y  
)28.  PKC  es  una  isoforma  novel
on una  aﬁnidad  mucho  mayor  por  el  DAG  que  las  isofor-
as PKC  convencionales29.  El  papel  especíﬁco  de  PKC  en
a RI  hepática  fue  examinado  en  un  estudio  en  el  que  se
tilizaron oligonucleótidos  antisentido  (OAS),  que  actúan
referentemente en  el  hígado  y  el  tejido  adiposo30.  Samuel
t al.  demostraron  en  ratas  que  la  disminución  de  la  expre-
ión hepática  de  PKC  mediante  OAS  especíﬁcos  las  protegía
el desarrollo  de  RI  hepática  inducida  por  lípidos,  a  pesar
el aumento  en  el  contenido  de  lípidos  hepáticos31.  Estos
esultados fueron  replicados  en  ratones  knockout  para  el
en PKC,  donde  también  se  observó  una  protección  frente
l desarrollo  de  RI  hepática  inducida  por  una  dieta  rica  en
rasa32. Posteriormente,  la  interacción  entre  DAG,  la  acti-
ación de  PKC  y  la  RI  hepática  ha  sido  demostrada  en
umerosos modelos  de  EHGNA  asociada  a  resistencia  hepá-
ica a  la  insulina33--44.
Estos modelos  para  la  resistencia  hepática  a  la  insulina
nducida por  lípidos  han  sido  translacionados  a  humanos.
umashiro et  al.  evaluaron  los  posibles  mecanismos  implica-
os en  la  RI  hepática  en  un  grupo  de  pacientes  con  obesidad
órbida y  EHGNA.  En  este  caso,  el  contenido  de  DAG  hepá-
ico y  la  activación  de  PKC  fueron  los  predictores  más  fuer-
es de  RI  hepática45. En  cambio,  no  encontraron  asociación
ntre la  sensibilidad  a  la  insulina  y  otros  factores  implicados
n el  desarrollo  de  RI  hepática,  tales  como  ceramidas,  mar-
adores de  estrés  del  retículo  endoplásmico  o  concentra-
iones de  citoquinas  inﬂamatorias.  Estos  resultados  fueron
eplicados en  otro  estudio  en  el  que  se  demostró  también  el
ontenido de  DAG  hepático  como  el  mejor  predictor  de  la  RI
epática en  humanos  obesos,  mientras  que  no  hubo  asocia-
ión con  el  contenido  de  ceramidas  o  marcadores  de  inﬂama-
ión hepáticos46.  De  hecho,  se  ha  sugerido  que  la  inﬂamación
epática es  una  consecuencia,  y  no  una  causa,  de  la  resisten-
ia a  la  insulina.  Por  lo  tanto,  aunque  el  exceso  de  ingesta  de
alorías conduce  a la  obesidad,  solo  aquellos  que  desarrollan
steatosis hepática  desarrollarán  RI.  Estos  resultados  sostie-
en la  hipótesis  de  que  el  paso  clave  en  la  patogénesis  de  la
esistencia a la  insulina  hepática  consiste  en  la  acumulación
e DAG,  dando  lugar  a  la  activación  de  PKC.
ecanismos implicados en la acumulación
epática  de diacilgliceroles
os  DAG  pueden  acumularse  en  el  hígado  por  diferentes
otivos. En  primer  lugar,  por  un  incremento  del  transporte
e quilomicrones  remanentes  hacia  el  hígado.  En  segundo
ugar, por  un  incremento  de  la  liberación  de  AG  por  parte  de
os adipocitos.  En  tercer  lugar,  la  hiperinsulinemia  pospran-
ial debido  a la  RI  en  el  músculo  esquelético  puede  derivar
 IN LIVER OF MORBIDLY etabólicas  y  la  lipotoxicidad  en  el  desarrollo  de  esteatosis
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n un  aumento  de  la  lipogénesis  de  novo  hepática,  causando
n aumento  del  contenido  hepático  de  DAG.  Finalmente,  la
isminución de  la  función  mitocondrial  puede  también  estar
articipando en  la  acumulación  del  contenido  hepático  de
Cómo  citar  este  artículo:  Berlanga  A,  et  al.  Papel  de  las  lipasas  metabólicas  y la  lipotoxicidad  en  el  desarrollo  de  esteatosis
hepática  y  esteatohepatitis  no  alcohólica.  Clin  Invest  Arterioscl.  2015.  http://dx.doi.org/10.1016/j.arteri.2015.03.003
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Figura  1  A.  Sen˜alización  hepática  de  la  insulina.  La  insulina,  a  su  llegada  al  hepatocito,  se  une  y  activa  el  receptor  tirosina
cinasa de  la  insulina  (RTKI),  el  cual  promueve  la  fosforilación  del  sustrato  del  receptor  de  la  insulina  (SRI),  siendo  el  SRI2  el  más
importante  a  nivel  hepático.  La  fosforilación  de  SRI2  genera  sitios  de  unión  para  la  quinasa  fosfatidilinositol  3  ----PI(3)K----.  La  unión
de  PI(3)K  a  SRI2  convierte  el  lípido  de  membrana  fosfatidilinositol  4,5-bifosfato  (PIP2)  en  fosfatidilinositol  3,4,5-trifosfato  (PIP3)
que,  a  su  vez,  recluta  Akt2.  Bajo  condiciones  de  estímulo  de  insulina,  la  proteína  cinasa  D  (PDK1)  es  fosforilada  y  activa  Akt2,  que
parece  suprimir  la  producción  hepática  de  glucosa  mediante  2  mecanismos  principales:  primero,  la  disminución  de  la  expresión
de  las  enzimas  gluconeogénicas  mediante  la  fosforilación  y  la  exclusión  nuclear  de  la  proteína  FOXO1,  que  inhibe  la  activación
de  la  expresión  de  proteínas  gluconeogénicas  como  la  glucosa-6  fosfatasa  (G6Pasa)  y  la  fosfoenolpiruvato  carboxiquinasa  (PEPCK),
dando  lugar  a  la  supresión  de  la  gluconeogénesis  hepática;  y  en  segundo  lugar,  el  aumento  de  la  actividad  de  la  glucógeno  sintasa
(GS)  mediante  la  fosforilación  e  inactivación  de  la  quinasa  glucógeno  sintasa  3  (GSK3).  En  su  forma  inactiva  (fosforilada),  GSK3  no
cataliza  la  fosforilación  e  inactivación  de  la  GS,  permitiendo  así  la  síntesis  de  glucógeno  hepática.B.  Mecanismos  moleculares  de
DAG-PKC  que  median  la  resistencia  a  la  insulina  hepática.  La  acumulación  hepática  de  DAG  permite  la  activación  y  translocación  de
PKC  hacia  la  membrana  plasmática,  lo  que  provoca  la  inhibición  del  receptor  quinasa  de  la  insulina  y  su  sen˜alización  intracelular.
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Figura  2  Mecanismos  implicados  en  la  acumulación  hepática  de  DAG.
El aumento  en  el  contenido  hepático  de  DAG  es  el  resultado  de  un  desequilibrio  entre  la  captación/liberación  de  ácidos  grasos
(AG),  la  tasa  de  oxidación  mitocondrial  de  AG  y  la  conversión  de  los  DAG  a  triglicéridos  (TG)  durante  la  lipogénesis  hepática.  Que
la  ratio  de  la  ingesta  energética  sea  superior  al  gasto  energético  es  una  de  las  causas  de  la  EHGNA  y  resistencia  a  la  insulina  (RI)
hepática inducida  por  el  mecanismo  DAG-PKC.  La  predisposición  de  factores  genéticos,  como  las  variantes  genéticas  de  APOC3
que  provocan  un  aumento  de  las  concentraciones  plasmáticas  APOC3,  dan  lugar  a  la  supresión  de  la  actividad  de  la  lipoproteína
lipasa, el  aumento  de  quilomicrones  remanentes  posprandiales,  y  el  aumento  de  la  captación  hepática  de  AG,  contribuyendo  al
incremento  del  contenido  hepático  de  DAG.  Defectos  en  el  almacenamiento  lipídico  en  los  adipocitos,  tales  como  las  lipodistroﬁas,
así  como  alteraciones  genéticas  o  adquiridas  en  la  oxidación  mitocondrial  de  AG,  pueden  contribuir  a  la  acumulación  hepática  de
DAG  y  consecuente  desarrollo  de  EHGNA  y  RI  hepática.  Finalmente,  los  ácidos  grasos  liberados  durante  la  lipólisis  en  los  adipocitos
entrarían  en  el  hígado  mediante  transportadores  especíﬁcos  de  AG  (FATP2/5),  aumentando  el  contenido  hepático  de  DAG.
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Dipòsit Legal: T 1705-2015DAG47 (ﬁg.  2).  Cabe  mencionar  además  que  el  sistema  endo-
cannabinoide parece  tener  un  papel  emergente  en  el  des-
arrollo de  RI  hepática  y  acumulación  de  lípidos  en  el  hígado.
Sistema  endocannabinoide  en  el  tejido  hepático
Los  endocannabinoides  entran  en  las  células  hepáticas
mediante transportadores  especíﬁcos,  tales  como  proteí-
nas de  unión  de  ácidos  grasos  (FABPs),  FABP5  y  FABP7,
actuando48,49 sobre  los  receptores  de  canabinoides  1  (CB1)
y 2  (CB2).  Tanto  los  receptores  de  endocanabinoides  como
endocanabinoides especíﬁcos,  como  el  2-aciletanolamida
(2-AE), se  encuentran  incrementados  en  el  hígado  de  mode-
los de  ratón  con  obesidad  inducida  por  la  dieta50,51.  Además,
en un  estudio  propio  realizado  en  mujeres  con  obesidad  mór-
bida y  EHGNA,  observamos  que  la  expresión  hepática  de
CB1 se  encuentra  signiﬁcativamente  incrementada  en  muje-
res con  esteatohepatitis  comparadas  con  las  que  presentan
únicamente esteatosis  hepática52.  Parece  que  la  activación
de CB1  podría  activar  la  lipogénesis  hepática  mediante  la
inducción de  estrés  en  el  retículo  endoplasmático,  así  como
la activación  de  factores  de  transcripción  (por  ejemplo
SREBP1c)53,  proceso  que  estaría  contribuyendo  a  la  forma-Cómo  citar  este  artículo:  Berlanga  A,  et  al.  Papel  de  las  lipasas  m
hepática  y  esteatohepatitis  no  alcohólica.  Clin  Invest  Arteriosc
ción de  DAG.  Finalmente,  el  DAG  acumulado  podría  ser
transformado en  2-AE  de  nuevo,  dando  lugar  a  un  bucle  de
retroalimentación positiva  que  estaría  induciendo  y  agra-
vando la  esteatosis  y  la  RI  hepática54.
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cumento  de  la  ingesta  calórica
a  mayor  causa  de  la  HGNA  en  los  países  desarrollados
e atribuye  especialmente  a  un  desequilibrio  energético,
onde la  ingesta  calórica  excede  al  gasto  calórico,  con-
uciendo a  un  aumento  de  lípidos  liberados  hacia  el
ígado55--57.
En  este  sentido,  Jonayvaz  et  al.  demostraron  que  los
atones que  seguían  una  dieta  cetogénica  rica  en  grasa
esarrollaban esteatosis  hepática  severa  y RI  a pesar  de
anifestar un  incremento  de  gasto  energético  y  pérdida  de
eso. En  este  caso,  el  contenido  de  DAG  hepático  fue  incre-
entado en  un  350%  debido  a  la  activación  de  PKC,  a  la
isminución de  la  fosfoliración  de  IRS2  inducida  por  insu-
ina, y  a  la  disminución  de  la  supresión  de  la  producción
epática de  glucosa  durante  un  clamp  hiperinsulinémico-
uglucémico.
En humanos  diferentes  estudios  sugieren  que  la  moviliza-
ión regional  de  los  TG  circulantes  y  el  transporte  de  ácidos
rasos se  encuentran  alterados  en  los  pacientes  obesos  que
adecen EHGNA.  La  lipoproteína  lipasa  (LpL)  hidroliza  los
G circulantes,  seguido  por  la  absorción  de  estos  en  el
ejido hepático  a  través  de  los  transportadores  celularesetabólicas  y  la  lipotoxicidad  en  el  desarrollo  de  esteatosis
l.  2015.  http://dx.doi.org/10.1016/j.arteri.2015.03.003
ATP y  CD3658.  La  actividad  LpL  en  el  tejido  adiposo  en
espuesta a  la  insulina  parece  estar  disminuida  en  pacien-
es con  obesidad59,  mientras  que  la  EHGNA  se  ha  asociado
on el  incremento  de  la  expresión  hepática  de  LpL,  FATP  y
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D3660--62.  En  general,  parece  que  la  sobreexpresión  hepá-
ica de  LpL63,64 o  de  CD36  provoca  la  acumulación  hepática
e lípidos,  así  como  la  resistencia  a  la  insulina  hepática65,
ientras que  la  supresión  hepática  de  FATP  protege  contra
l desarrollo  de  esteatosis  hepática  e  IR66.
En  su  conjunto,  estos  estudios  sugieren  que  en  la  obe-
idad inducida  por  un  aumento  de  la  ingesta  calórica  los
cidos grasos  son  transportados  desde  el  tejido  adiposo  hacia
l hígado  y  el  músculo  esquelético,  donde  son  reesteriﬁca-
os en  DAG,  induciendo  así  resistencia  a  la  insulina  en  estos
rganos.
isminución  de  la  función  mitocondrial
n  el  hepatocito  la  -oxidación  mitocondrial  es  la  princi-
al ruta  de  oxidación  de  los  ácidos  grasos67. Las  coenzimas
educidas ﬂavín  adenín  dinucleótido  y  nicotinamida  ade-
ina dinucleótido,  generadas  en  el  propio  proceso  y  en  la
xidación del  acetil-CoA  mediante  el  ciclo  de  los  ácidos  tri-
arboxílicos, donan  sus  electrones  a  la  cadena  respiratoria,
roduciéndose adenosín  trifosfato  (ATP)  por  la  fosforilación
e la  adenosín  difosfato  mediada  por  la  ATP  sintasa.  Ade-
ás, las  mitocondrias  son  también  la  principal  fuente  de
species reactivas  del  oxígeno  (ROS)68.  Las  ROS  producidas
n este  y  otros  procesos  son  neutralizadas  por  sistemas  enzi-
áticos, sobresaliendo  la  superóxido  dismutasa,  la  catalasa
 la  glutatión  peroxidasa,  y  por  defensas  celulares  vitamíni-
as, principalmente  la  vitamina  E  y  la  C.  En  pacientes  con
HGNA se  ha  descrito  disfunción  mitocondrial,  anomalías
ltraestructurales69,70,  actividad  reducida  de  los  comple-
os de  la  cadena  respiratoria68,71,  fosforilación  oxidativa
eﬁciente, una  menor  capacidad  para  sintetizar  ATP,  un  des-
enso  en  la  concentración  de  ATP  intracelular72 y  dan˜o  en  el
DN mitocondrial73.
Zhang  et  al.44 demostraron  que  la  disminución  de  la
unción mitocondrial  hepática  puede  ser  un  factor  predis-
onente de  EHGNA  y  RI  hepática.  Este  estudio  observó
ue los  ratones  Knockout  para  acil-CoA  deshidrogenesa
e cadena  larga,  los  cuales  tienen  reducida  la  función
itocondrial en  el  hígado,  son  propensos  a  padecer  estea-
osis hepática  asociada  a  un  incremento  del  contenido  de
AG, a  la  activación  de  PKC  y  al  desarrollo  de  RI  hepá-
ica cuando  estos  son  alimentados  con  una  dieta  rica  en
rasa. En  humanos  la  asociación  de  la  disminución  de  la
xidación hepática  con  EHGNA  es  menos  clara,  ya  que  exis-
en estudios  discrepantes.  Algunos  han  demostrado  una
isminución de  la  oxidación74,75,  mientras  que  otros  han
ugerido un  incremento  en  el  metabolismo  mitocondrial
epático76.
efectos  en  el  almacenamiento  lipídico
as  lipodistroﬁas  son  un  grupo  de  síndromes  de  carácter  con-
énito u  adquirido  cuya  característica  clínica  principal  es
a pérdida  parcial  o  completa  del  tejido  adiposo.  A  nivel
etabólico se  caracterizan  por  una  severa  resistencia  a  la
nsulina, hipertrigliceridemia  grave,  bajos  niveles  circulan-
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es de  leptina,  adiponectina  y  colesterol  HDL,  causado  por
a acumulación  ectópica  de  grasa,  lo  que  incluye  el  desarro-
lo de  la  EHGNA77.  El  80%  de  los  pacientes  con  lipodistroﬁa
umplen los  criterios  deﬁnitorios  de  SM78, sin  embargo,
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resentan  bajos  niveles  de  hormonas  derivadas  de  los  adi-
ocitos en  comparación  con  pacientes  con  SM  asociado  a  la
besidad73. Así,  las  lipodistroﬁas,  situaciones  en  las  que  no
xiste expansión  del  tejido  adiposo  subcutáneo  ni  visceral,
frecen una  posibilidad  única  para  evaluar  de  forma  especí-
ca el  papel  del  cúmulo  hepático  de  grasa  en  el  desarrollo
e la  EHGNA47.
Los  ratones  que  expresan  the  dominant-negative  protein
-ZIP/F1 carecen  prácticamente  de  tejido  adiposo  blanco
ratones sin  grasa)  y  desarrollan  acumulación  ectópica  de
rasa en  el  hígado  y  en  el  músculo  esquelético,  dando
ugar a  la  aparición  de  una  marcada  RI  periférica  y  hepá-
ica. Esta  RI  puede  ser  corregida  mediante  el  trasplante  de
ejido adiposo  blanco  procedente  de  ratones  sanos,  lo  que
e traduce  en  una  disminución  de  la  cantidad  grasa  hepática
cumulada y  de  la  RI,  tanto  del  tejido  hepático  como  de  teji-
os periféricos79. Además,  Shimomura  et  al.,  utilizando  de
uevo un  modelo  murino  de  lipodistroﬁa,  demostraron  tam-
ién su  reversibilidad  mediante  la  administración  sistémica
e leptina  recombinante80.
En  humanos  se  han  estudiado  también  pacientes  con
ipodistroﬁa relacionada  con  la  mutación  en  la  perilipina-
, responsable  de  la  inhibición  de  la  triglicérido-lipasa
ntracelular.  En  estos  pacientes,  debido  al  aumento  de  la
ipólisis, se  observa  una  reducción  del  tejido  graso  sub-
utáneo y  el  desarrollo  de  EHGNA81.  En  los  pacientes  con
ipodistroﬁa también  se  ha  podido  demostrar  beneﬁcio  de  la
dministración exógena  de  leptina  recombinante82.  Peter-
en et  al.,  observaron  que  la  administración  exógena  de
eptina en  pacientes  lipodistróﬁcos  reducía  signiﬁcativa-
ente el  contenido  lipídico  hepático  y  muscular,  debido
rincipalmente a  la  disminución  de  la  ingesta  calórica,
on la  consiguiente  mejora  en  la  sensibilidad  a  la  insu-
ina tanto  hepática  como  de  los  tejidos  periféricos83.
ecientemente, se  ha  comprobado  que,  en  pacientes
on diferentes  grados  de  lipodistroﬁa,  la  terapia  sustitu-
iva con  leptina  mejoraba  el  dan˜o  histológico  del  tejido
epático77.
En  conjunto,  los  estudios  realizados  en  modelos  animales
 en  pacientes  lipodistróﬁcos  demuestran  una  clara  disocia-
ión entre  la  cantidad  de  tejido  graso  corporal  global  o  la
uantía del  tejido  graso  visceral,  y  el  grado  de  RI  hepática,
ugiriendo que  la  distribución  y  acumulación  especíﬁca  del
ejido graso  al  nivel  del  hígado  y  del  músculo  esquelético,
o la  cantidad  grasa  corporal  total,  es  la  que  determina  la
I hepática  y  muscular84.
Este  último  concepto  estaría  apoyado  por  el  papel  que
l receptor  PPAR  estaría  desempen˜ando  en  el  desarrollo
e la  esteatosis  hepática.  PPAR  está  altamente  expresado
n el  tejido  adiposo,  ejerciendo  un  papel  clave  en  la  cap-
ación de  los  ácidos  grasos  por  parte  de  los  adipocitos,
sí como  en  su  diferenciación  celular.  Existen  pacientes
on ciertas  mutaciones  que  tienen  disminuida  la  activi-
ad de  PPAR.  Estos  desarrollan  síndrome  metabólico  y
HGNA, causado  por  el  aumento  del  ﬂujo  lipídico  hacia  el
ígado85. A  pesar  de  que  PPAR  está  altamente  expresado
n el  tejido  adiposo,  se  expresa  también  a  nivel  hepático
ero en  menor  grado.  Ratones  deﬁcientes  en  la  actividad
N LIVER OF MORBIDLY etabólicas  y la  lipotoxicidad  en  el  desarrollo  de  esteatosis
l.  2015.  http://dx.doi.org/10.1016/j.arteri.2015.03.003
epática de  PPAR  están  protegidos  contra  el  desarrollo  de
steatosis hepática,  sugiriendo  que  PPAR  desempen˜a  un
apel  importante  en  la  regulación  del  cúmulo  de  lípidos
epáticos86.  Pacientes  en  tratamiento  con  tiazolidindionas,
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fármacos  agonistas  de  PPAR,  presentan  una  disminución  de
la acumulación  de  lípidos  a  nivel  hepático  y  del  músculo
esquelético, favoreciéndose  el  depósito  lipídico  en  el  tejido
graso subcutáneo  y  el  aumento  de  la  sensibilidad  hepática  a
la insulina87,88.
Así,  los  conocimientos  aportados  por  los  estudios  de  las
lipodistroﬁas parecen  apuntar  a  que  la  resistencia  hepática
a la  insulina  está  determinada  por  el  cúmulo  especíﬁco  de
grasas a  nivel  hepático,  y  no  por  el  grado  de  obesidad  glo-
bal, y  en  segundo  lugar,  resaltan  la  importancia  del  tejido
adiposo y  de  su  capacidad  adaptativa  para  almacenar  el
exceso de  grasas,  hipertroﬁándose,  protegiendo  al  hígado
de un  cúmulo  lipídico  excesivo.
Resistencia  a  la  insulina  en  el  músculo  esquelético
En  este  apartado  se  pretende  dilucidar  el  papel  de  la  RI
muscular en  la  patogénesis  de  la  EHGNA  y  la  RI  hepática.
Papel  del  exceso  de  ácidos  grasos  libres  en  la  resistencia
a  la  insulina  muscular
El potencial  de  los  ácidos  grasos  libres  (AGL)  para  alte-
rar el  metabolismo  glucídico  muscular  fue  propuesto  hace
más de  50  an˜os89,  y  desde  entonces  ha  sido  ampliamente
investigado. Diferentes  autores90--96 han  conﬁrmado  que  un
incremento en  la  concentración  plasmática  de  AGL  altera
la sen˜alización  de  la  insulina  y  causa  insulinorresistencia
muscular en  individuos  sanos.  Además,  se  ha  demostrado
que una  disminución  de  la  concentración  plasmática  de  AGL
secundaria a  acipimox,  análogo  del  ácido  nicotínico  e  inhi-
bidor de  la  lipólisis  del  tejido  adiposo,  mejora  rápidamente
la sensibilidad  a  la  insulina  muscular97.
Así  mismo,  numerosos  estudios  han  demostrado  una
fuerte relación  entre  los  lípidos  intramiocelulares  y  la  RI
muscular55,56,98.  En  adultos  no  diabéticos  con  normopeso  el
contenido en  TG  intramiocelular  es  un  predictor  de  RI  mus-
cular mucho  más  potente  que  los  ácidos  grasos  circulantes99,
lo que  sugiere  que,  en  sujetos  obesos,  los  lípidos  intramio-
celulares pueden  estar  desempen˜ando  un  papel  causal  en
la RI  muscular.  De  hecho,  sujetos  obesos  insulinosensibles  o
insulinorresistentes  se  distinguen  según  el  cúmulo  lipídico
muscular y  hepático100.
Por otro  lado,  es  importante  sen˜alar  que  la  RI  muscu-
lar correlaciona  con  una  variedad  de  metabolitos  lipídicos
tóxicos, consecuencia  de  una  oxidación  incompleta  de  áci-
dos grasos,  como  acilcarnitinas,  ceramidas  y  DAG96,101--104.
En modelos  murinos,  cuando  se  aumenta  los  AG  en  plasma
mediante la  infusión  de  Liposyn® +  heparina  para  activar  la
LpL, la  RI  muscular  aparece  a  las  3  h,  a  consecuencia  del
aumento de  DAG  y  de  la  activación  de  PKC105.  Sin  embargo,
no se  observan  cambios  en  el  contenido  de  TG  o  cera-
mida muscular  en  ese  momento,  por  lo  que  es  importante
diferenciar entre  los  distintos  lípidos  que  participan  en  la
patogénesis de  la  RI  muscular.  Los  hallazgos  de  RI  muscu-
lar mediada  por  DAG  han  sido  conﬁrmados  en  humanos  por
Itani et  al.106.  Además,  en  la  patogénesis  de  RI  muscular,
es importante  tener  en  cuenta  que  el  músculo  esquelé-
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tico también  es  el  objetivo  de  citoquinas  proinﬂamatorias
circulantes como  factor  de  necrosis  tumoral  alfa  e  interleu-
cina 6.  Finalmente,  macrófagos  inﬂamatorios  M1  activados
procedentes del  tejido  adiposo  pueden  inﬁltrar  el  músculo
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squelético  y  causar  RI  de  una  manera  similar  a  lo  que  ocurre
n el  tejido  adiposo107.
nsulinorresistencia  en  músculo  esquelético  en  pacientes
on esteatohepatitis  no  alcohólica
egún la  literatura  un  aumento  moderado  en  la  adiposidad
 en  la  concentración  plasmática  de  AGL  puede  causar  lipo-
oxicidad muscular.  Por  tanto,  no  es  de  extran˜ar  que,  en
acientes obesos  con  EHGNA,  la  RI  muscular  esté  completa-
ente establecida108--110,  e  incluso  en  individuos  no  obesos
on esteatohepatitis  no  alcohólica  (EHNA)  si  presentan  RI  en
l tejido  adiposo111--113. En  cambio,  individuos  obesos  sin  RI
n el  tejido  adiposo  se  comportan  desde  el  punto  de  vista
etabólico como  sujetos  delgados,  con  casi  normal  insuli-
osensitividad muscular  y  habitualmente  sin  desarrollo  de
HGNA108,111,114.
La RI  primaria  en  el  músculo  esquelético  puede  condu-
ir a una  redistribución  de  los  sustratos  hacia  el  hígado,
ando lugar  a la  aparición  de  esteatosis  hepática  y,  pos-
eriormente, RI  hepática  a  través  del  cúmulo  hepático  de
AG con  la  activación  de  PKC.  Esta  hipótesis  ha  sido  res-
aldada en  estudios  de  modelos  murinos  que  presentan
na inactivación  especíﬁca  del  gen  del  receptor  de  insu-
ina (MIRKO)115. La  RI  muscular  selectiva  en  estos  ratones
omporta una  hiperinsulinemia  compensatoria  con  redistri-
ución de  los  sustratos  hacia  lugares  ectópicos,  tales  como  el
ígado. Además,  ratones  que  carecen  del  transportador  de
lucosa muscular  (GLUT4)  presentan  una  pérdida  casi  com-
leta de  la  captación  muscular  de  glucosa  estimulada  por  la
nsulina, que  se  asocia  a  esteatosis  hepática  y  RI116.  Estos
allazgos se  han  corroborado  también  en  humanos.  Así,  en
ndividuos con  RI  muscular  selectiva,  observada  en  sujetos
anos, jóvenes,  delgados  o  en  individuos  en  el  cuartil  infe-
ior de  insulinosensibilidad  global,  los  hidratos  de  carbono
ngeridos se  desvían  de  la  síntesis  de  glucógeno  muscular
acia la  lipogénesis  hepática,  predisponiendo  a  estos  indi-
iduos a  RI  hepática  y  aparición  de  EHGNA117 (ﬁg.  3).  Por
tra parte,  un  estudio  reciente  ha  demostrado  que  una  sola
esión de  ejercicio  revierte  los  defectos  en  el  transporte
e la  glucosa  muscular  estimulada  por  insulina,  así  como
os defectos  en  la  síntesis  de  glucógeno118.  Esta  mejoría  se
videncia por  una  disminución  de  la  lipogénesis  hepática
e novo  y  por  la  reducción  de  la  síntesis  hepática  de  TG
eta después  de  una  dieta  rica  en  hidratos  de  carbono.  Por
o tanto,  se  demuestra  que  la  RI  muscular  puede  ser  una
iana terapéutica  para  la  prevención  y  el  tratamiento  de  la
HGNA118.  En  este  sentido,  Haufe  et  al.  demostraron  que
l efecto  de  la  mejora  de  la  condición  física  sobre  la  insu-
inosensibilidad en  pacientes  con  sobrepeso/obesidad  está
ediada  a  través  de  una  reducción  en  el  contenido  de  grasa
epática119. Además,  se  ha  objetivado  que  el  ejercicio  cró-
ico sin  reducción  en  el  peso  corporal  o en  la  grasa  corporal
otal también  conduce  a  una  reducción  en  el  contenido  de
rasa hepática120.
En resumen,  tanto  estudios  en  ratones  como  en  huma-
os apoyan  el  concepto  de  que  la  RI  muscular  selectiva,
ue es  una  de  las  alteraciones  metabólicas  más  tempranas
 IN LIVER OF MORBIDLY etabólicas  y  la  lipotoxicidad  en  el  desarrollo  de  esteatosis
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etectadas en  jóvenes  delgados  descendientes  de  padres
on diabetes  tipo  2,  puede  ser  un  factor  importante  y  tem-
rano en  la  patogénesis  de  la  EHGNA  y  la  resistencia  hepática
 la  insulina.
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Síntesis de glucógeno
↓ Síntesis de glucógenoSíntesis de glucógeno
Sensible a la insulina Resistente a la insulina
↑ Lipogénesis de  novo
Glucosa
Figura  3  La  resistencia  a  la  insulina  en  el  músculo  esquelético  contribuye  a  la  lipogénesis  hepática.
En los  sujetos  insulinosensibles  la  insulina  estimula  la  síntesis  de  glucógeno  tanto  en  tejido  muscular  como  hepático.  Sin  embargo,
en  aquellos  que  presentan  resistencia  a  la  insulina  en  el  músculo  esquelético,  esta  hormona  no  es  capaz  de  promover  la  síntesis
de  glucógeno,  redistribuyendo  el  sustrato  hacia  el  hígado,  lo  que  contribuye  a  un  incremento  de  la  lipogénesis  de  novo  hepática.
El  aumento  de  la  síntesis  de  lípidos  en  el  hígado  de  pacientes  con  resistencia  a  la  insulina  en  el  músculo  esquelético  promueve  el
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actores  genéticos
n  los  últimos  an˜os  se  han  descrito  variantes  genéticas  de
istintos genes  que  hacen  más  suceptibles  a  los  individuos
ortadores a  desarrollar  EHGNA  y  RI  cuando  se  exponen  a
actores ambientales.
polipoproteína  C3
a apolipoproteína  C3  (APOC3)  es  una  proteína  que  forma
arte de  las  lipoproteínas  de  muy  baja  densidad,  que  se
ncarga de  inhibir  la  actividad  lipoproteín  lipasa  con  el  ﬁn
e regular  la  distribución  de  lípidos  en  los  diferentes  órganos
 tejidos  del  cuerpo.
Recientemente,  Petersen  et  al.  han  demostrado  que  un
rupo de  indios  asiáticos,  varones,  sanos  y  delgados,  que
resentan una  de  las  2  variantes  genéticas  (C-482  T/T-455  C)
n el  elemento  de  respuesta  a  la  insulina  del  gen  APOC3  se
ncuentran en  un  riesgo  más  elevado  de  desarrollar  EHGNA
 RI.  Las  concentraciones  plasmáticas  de  APOC3,  así  como
a hipertrigliceridemia  posprandial  de  los  individuos  que
oseen este  polimorﬁsmo,  son  aproximadamente  un  30%
ás elevadas  comparadas  con  los  sujetos  homozigotos  para
POC3  (C-482/T-455)121.  Además,  después  de  ser  sometidos
 una  infusión  intravenosa  de  lípidos,  estos  sujetos  presen-
aron una  disminución  de  la  hidrólisis  de  triglicéridos  y unCómo  citar  este  artículo:  Berlanga  A,  et  al.  Papel  de  las  lipasas  m
hepática  y  esteatohepatitis  no  alcohólica.  Clin  Invest  Arteriosc
umento de  la  hipertrigliceridemia  posprandial  y  quilomi-
rones remanentes,  debido  a  la  exagerada  inhibición  de  la
ctividad LpL,  permitiendo  así  el  desarrollo  de  EHGNA  y  RI.
ambién se  pudo  observar  una  reversión  de  la  esteatosis
v
v
R
depática  y  RI  en  estos  sujetos  después  de  una  modesta
érdida de  peso121.  Sin  embargo,  cabe  destacar  que  las
ariantes genéticas  de  APOC3  no  son  la  causa  directa  del  des-
rrollo  de  esteatosis  hepática,  pero  suponen  una  condición
e predisposición  en  aquellos  individuos  que  son  portadores,
iendo más  susceptibles  a desarrollar  EHGNA  y  RI  cuando
e exponen  a  factores  ambientales  tóxicos,  tales  como  una
ieta hipercalórica  y  rica  en  grasas.  De  acuerdo  a  esta  hipó-
esis, Lee  et  al.  han  demostrado  recientemente  que  ratones
ue sobreexpresan  APOC3  no  presentan  esteatosis  hepática
 RI  cuando  son  alimentados  con  dieta  control.  Sin  embargo,
uando esta  es  remplazada  por  una  dieta  rica  en  grasas  des-
rrollan esteatosis  hepática  severa  con  un  incremento  del
ontenido hepático  de  DAG,  de  la  activación  de  PKC  y  RI40.
diponutrin
tro grupo  en  riesgo  de  desarrollo  de  EHGNA  y  RI  hepática
on adultos  y  nin˜os  hispanos122.  En  esta  población  se  ha  visto
ue la  sustitución  de  isoleucina  por  metionina  en  la  posi-
ión 148  (I148M)  de  la  enzima  PNPLA3,  conocida  también
omo adiponutrin,  codiﬁcada  por  el  gen  PNPLA3,  se  encuen-
ra fuertemente  asociada  al  contenido  hepático  de  TG  y
esarrollo de  EHGNA,  incluyendo  esteatohepatitis,  cirrosis
 hepatocarcinoma123--127. Sin  embargo,  a  diferencia  de  lasetabólicas  y la  lipotoxicidad  en  el  desarrollo  de  esteatosis
l.  2015.  http://dx.doi.org/10.1016/j.arteri.2015.03.003
ariantes del  gen  APOC3  descritas  en  la  sección  anterior,  las
ariantes genéticas  de  PNPLA3  no  se  encuentran  asociadas  a
I, sugiriendo  que  la  enfermedad  de  EHGNA  puede  disociarse
e la  RI  hepática128--130.
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Figura  4  Vías  metabólicas  implicadas  en  la  acumulación  hepática  de  DAG.
La vía  del  glicerol-3-fosfato  (glicerol  3P)  representa  la  ruta  de  la  lipogénesis  de  novo  en  la  síntesis  de  triglicéridos  y  fosfolípidos.  La
glicerol-fosfato-acil-transferasa  (GPAT)  cataliza  la  acetilación  de  glicerol  3P  con  acil-CoA  para  generar  ácido  lisofosfatídico  (LPA),  lo
que parece  ser  el  paso  limitante  en  la  síntesis  de  triglicéridos  (TG).  Posteriormente,  las  enzimas  acil-glicerol-fosfato-acil-transferasa
(AGPAT), fosfatasa  del  ácido  fosfatídico  (PAP)  y  diacilglicerol  aciltransferasa  (DGAT)  catalizan  la  formación  de  ácido  fosfatídico  (PA),
diacilglicerol  (DAG)  y  TG,  respectivamente.  Los  DAG  activan  la  translocación  de  PKC  hacia  la  membrana  plasmática,  inhibiendo  la
activación  del  receptor  de  la  insulina.  Los  ácidos  LPA  y  PA  que  no  han  sido  sintetizados  en  el  retículo  endoplasmático  (RE)  requieren
la  translocación  a  través  del  citosol  para  la  síntesis  de  TG  en  el  RE.  En  el  hígado  los  TG  pueden  depositarse  en  vacuolas  intracelulares
o  ser  exportados  en  lipoproteínas  de  muy  baja  densidad  (VLDL).  En  las  vacuolas,  durante  la  lipólisis,  la  conversión  de  TG  a  DAG
es  mediada  por  la  lipasa  de  triglicéridos  del  tejido  adiposo  (ATGL).  Los  DAG  pueden  ser  hidrolizados  a  monoacilglicerol  (MAG)  por
la  hormona  sensible  a  la  lipasa  (HSL)  y,  posteriormente,  a  glicerol  por  la  lipasa  de  monoglicéridos  (MGL),  que  puede  ser  utilizado
como  sustrato  para  la  gluconeogénesis.  Estas  reacciones,  al  liberar  ácidos  grasos,  contribuyen  a  su  acumulación  hepática.  Los  DAG
provenientes  de  lipólisis  intravacuolar  y  de  la  vía  de  la  fosfolipasa  C,  que  libera  DAG  a  partir  de  lípidos  de  membrana,  podrían
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Dipòsit Legal: T 1705-2015activar  la  PKC  y  la  resistencia  hepática  a  la  insulina  (RI).  Sin  e
PNPLA3  pertenece  a  la  familia  de  proteínas  que  com-
parten un  dominio  evolutivo  identiﬁcado  por  primera  vez
en la  patatina,  la  principal  proteína  de  los  tubérculos  de
patata131.  El  genoma  humano  codiﬁca  9  proteínas  que  con-
tienen el  dominio  de  la  patatina,  de  los  cuales  PNPLA3  está
estrechamente relacionada  con  PNPLA2,  la  mayor  hidro-
lasa de  TG  del  tejido  adiposo132,133.  PNPLA3  se  expresa
predominantemente  en  el  hígado  y  en  el  tejido  adiposo
humano134,  y  se  encuentra  frecuentemente  asociada  a  mem-
branas y  vacuolas  lipídicas135.  Esta  proteína  está  altamente
regulada en  respuesta  a  estímulos  nutricionales,  tanto  a
nivel transcripcional  como  postranslacional.  Su  expresión
se suprime  en  estado  de  ayunas,  mientras  que  aumenta  en
respuesta a  la  presencia  de  glucosa  e  insulina,  donde  el
factor de  transcripción  SREBP1c  se  encarga  de  estimular  su
transcripción136.Cómo  citar  este  artículo:  Berlanga  A,  et  al.  Papel  de  las  lipasas  m
hepática  y  esteatohepatitis  no  alcohólica.  Clin  Invest  Arteriosc
Se sugiere  que  PNPLA3  presenta  tanto  función  lipasa
como de  transacilación,  y  que  la  mutación  I148M  causa  la
pérdida de  la  función  lipasa  del  gen137,  contribuyendo  así
al aumento  del  contenido  de  TG  hepáticos.  Yongcheng  et
r
l
l
tgo,  estos  2  últimos  mecanismos  no  están  del  todo  dilucidados.
l.  demostraron  que  PNPLA3  cataliza  la  hidrólisis  de  los  3
ayores glicerolípidos  (TG,  DAG  y  MAG),  con  mayor  prefe-
encia por  los  ácidos  grasos  C18:1,  y que  la  mutación  I148M
educe la  actividad  hidrolasa  contra  los  3  glicerolípidos.  Sin
mbargo, cabe  destacar  que,  prácticamente,  en  la  mayo-
ía de  estos  estudios  se  han  incluido  individuos  obesos  como
ujetos controles,  los  cuales  presentan  casi  siempre  algún
rado de  esteatosis  hepática  asociada  a  RI,  haciendo  difícil
iscernir si  las  variantes  genéticas  de  PNPLA3  con  EHGNA
stán participando  o  no  en  la  RI  hepática.  Para  identiﬁ-
ar si  la  mutación  conﬁere  un  riesgo  independiente  en  el
esarrollo de  RI  hepática,  sería  importante  evaluar  la  sen-
ibilidad a  la  insulina  hepática  en  individuos  delgados  con
HGNA portadores  de  la  mutación  I148M136.
En concordancia  a  los  resultados  obtenidos  en  humanos,
a sobreexpresión  del  gen  mutante  I148  M  de  PNPLA3  enetabólicas  y  la  lipotoxicidad  en  el  desarrollo  de  esteatosis
l.  2015.  http://dx.doi.org/10.1016/j.arteri.2015.03.003
atones se  asoció  a  un  aumento  del  taman˜o  de  las  vacuolas
ipídicas y  acumulación  de  TG  hepáticos135,136.  Sin  embargo,
a sobreexpresión  de  PNPLA3  no  mutado  no  cambió  el  con-
enido de  lípidos  hepáticos  en  ratones135,136,138. Por  otro
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0  
ado,  los  ratones  Knockout  para  PNPLA3  no  desarrollaron
steatosis hepática  ni  trastornos  en  el  metabolismo  de  la
lucosa139,140.
ol de la  compartimentación intracelular de
iacilgliceroles:  disociación de la enfermedad
el  hígado graso no alcohólico y la resistencia
 la  insulina hepática
l  modelo  descrito  anteriormente,  que  explica  la  relación
ntre DAG,  PKC  y  RI  hepática,  se  centra  principalmente  en
a incapacidad  de  la  insulina  para  alterar  el  metabolismo
e la  de  glucosa  hepática.  Sin  embargo,  la  capacidad  de
a insulina  para  activar  la  lipogénesis  parece  estar  intacta
n la  mayoría  de  los  modelos  de  EHGNA.  Por  ello,  aunque
a EHGNA  se  encuentra  fuertemente  asociada  a  RI  hepá-
ica y  DM2,  recientemente  se  ha  descrito  la  «paradoja  de
a resistencia  hepática  a  la  insulina  selectiva»,  en  la  que  se
ropone la  existencia  de  una  disociación  entre  la  EHGNA  y
a RI  hepática141,142.
Experimentalmente  es  posible  inducir  resistencia  a  la
nsulina sin  EHGNA,  o  inducir  EHGNA  sin  resistencia  a  la  insu-
ina bajo  ciertas  condiciones.  Por  ejemplo,  el  bloqueo  de  la
ecreción hepática  de  lipoproteínas  de  muy  baja  densidad
on una  dieta  deﬁciente  en  colina,  o  mediante  la  modiﬁ-
ación genética  de  la  maquinaria  de  exportación,  aumenta
as concentraciones  de  TG  hepáticos  pero  no  induce  RI  en
atones143,144.  Por  otro  lado,  los  factores  de  transcripción
hREBP y  SREBP1  han  sido  recientemente  implicados,  de
orma independiente,  en  la  disociación  de  EHGNA  y  RI  hepá-
ica tanto  en  ratones  como  en  humanos145,146.  Para  explicar
sta paradoja  y  la  RI  hepática  selectiva,  Cantley  et  al.
xaminaron la  localización  subcelular  de  DAG  en  células
epáticas y  observaron  que  el  knockdown  del  gen  CGI-58,
ctivador de  la  lipasa  de  triglicéridos  del  tejido  adiposo
ATGL) que  participa  en  la  hidrólisis  de  TG,  promueve  la
cumulación de  DAG  en  gotas  lipídicas,  evitando  así  la  acu-
ulación de  DAG  en  la  membrana  celular  y  la  translocación
e PKC  hacia  la  membrana  celular147.  Estos  resultados  con-
uerdan con  otros  estudios  realizados  tanto  en  humanos45
omo  en  modelos  animales38,148,149,  sugiriendo  que  la  com-
artimentación de  DAG  en  el  hepatocito  podría  ser  un  factor
mportante en  la  patogénesis  de  la  resistencia  hepática  a  la
nsulina.
La acumulación  hepática  de  DAG  puede  resultar  de  la
ía glicerol  3-fosfato,  que  representa  la  ruta  de  la  lipogé-
esis en  la  síntesis  de  TG  y  fosfolípidos.  Por  otro  lado,  los
AG intracelulares  también  pueden  derivar  de  la  hidrólisis
e TG  compartimentados  en  gotas  lipídicas,  mediada  por  la
ipasa ATGL,  así  como  de  la  activación  de  la  fosfolipasa  C,
ue libera  DAG  a  partir  de  lípidos  de  membrana  (ﬁg.  4).  De
ué manera  los  DAG  que  derivan  de  estas  2  últimas  vías  pue-
en conducir  a  la  activación  PKC  y  a  la  RI  hepática  no  se
a determinado  todavía.  Sin  embargo,  los  resultados  obteni-
os usando  OAS  especíﬁcos  para  CGI-58  indican  claramente
ue los  lípidos  secuestrados  en  gotas  lipídicas  no  promue-
N OF FATTY ACID METABOLISM AND CANNABINOID RECEPTO
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ga Bustos 
al: T 1705-2015Cómo  citar  este  artículo:  Berlanga  A,  et  al.  Papel  de  las  lipasas  m
hepática  y  esteatohepatitis  no  alcohólica.  Clin  Invest  Arteriosc
en la  activación  PKC  y  resistencia  hepática  a  la  insulina,
 que  la  compartimentación  de  DAG  y  TG  en  compartimen-
os neutros,  en  los  cuales  se  estaría  evitando  la  activación
e PKC,  podrían  explicar  por  qué  el  contenido  hepático  de
A
e
r
e PRESS
A.  Berlanga  et  al
AG  no  siempre  se  correlaciona  con  la  RI  hepática  en  algunos
odelos animales47.
onclusiones
as  lipasas  metabólicas  son  las  enzimas  responsables  de  la
idrólisis de  TG  tanto  en  tejido  adiposo  como  hepático.  La
ipólisis  en  el  tejido  adiposo  provoca  un  aumento  del  ﬂujo  de
G hacia  el  hígado,  promoviendo  así  el  desarrollo  de  estea-
osis hepática150.  Existe  una  creciente  evidencia,  no  solo  en
odelos animales  de  EHGNA,  sino  también  en  humanos  con
HGNA asociada  a  obesidad,  a  DM2  y a  lipodistroﬁa,  que  la
steatosis hepática  está  fuertemente  vinculada  al  desarro-
lo de  RI  hepática.  Por  lo  tanto,  si  los  lípidos  hepáticos  son
ediadores importantes  para  la  RI  hepática,  es  de  esperar
ue la  reducción  de  la  esteatosis  hepática  en  pacientes  con
HGNA y  DM2  conlleve  a  la  reducción  de  la  RI  hepática.
La  EHGNA  aparece  cuando  la  ratio  de  lípidos  suministra-
os hacia  el  hígado  excede  a  la  oxidación  y  a  la  exportación
ipídica hepática.  Por  otro  lado,  un  gran  número  de  estudios,
anto en  seres  humanos  como  en  modelos  animales,  han
emostrado que  la  acumulación  hepática  de  DAG  permite
a activación  de  PKC,  dando  lugar  a  la  aparición  de  resis-
encia hepática  a  la  insulina.  Además,  la  compartimentación
el DAG  acumulado  parece  ser  un  factor  crucial  para  el  des-
rrollo de  RI  hepática,  pudiendo  explicar  por  qué  algunos
acientes y  modelos  murinos  con  EHGNA  no  desarrollan  RI
epática. Así,  el  mecanismo  DAG-PKC  parece  desempen˜ar
n papel  primordial  en  el  desarrollo  de  la  EHGNA  asociada
 la  RI  hepática.  Por  todo  ello,  para  el  tratamiento  de  la
HGNA y  la  DM2  resulta  de  gran  interés  todas  aquellas  tera-
ias que  van  dirigidas  a  reducir  la  liberación  de  ácidos  grasos
acia el  hígado,  a  suprimir  la  producción  de  DAG  o  a  aumen-
ar la  oxidación  mitocondrial  de  los  AG151.
Aparte de  la  pérdida  de  peso,  no  existen  actualmente
erapias efectivas  para  la  EHGNA.  Por  dicho  motivo,  la
nvestigación actual  se  centra  en  la  comprensión  de  la  enfer-
edad subyacente  a la  esteatosis  hepática,  con  la  ﬁnalidad
e identiﬁcar  nuevas  dianas  terapéuticas.  En  este  sentido,
e ha  sugerido  que  nuevas  terapias  dirigidas  a  prevenir
a acumulación  hepática  de  DAG  y  la  activación  de  PKC
odrían ser  efectivas84.  Por  otro  lado,  pequen˜os  péptidos
irigidos a revertir  la  función  enzimática  correcta  de  las
ariantes genéticas  de  PNPLA3  asociadas  a  la  progresión  de
a EHGNA  y  la  esteatohepatitis  no  alcohólica  podrían  pro-
orcionar un  enfoque  innovador  para  el  tratamiento  de  la
HGNA.
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